The Synthesis of Biologically Active Guanidines by Harper, Philip Mark
  
 
 
The Synthesis of Biologically 
 Active Guanidines  
 
 
A thesis presented for the degree of 
Doctor of Philosophy 
in the 
School of Chemistry 
by 
Philip Mark Harper 
 
 
Prifysgol Bangor University 
© March 2016 
 
 
  
 
 
Declaration and Consent 
 
Details of the Work 
I hereby agree to deposit the following item in the digital repository maintained by Bangor 
University and/or in any other repository authorized for use by Bangor University. 
Author Name: ……………………………………………………………………………… 
Title: ……………………………………………………………………..……………..…… 
Supervisor/Department: ....................................................................................................... 
Funding body (if any): .......................................................................................................... 
Qualification/Degree obtained: …………………………………………………………… 
This item is a product of my own research endeavours and is covered by the agreement below 
in which the item is referred to as “the Work”.  It is identical in content to that deposited in 
the Library, subject to point 4 below. 
Non-exclusive Rights 
Rights granted to the digital repository through this agreement are entirely non-exclusive.  I 
am free to publish the Work in its present version or future versions elsewhere. 
I agree that Bangor University may electronically store, copy or translate the Work to any 
approved medium or format for the purpose of future preservation and accessibility.  Bangor 
University is not under any obligation to reproduce or display the Work in the same formats 
or resolutions in which it was originally deposited. 
Bangor University Digital Repository 
I understand that work deposited in the digital repository will be accessible to a wide variety 
of people and institutions, including automated agents and search engines via the World 
Wide Web. 
I understand that once the Work is deposited, the item and its metadata may be incorporated 
into public access catalogues or services, national databases of electronic theses and 
dissertations such as the British Library’s EThOS or any service provided by the National 
Library of Wales.  
  
 
 
I understand that the Work may be made available via the National Library of Wales Online 
Electronic Theses Service under the declared terms and conditions of use 
(http://www.llgc.org.uk/index.php?id=4676). I agree that as part of this service the National 
Library of Wales may electronically store, copy or convert the Work to any approved 
medium or format for the purpose of future preservation and accessibility.  The National 
Library of Wales is not under any obligation to reproduce or display the Work in the same 
formats or resolutions in which it was originally deposited. 
 
Statement 1: 
This work has not previously been accepted in substance for any degree and is not being 
concurrently submitted in candidature for any degree unless as agreed by the University for 
approved dual awards. 
 
Signed ………………………………………….. (candidate) 
Date …………………………………………….. 
 
Statement 2: 
 
This thesis is the result of my own investigations, except where otherwise stated.  Where 
correction services have been used, the extent and nature of the correction is clearly marked 
in a footnote(s). 
All other sources are acknowledged by footnotes and/or a bibliography. 
 
Signed …………………………………………. (candidate) 
Date ……………………………………………. 
 
 
  
 
 
Statement 3: 
 
I hereby give consent for my thesis, if accepted, to be available for photocopying, for inter-
library loan and for electronic storage (subject to any constraints as defined in statement 4), 
and for the title and summary to be made available to outside organisations. 
 
Signed …………………………………………. (candidate) 
Date ……………………………………………. 
 
Statement 4: 
 
Choose one of the following options  
a)      I agree to deposit an electronic copy of my thesis (the Work) in the Bangor 
University (BU) Institutional Digital Repository, the British Library ETHOS 
system, and/or in any other repository authorized for use by Bangor 
University and where necessary have gained the required permissions for the 
use of third party material. 
 
b)      I agree to deposit an electronic copy of my thesis (the Work) in the Bangor 
University (BU) Institutional Digital Repository, the British Library ETHOS 
system, and/or in any other repository authorized for use by Bangor 
University when the approved bar on access has been lifted. 
 
c)      I agree to submit my thesis (the Work) electronically via Bangor 
University’s e-submission system, however I opt-out of the electronic 
deposit to the Bangor University (BU) Institutional Digital Repository, the 
British Library ETHOS system, and/or in any other repository authorized for 
use by Bangor University, due to lack of permissions for use of third party 
material. 
 
Options B should only be used if a bar on access has been approved by the University. 
 
  
 
 
 
In addition to the above I also agree to the following: 
1. That I am the author or have the authority of the author(s) to make this agreement 
and do hereby give Bangor University the right to make available the Work in the 
way described above. 
2. That the electronic copy of the Work deposited in the digital repository and covered 
by this agreement, is identical in content to the paper copy of the Work deposited in 
the Bangor University Library, subject to point 4 below. 
3. That I have exercised reasonable care to ensure that the Work is original and, to the 
best of my knowledge, does not breach any laws – including those relating to 
defamation, libel and copyright. 
4. That I have, in instances where the intellectual property of other authors or copyright 
holders is included in the Work, and where appropriate, gained explicit permission 
for the inclusion of that material in the Work, and in the electronic form of the Work 
as accessed through the open access digital repository, or that I have identified and 
removed that material for which adequate and appropriate permission has not been 
obtained and which will be inaccessible via the digital repository. 
5. That Bangor University does not hold any obligation to take legal action on behalf 
of the Depositor, or other rights holders, in the event of a breach of intellectual 
property rights, or any other right, in the material deposited. 
6. That I will indemnify and keep indemnified Bangor University and the National 
Library of Wales from and against any loss, liability, claim or damage, including 
without limitation any related legal fees and court costs (on a full indemnity bases), 
related to any breach by myself of any term of this agreement. 
 
Signature: …………………………………………  Date : ………………………………. 
  
 
 
Contents 
Acknowledgements ........................................................................................................ i 
Abstract .......................................................................................................................... ii 
Abbreviations ................................................................................................................. iii 
Section A: Novel Anti-cancer Pro-drugs 
1.0 Introduction ............................................................................................................ 6 
1.1 Cancer ...................................................................................................................... 6 
1.2 Pro-drug Therapy ..................................................................................................... 7 
1.3 Pro-drugs in Cancer Chemotherapy ......................................................................... 9 
1.4 Tumour Activated Anti-Cancer Pro-drugs ............................................................... 10 
1.4.1 Quinones ............................................................................................................... 11 
1.4.2 Nitroaromatic Compounds .................................................................................... 13 
1.4.3 Aliphatic N-oxides ................................................................................................ 14 
1.4.4 Aromatic N-oxides ................................................................................................ 15 
1.5 Quinone Release Strategies ...................................................................................... 16 
1.5.1 A Redox Activated Drug Delivery System ........................................................... 19 
1.6 Nitrogen Mustards .................................................................................................... 19 
1.6.1 Strategies to Improve the Biological Potential of Mustards ................................. 22 
1.7 Tirapazamine ............................................................................................................ 24 
1.8 Previous Work by the Murphy Group ...................................................................... 29 
1.8.1 Background to the Study ....................................................................................... 29 
1.9 Aims ......................................................................................................................... 32 
2.0 Results and Discussion- Anti-cancer Pro-drugs .................................................. 35 
2.1 An Effective Synthesis of the Phenyl Mustard Standard ......................................... 35 
  
 
 
2.2 Tirapazamine Based Pro-drugs ................................................................................ 41 
2.3 Preparation of N-alkylated Tirapazamine Derivatives ............................................. 49 
2.4 The Direct Alkylation Approach .............................................................................. 54 
2.5 Alkoxymethyl Derivatives of Tirapazamine ............................................................ 60 
3.0 Conclusions and Future Work .............................................................................. 67 
Section B: The Synthesis of Guanidine Containing Natural products From the Sea 
Sponge Monancora Arbuscula 
4.0 Introduction ............................................................................................................ 71 
4.1 Leishmaniasis ........................................................................................................... 71 
4.2 The Role of Natural products in Medicine ............................................................... 73 
4.3 Marine Natural Products .......................................................................................... 74 
4.3.1 Guanidine Containing Natural Products ............................................................... 74 
4.4 The Crambines and the Batzelladine Alkaloids ....................................................... 75 
4.5 The Batzelladine Alkaloids ...................................................................................... 78 
4.6 Arbusculidine A ....................................................................................................... 79 
4.6.1 The Ptilocaulin Family of Alkaloids ..................................................................... 80 
4.6.2 The Synthesis of Ptilocaulin Alkaloids ................................................................. 84 
5.0 Results and Discussion ........................................................................................... 90 
5.1 Synthetic Approaches to Monalidine A (184) and Arbusculidine A (185) ............. 90 
5.2 The Synthesis of Monalidine A................................................................................ 90 
5.2.1 Synthesis of MonalidineA ..................................................................................... 90 
5.2.2 Conclusions and Biological Studies of Monalidine A .......................................... 97 
5.3 Approaches towards the Synthesis of Arbusculdine A ............................................ 99 
6.0 Conclusions .............................................................................................................. 115 
  
 
 
7.0 Experimental .......................................................................................................... 116 
7.1 General Experimental Synthetic Procedures ............................................................ 116 
7.2 Preparative Methods................................................................................................. 117 
8.0 References ............................................................................................................... 176 
9.0 Appendices .............................................................................................................. 182  
i 
 
 
 
Acknowledgements 
I would firstly like to thank my supervisor Dr Paddy Murphy for his invaluable help, 
support and patience over the duration of my BSc, MSc and during my PhD and for the write 
up period for this thesis. I would also like to thank all members of the research group 
especially Matthew Buck and Dr Dan Evans for their technical input and for the fun we have 
had over the past few years. Thanks must also go to Dr M. Jaffar at Morvus Technology Ltd 
for the help and support early in the PhD project. Thanks also go to Morvus and the ESF for 
making this PhD position possible through their funding. I would also like to thank the 
support staff at Bangor University including the general office staff and the technicians, 
especially Gwynfor Davies for the loan of glassware and chemicals, often at a second’s 
notice.  
A special thank you must also go to Prof Roberto Berlinck at the University of Sao 
Paulo for giving me the opportunity to synthesise two new natural products and to Professor 
Tempone who evaluated one of them against various diseases. 
In addition I would like to thank my family and friends for their support and 
friendship during this project. 
Finally I would like to say thank you to my wife Enlli and to my daughter Lois for 
your help, encouragement and support during my PhD. 
ii 
 
 
 
Abstract 
Several new alkyl (147, 161 and 167) and alkoxy-methyl derivatives (171, 175) were 
prepared as analogues of the anti-tumour agent tirapazamine (38). These were prepared in 
an attempt to couple them to the pro-drug delivery agent 52.  
 
The bicyclic guanidine natural product monalidine A (186) was prepared as its 
hydrochloride salt from 2-undecanone via a novel 3-step synthesis. The biological activity 
of monalidine A (186) and one of its synthetic precursors were evaluated against 
Leishmaniasis infantum and Trypanosoma cruzi. Research towards the total synthesis of the 
tricyclic arbusculidine A (187) from cucumber aldehyde is reported. 
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1.0 Introduction  
1.1 Cancer 
Cancer is a leading cause of death globally, accounting for 8.2 million deaths in 2012, 
with the total number of cases expected to rise from 14 million to 22 million within the next 
two decades.1 
 
Figure 1. Leading cancer deaths 2012. 
According to the World Health Organization, cancer arises from the transformation 
of a single normal cell into a tumour cell through a multi stage process. As well as being the 
result of genetic factors, there are three major categories of external agents; 
 Ultraviolet and ionizing radiation 
 Chemical carcinogens including tobacco smoke and asbestos 
 Biological carcinogens including infections caused by viruses, bacteria and parasites 
The aim of current cancer treatments is to either cure or treat cancer, prolonging life, 
while improving the patient’s quality of life. The three main treatments for cancer include 
radiotherapy, surgery and chemotherapy, usually in a combination of the three. This thesis 
is concerned only with cancer chemotherapy.  
 
 
1.2 Pro-drug Therapy 
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Pro-drug technology is a concept that was first proposed by Albert and Harper in the 
1950’s2,3  
A pro-drug is a compound that, on administration, must undergo chemical conversion 
by metabolic processes before becoming an active pharmacological agent. Currently around 
10 % of the world’s approved medicines can be described as pro-drugs, including the non-
steroidal anti-inflammatory drug aspirin (1) and the antihistamine fexofenadine (2) (Figure 
2). 
. 
Figure 2. The analgesic aspirin and the antihistamine fexofenadine can be described as pro-drugs. 
There are two main classes of pro-drugs: carrier linked pro-drugs and bioprecursor 
pro-drugs. In the case of carrier linked pro-drugs, the active molecule (the drug) is 
temporarily linked to a carrier or pro-moiety via a bio-reversible covalent linkage. Once 
inside the body, the carrier linked pro-drug undergoes biotransformation, releasing the parent 
drug and the carrier. A bioprecursor pro-drug is transformed metabolically by hydration (e.g. 
lactones), oxidation (e.g. dexpanthenol (3)) or reduction (e.g. sulindac (4)) to the active 
agents.4,5,6 
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Figure 3. Type I pro-drugs. 
Based on the site of conversion into the pharmacologically active agent, the 
pro-drugs can be additionally classified into two groups.  
The first group consists of type I, which are those that are metabolised intracellularly. 
These can be divided into type IA, for example acyclovir (5) and zidovudine (6), which are 
metabolised at the cellular targets of their therapeutic actions, whereas type IB pro-drugs, 
including carbamazepine (7) and primidone (8), are converted into parent drugs by specific 
metabolic tissues such as the liver.  
The second group, Type II, are those metabolised extracellularly, and are divided 
into three groups. Firstly type IIA are metabolised in the milieu of the gastrointestinal fluid, 
for example loperamide oxide (9). Secondly, type IIB are metabolised within the circulatory 
system and/or other extracellular fluid compartments, for example aspirin (1) and 
bambuterol (10). Lastly type IIC are metabolised near or inside the therapeutic target cells, 
including XP-23829 (11). 
 
Figure 4. Type II pro-drugs. 
Esters of active agents with carboxyl, hydroxyl or thiol functionalities and phosphate 
esters of hydroxyl or amine functionalities are the most commonly used pro-drugs. 
Approximately half of the pro-drugs currently available on the market are activated via 
enzymatic hydrolysis by the ubiquitous esterases that are present throughout the body.4,7  
1.3. Pro-drugs in Cancer Chemotherapy 
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Chemotherapy is one of the primary treatments for cancer. The majority of anticancer 
drugs currently in use inhibit proliferation or arrest the cell cycle at a certain phase. Existing 
oncostatic drugs show poor selectivity, and as a consequence affect not only neoplastic cells 
but also rapidly proliferating normal cells, including the bone marrow, gut and hair follicles. 
The lack of selectivity and associated toxicity of anticancer drugs reduces their effectiveness 
for long term use. 
 
Scheme 1. The activation of capecitabine (12) in neoplastic cells. 
One promising approach to producing more effective and selective cancer 
chemotherapy agents is to utilise pro-drug technology. An anticancer pro-drug should be 
transported to neoplastic cells, where it will undergo transformation by native or 
recombinant enzymes.8 Capecitabine (12) is a triple pro-drug of 5-fluorouracil (15) approved 
for the therapy of solid tumours, including breast cancer and colorectal cancer, and may be 
considered a pioneer of anticancer pro-drugs.4 Following oral administration, capecitabine 
(12) is rapidly and extensively absorbed then metabolised by hepatic carboxyesterases, 
giving 5-deoxy-5-fluorocytidine (13). This intermediate is then converted into 5-
fluorouridine (14) by cytidine deaminase in the liver and tumour tissues, which is in turn 
eventually converted by thymine phosphoylases in the tumour tissue into highly cytotoxic 
5-fluorouracil (15).9 
Anticancer pro-drugs can be designed to target specific molecules that are 
overexpressed in tumour cells in comparison to normal cells including:- 
 Enzyme-activated pro-drugs antibody-directed enzyme pro-drug therapy (ADEPT) 
and gene-directed enzyme pro-drug therapy (GDEPT). 
 Targeting ligand-conjugating pro-drugs, antibody-drug conjugates, peptide-drug 
conjugates, aptamer-drug conjugates and folic acid-drug conjugates 
 Enzyme cleavable pro-drugs 
 Membrane transporter associated pro-drugs 
 Polymeric pro-drugs 
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The work described in this thesis relates to hypoxia-selective tumour activated 
pro-drugs (known as hypoxia-TAP). 
1.4. Tumour Activated Anti-cancer Pro-drugs 
There are several classes of tumour activated pro-drugs (TAPs) which have been 
explored as anti-cancer agents. Each of these classes is activated by reductases present under 
hypoxic conditions (Scheme 2). 
 
Scheme 2. Typical hypoxic reduction of tumour activated pro-drugs. 
1.4.1. Quinones 
Quinones were amongst the earliest compounds explored as hypoxia selective TAP, 
and are known to undergo single-electron reduction by cytochrome C P-450, the cytochrome 
reductase giving the semiquinone radical.10 This anionic radical is oxidized back to the 
quinone by molecular oxygen in normal healthy perfused cells, allowing for increased 
selectivity.  
 
Figure 5. The oxidation of the semiquonone radical with molecular oxygen.10 
Early studies explored the use of leaving groups on the 2-position with the aim of 
producing reactive quinone methide intermediates. Compounds such as 2-(hydroxymethyl)-
1,4-napthoquone N-methylcarbamate (18) and more recent analogues such as (19) have 
shown poor hypoxic selectivity (Figure 6).11  
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Figure 6. Examples of tumour activated quinones. 
However, the first clinical agent identified as a hypoxic selective TAP was the natural 
product mitomycin C (20), although only slight hypoxic selectivity was observed.11,12 
Porfiromycin  (21), an analogue of (20), displayed much higher levels of selectivity, with 
cytotoxicity being produced by a fragmentation process following reduction, which leads to 
cross-linked DNA via two guanine bases.13 A clinical study found porformomycin (21) to 
be useful when used in conjunction with radiotherapy in head and neck cancer.14 A potential 
drawback, however, is that quinones are good substrates for two electron reductases 
including DT diphosphorase (DTD, NQO1 and NAD(P)H) which may result in the non-
selective conversion to the active agent. Aziridinylquinones such as diaziquone (AZQ) (22), 
which are simple analogues of (20), appear to be activated primarily by DTD (Figure 7). 
 
Figure 7. Further tumour activated anticancer pro-drugs. 
In a similar series of analogues, there appeared to be a correlation between the rate 
of reduction and an increase in cytotoxicity in HT-29 cells.15 As a result a large amount of 
study was conducted into utilizing DTD (an enzyme which is over-expressed in some 
tumours) to activate quinone-based drugs. The best example of these drugs is indoloquinone 
EO9 (23). However, clinical testing of EO9 yielded disappointing results attributed to 
varying activity levels of DTD in clinical tumours, as well as the short half-life of the active 
drug.11,16,17 
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Figure 8. Further tumour activated quinone anticancer pro-drugs. 
In the past, quinones have also been used as triggers to release active drugs 
(effectors).11,18 Compounds such as 24 (Figure 8), which expels melphalan (27), (a nitrogen 
mustard) via reductively-induced cyclolactonisation (Scheme 3), and 25 where reduction 
causes a direct C-N cleavage resulting in the release of an aliphatic mustard are examples of 
this triggered release.11,19 
Scheme 3. The reductive release of melphalan from quinone 24. 
1.4.2. Nitroaromatic Compounds 
 
Scheme 4. Mechanistic pathway of the reductive activation for a nitroaromatic drug. 
Nitroaromatic compounds were also studied extensively as anti-cancer pro-drugs. 
These compounds undergo up to six one-electron transfer reductions (Scheme 4). Starting 
from 28, the first step gives the nitro-anion radical 29, which is re-oxidized by the molecular 
oxygen present in normoxic tissues to regenerate the parent compound. However, in hypoxic 
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tissue, further reduction processes produce first the nitroso compound 30, which then is 
reduced to the hydroxylamine radical 31, and after subsequent reductions to amine 33. 
Amine 33 is the cytotoxic species that is responsible for cell death.20  
 
 
Figure 9. Nitroaromatic anticancer pro-drugs. 
Of the nitroaromatic class of pro-drugs, the 2-nitroimidazoles such as misonidazole 
34 and etanidazole 35 (Figure 9) have been studied most extensively as oxygen-mimetic 
radiosensitisers. They are also selectively metabolised under hypoxic conditions to give 
various ill-defined alkylating species. Unfortunately, they are only weakly cytotoxic and are 
moderately selective to hypoxic cells of normal oxygenated tissue culture.21–24 A further 
nitroaromatic hypoxia- activated pro-drug is dinitrobenzamide 
5-(1-aziridinyl)-2,4-dinitrobenzamide (CB1954) (36), which has been used widely for gene 
therapy.25 
1.4.3. Aliphatic N-oxides 
 
Figure 10. AQ4N, Tirapazamine and cyclophosmamide. 
Aliphatic N-oxides are among the most widely used anticancer drugs (Figure 10). 
Polycyclic agents with cationic tertiary amine side chains allow for good cell uptake and 
binding of DNA. They are excellent cytotoxins, but these properties are dependent on 
cationic side chains, and are not present in the N-oxides.11, 26 Enzymatic reduction of 
aliphatic N-oxides into the corresponding tertiary amines is inhibited by the presence of 
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oxygen, possibly due to competition of the drug and oxygen at the active site of the enzyme. 
Therefore, aliphatic N-oxides have been explored extensively as hypoxia selective tumour 
activated pro-drugs.27, 28 The drug AQ4N (37) (Figure 10) is probably the best representative 
of the class, but was found to not be significantly active as a sole agent. However, combined 
with radiation (which kills oxygenated cells) and by increasing the hypoxic fraction of 
tumours by either clamping blood vessels or by using vasodilators, the drug becomes 
therapeutically useful.26 In combination with cyclophosphamide, the effectiveness of 37 
against murine tumour models was superior compared to similar combinations of 
tirapazamine (38) and cyclophosphamide (39).29 
Other N-oxide derivatives of DNA intercalating agents have been realised as hypoxia 
selective agents, including nitracine N-oxide (40) (Figure 11). 40 has a lower DNA-binding 
efficiency and better distributive properties when compared to nitracine (41), which is a very 
potent cytotoxin with only moderate selectivity.11,30,31 These improved properties of the N-
oxide are attributed to it being a bis-bioreductive compound requiring two separate reductive 
steps for full activation. However, 40 was found to have low diffusion rates and low activity 
against KHT tumours, due to its metabolism, which occurred too rapidly outside the target 
cells. Studies have been conducted to improve 40 by lowering its reduction potential through 
chromophore substitution and by changing the steric environment of the N-oxide.32 Neither 
of these approaches were successful in improving the in vivo activity of the drug.11,33 
 
Figure 11. Nitracine N-oxide and nitracine. 
1.4.4. Aromatic N-oxides 
Aromatic N-oxides are similar to aliphatic N-oxides. The cytotoxicity of the drug is 
masked by being in the N-oxide form. The best known example of this class is tirapazamine 
(38), which was probably the first clinically useful tumour-activated pro-drug (see section 
1.7).11,34 Related compounds such as the quinoxalinecarbonitrile 1,4-di-oxides are also 
potent and highly selective hypoxia specific pro-drugs. In these compounds, for example 42 
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to 49 (Figure 12), the nitrogen at the 2-position of the benzotriazaine unit in 36 (TPZ) (Figure 
12) is replaced with a C-CN unit. Structural studies which encompassed the relationship 
between chemical structure and biological activity revealed that hypoxic selectivity is 
maintained even when the 3-amino group is replaced by H or NHR, but not when replaced 
with Cl 42. However, soluble analogues such as 43 remain potent and retain their hypoxic 
selectivity. The 2-quinoxalinecarbonitrile-1,4-dioxide 45 was found to be relatively potent 
but not as selective as expected. This low selectivity was thought to be due to the presence 
of the rigid aniline moiety at the 3 position of the quinoxaline ring. The same effect was 
noted in the case of arylpiperazines also.11,35 This type of amine is different from the aliphatic 
(N,N-dialkylamino)alkylamino chains present in compounds 46, 47 and 48 have, in addition 
shown activity against tuberculosis in in-vitro screens, although it is unclear5 as to whether 
their hypoxic selectivity has a part to play in this.11,35 Other compounds such as the 
imidazo(1,2-α)quinoxaline N-oxides 49 are activated by P450 reductase and cytochrome b5 
reductase, and lead to DNA strand cleavage.11,36 
 
Figure 12. Tirapazamine (38) and the quinoxalinecarbonitriles 42-49.  
1.5. Quinone Release Strategies  
It has been shown that quinones can undergo a two electron reduction by hQNO1 to 
form hydroquinones, which are then able to cyclise, leading to the release of a therapeutic 
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agent which is coupled to the quinone through the carboxylic acid group as an ester or an 
amide. The basis of the research by the Murphy group37 follows findings38 by Milstein and 
Cohen, who studied the kinetics of lactonisation for a series of o-hydroxyhydrocinnamic 
acids 50a-d (Table 1). 
 
Scheme 5. Lactonisation of o-hydroxyhydrocinnamic acids.38 
 
Entry Compound  
No. of 
methyl 
groups in 
trimethyl 
lock 
positions  
Relative Rate  
Lactone 
(%)*  
  50 
1 A 0 1 3.6 
2 B 1 6.7 38.3 
3 C 2 4.4 x 103 96.2 
4 D 3 3.4 x 1011 >99.0  
Table 1. Effect of the trimethyl lock on the relative rates of lactonisation 
*At 30 °C, in 20% dioxane, μ = 0.3 M. 
Their research investigated the effect of structural differences on the rate of 
lactonisation of the lactone system 50 (Scheme 5).38 Initially, they found that the addition of 
methyl substituent at the R2 position in 50a to give 50b, (entry 2) resulted in a 6.7 fold 
increase in the rate of lactonisation when compared to the unsubstituted 50a. The addition 
of two methyl substituents at the R1 position 50c, (entry 3) had a marked effect, increasing 
the relative rate of lactonisation by 4.4 x 103 when compared to 50a. A combination of both 
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these modifications, in which both the R1 and R2 positions 50d, (entry 4) have methyl 
substituents, led to a 3.4 x 1011 increase in the relative rate of lactonisation when compared 
to 50a. This system was referred to as the “trimethyl lock”, and its effect on the rate of 
lactonisation became of great interest as a trigger for molecular release in chemistry, biology, 
and pharmacology.39 This effect has its basis in what is variously called the “Thorpe–Ingold 
effect” or the “gem-dimethyl effect” or “angle compression”, which is where increasing the 
size of two substituents on a tetrahedral center leads to enhanced rates of reaction between 
the other two substituents. The effect was first reported by Beesley, Thorpe and Ingold in 
1915 as part of a study of cyclization reactions.37,40 In the case of the lactones 51 (Scheme 
5), this placement of increasing numbers of methyl substituents increases steric crowding, 
and favours a conformation which is favourable towards the formation of the lactones by 
cyclisation, in particular for lactone 51d.38 
In 1989, Carpino et al. studied the cyclisation of esters and amides derived from the 
acid 52 (Scheme 6). They prepared a number of compounds 52a-f, which were then reduced 
with sodium dithionite to give their respective hydroquinone intermediates 53a-f, which then 
underwent cyclisation to give the lactone 26, releasing the molecule “R-H” (Scheme 6).37 
 
Scheme 6. Reduction of trimethyl-locked quinones to 
the respective hydroxyquinone and lactone 26. 
All of these compounds showed fast or relatively fast cyclisation half-lives (t1/2), 
which was thought to be due to the presence of the trimethyl lock. Carpino also suggested 
that if quinones such as 52 were to be used as a drug delivery system (R = drug), the rate of 
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cyclisation could be tailored to give faster or slower release rates by changing the 
substituents.37 
1.5.1. A Redox Activated Drug Delivery System 
The release of a drug entity from the benzoquinone 52 has been represented by 
numerous studies, and forms the basis of this research. Reduction of 52 at the quinone center 
by a reductase such as hNQO1 results in the production of the hydroquinone 53, which then 
undergoes cyclisation to form the lactone 26 and the active drug (Scheme 7).39 
 
Scheme 7. General enzymatic mechanism of benzoquinone drug delivery system. 
Since hNQO1 is overexpressed in hypoxic tumour tissues, it is hoped that the drug 
will be selectively activated in these regions. However, hNQO1 is also present in many 
normal cells, including the kidneys, bone marrow and endothelial cells, as well as stomach 
and bronchial epithelia. This redo benzoquinone drug-delivery system was designed to 
improve the therapeutic index of a given compound, and should not release the drug unless 
the quinone ‘trigger’ is reduced to give the hydroquinone 53. This increase in selectivity 
reduces general toxicity and therefore any side effects associated with chemotherapeutic 
agents.41 Research has also been carried out to develop protease-,42 esterase-43,44 and 
phosphatase-43 activated pro-drugs. However, this thesis will focus on redox-activated 
delivery systems only.  
Although many different functional groups have been investigated, our interest lies 
with mustards and guanidines as the drug substituents, and these will be discussed in the 
following sections.37 
1.6. Nitrogen Mustards 
The “so-called” nitrogen mustards of the general form 54 were first reported in 1942, 
and are analogues of the sulfur mustard gas 55, which was used as a chemical weapon in 
World War I.45 
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Figure 13. Mustards are powerful DNA alkylating agents. 
These mustards are powerful DNA alkylating agents (Scheme 8) and have been 
extensively used in cancer chemotherapy.46 Chlorine is a good leaving group, facilitating 
nucleophilic attack of the nitrogen in the mustard 54, which cyclises to form an aziridinium 
ion 57.37 This strained three membered ring system readily undergoes alkylation, 
preferentially at the N-7 position of guanine 56, to form the monoalkylation adduct 58.37 
Minor alkylations can also occur at other sites such as the N-3 position of adenine.37,47 This 
process is then repeated with the cyclisation of the adduct 58, to form the aziridinium ion 
59, which undergoes alkylation to give the crosslinked DNA 60. These bifunctional adducts 
can generate an interstrand crosslink that is as much as 100 fold more cytotoxic than its 
monofunctional adduct.37 Crosslinking can occur between two complementary strands of 
DNA (interstrand) or on the same strand of DNA (intrastrand) (Figure 19).37  
 
Scheme 8. DNA crosslinking by a nitrogen mustard. 
Interstrand crosslinks are essential for maximal cell killing,37 since they prevent two 
opposing strands in DNA from separating during replication or transcription. The end result 
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is the inhibition of DNA synthesis. There has been found to be a direct correlation between 
interstrand crosslinking and cytotoxicity.48 
The simplest member of the nitrogen mustard family is mechlorethamine (61) 
(Figure 15)47, which was the first clinically useful anti-tumour substance.47 The problem is 
that mechlorethamine 61 reacts rapidly with biological material and water, making it highly 
vesicant (causing severe skin, eye and mucosal pain and irritation) and chemically labile. To 
overcome these problems, the methyl group in 61 has been replaced with an aromatic ring 
(Figure 16). This lowers its reactivity, giving more time for its absorption and distribution 
before DNA alkylation and allows for oral administration. 
 
Figure 14. Mustards cause crosslinking between complimentary strands of DNA.37 
 
Figure 15. The nitrogen mustard mechlorethamine. 
However, the simplest aromatic mustard 62 is insoluble in water. Although its 
carboxylic acid analogue 63 is soluble, it is inactive.37 To overcome this solubility issue a 
considerable amount of research has been carried out, developing more water-soluble 
N-mustards.49,50 It was found that the addition of alkyl spacers gave water-soluble active 
compounds such as chlorambucil 64 and melphalan 27 (Figure 16).37 
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Figure 16. Aromatic nitrogen mustards. 
For over 50 years, chlorambucil 64 has been used in the treatment of chronic 
lympocytic leukemia.51 Melphalan 27 is used in certain types of bone marrow tumours, 
including multiple myeloma,37 and cancers such as ovarian, breast52 and colorectal.37,53 
1.6.1. Strategies to Improve the Biological Potential of Mustards 
 
Figure 17. DNA-affinic molecules which have been linked to mustard residues. 
Mustard compounds have a number of drawbacks for cancer chemotherapy.54 Their 
high reactivity means that they are chemically unstable.54 This lowers their therapeutic 
efficacy, since they react with other cellular components such as proteins, inducing severe 
side effects.55 One strategy has been to design and synthesise DNA-directed alkylating 
agents by linking the N-mustard residue to DNA-affinic molecules such as acridines 
6556,56,57, 9- anilinoacridines 6654,55,57,58 quinolines 6750,59,60 or quinazolines 6850 (Figure 17). 
 
Figure 18. The 9-anilinoacridine N-mustard derivative 69. 
These conjugates exhibit higher cytotoxicity and potency than their corresponding 
untargeted N-mustard derivatives.55 The 9-anilinoacridine derivative 69 (Figure 18) was 
  
22 
 
found to possess potent therapeutic efficacy against human xenografts in vivo, and has the 
capability to induce DNA interstrand crosslinking in tumour cells54,61 
 
Scheme 9. The synthesis and activation of Volpatos mustard.41 
Another strategy to minimise side effects is to prepare N-mustard pro-drugs,37,62–66 
which can be activated selectively at the tumour site by enzymatic hydrolysis. Previous 
researchers67 used the benzoquinone drug delivery system 52 (Scheme 9) to synthesise a 
methyl ester of melphalan with a trimethyl lock. This was attached via an amide linker to 
the quinone, to give the pro-drug 2437,68 and was investigated as a method of increasing the 
oral absorption of the methyl ester melphalan across the intestine. The uptake, accumulation, 
activation and transport of the pro-drug 24 was determined using Caco-2 cell monolayers, 
and results showed potential for improving intestinal drug delivery.67  
 
Figure 19. The methyl ester of melphalan with a trimethyl lock. 
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In 2007 Volpato et al. prepared the pro-drug 71 using the aniline mustard 70 
according to scheme 9. The pro-drug was obtained by reacting 52 with NHS and DCC to 
give the activated ester 52a, which was then reacted with 70 to give the pro-drug 71. The 
aim of their experiment was to show that 71 could be reduced by hNQO1 to release the 
aniline mustard 70. HPLC of the reaction progress showed that 71 was reduced to give the 
unstable hydroquinone, which underwent spontaneous cyclisation to produce the lactone 26 
and the mustard 70. Later chemoselectivity studies found 71 to be selectively toxic to cells 
that overexpress hNQO1.41 
1.7. Tirapazamine 
In 195569 Ambramovitch and Schofield reported the use of the Bamberger triazine 
synthesis to produce benzo-1,2,4-triazines such as 76 (Scheme 10).69 
 
Scheme 10. Bamberger triazine synthesis. 
Inspired by the lack of knowledge about the benzotriazines and by the apparent anti-
malarial activity and potential antibiotic properties of the 1,2,4-benzotriazines and their N-
oxides, Schofield reported the synthesis of further substituted 1,2,4-benzotriazines. Around 
1957 Schofield undertook experiments which involved the oxidation of benzo-1,2,4-
triazines in order to produce the corresponding N-oxide derivatives.70 Schofield found that 
an amino group must be present on the 3 position in order for oxidation to occur. It was also 
found that further oxidation of the N-oxide 77 with peracetic acid gave the di-oxide which 
is now known as tirapazamine (38).70 
 
Figure 20. 3-Amino-1,2,4-benzotriazine-1-oxide 77 and TPZ (38). 
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However, it was not until the mid-1980s, that Brown and Lee discovered that TPZ 
(38) killed cancer cells at extremely low concentrations of oxygen, and that its differential 
selectivity for hypoxic cells over aerobic cells was much larger than that of any other drug 
at the time. They also showed that the concentration of TPZ required under aerobic 
conditions to produce equal cell kills was in the range of 50-300 µM compared to that of 
mitomycin C (20) (page 11), which is in the range of 1-5 µM.34 TPZ (38) appears to be a 
good substrate for a broad range of intercellular reductases that allow for TPZ (38) to 
undergo single electron reductions. This in turn allows for TPZ (38) to be protonated, and to 
produce a neutral radical that is capable of abstracting hydrogen atoms from 
macromolecules, including DNA, where it results in both single and double strand breaks. 
However, under aerobic conditions, oxygen can remove the additional electron from the 
radical, and back-oxidise it to its non-toxic parent molecule TPZ. 
TPZ (38) has since been the studied in numerous clinical trials as a single agent. 
Although TPZ (38) gave good activities within in-vitro studies as a sole agent, poor activities 
were observed when using TPZ (38) as a sole agent in in-vivo studies. This is thought to be 
due to the rapid metabolism of TPZ (38) outside the cell nucleus and poor cell penetration. 
However, in combinations with radiation and cisplatin (78), the reported activities in head 
and neck cancer were encouraging.72  
 
Figure 21. Cisplatin (78). 
Subsequently, a large amount of research to improve the cell penetrative properties 
of TPZ (38) has been conducted.73  
A study74 into the benzotriazine-1,4-dioxide series of TPZ analogues demonstrated 
that neutral non-charged analogues allowed for increased tissue diffusion coefficients, which 
were measured using multicellular layer cultures of analogues with increased lipophilicity. 
In the same study74  an evaluation of a series of 3-aminoalkylamino-benzotriazine-1,4-
dioxides was reported, concluding that substituents on the benzene ring of the analogue can 
be used to predictably tailor the reduction potential. Highest values for hypoxic cytotoxicity 
ratios were achieved by adding electron-donating substituents to the benzene ring. In 
addition, compounds such as 79-83 (Figure 21) demonstrated good cell penetration when 
compared to TPZ, due to an increase in the lipophilic nature of the R group present on the 
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NH2.
75 Denny also found that the removal of hydrogen bond donors at the NH-R 3-position 
could further increase tissue diffusion coefficients, but alkyl substituents such as in 79 raised 
the reduction potentials. This could be countered further by adding electron donating 
substituents onto the benzene ring such as in 80 and 83.73,75 
 
Figure 22. The benzotriazine-1,4-dioxide TPZ analogues reported by Denny.74 
Denny also reported the preparation of forty novel TPZ analogues which all 
contained the 1,2,4-benzotriazine core, with the goal of increasing the knowledge of the 
structure activity relationship (SAR) of these compounds. Various factors were considered, 
relating to modifications of the triazine-ring substituents and their effect on the 1-electron 
reduction potential, the overall cytotoxicity, and any hypoxic selectivity.22 The structures 
reported by Denny in 2008 were novel tricyclic analogues of TPZ (38), with a range of 
structures incorporating cycloalkyl, oxygen- and nitrogen-containing rings which were fused 
in a linear or angular fashion to the benzotriazine core (Figure 23). These compounds also 
contained a range of lipophilic side chains which could be considered neutral and charged at 
physiological pH. The resulting tirapazamine analogues displayed hypoxia-selective 
cytotoxicity in vitro. The compounds containing fused cycloalkyl rings in combination with 
either the 3-aminoalkyl or 3-alkyl substituents, such as in 84 were sufficiently electron–
donating to allow for the one -electron potential to be in an appropriate range for optimal 
hypoxic metabolism. The stronger electronic and polar influence of the “oxa” rings (e.g. 85) 
were more difficult to balance electronically, which often led to poor reductive properties. 
The use of amine-containing substituents (e.g. 86) increased aqueous solubility, but provided 
either unstable analogues or analogues with only modest activity. The lipophilic nature of 
the cycloalkyl rings also increased lipophilicity, and led to increased diffusion coefficients, 
which combined with weakly basic morpholine side chains, gave the best balance of 
solubility and increased diffusion. 
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Figure 23. Fused ring derivatives of tirapazamine (38).73 
Analogues 87-96 (Figure 24) were found to give modest cell kill values with high 
hypoxic cytotoxicity differentials. The analogues all contain solubilising groups that are 
attached via the 3-alkyl substituent or the 7-position of the indane ring. The analogues show 
improved lipophilic properties, and benefit from balanced electron-donating effects derived 
from the fused rings. 
Following this work, studies by Denny in 201276 into multicellular layer culturing of 
CEN209 (97) (Figure 25) demonstrated that it possessed greater diffusion coefficients when 
compared to TPZ (38), indicating greater cell penetrative properties.76 The morpholine 
derivative 97 was also found to show the greatest selectivity and increased cytotoxicity in 
xenograft models when compared to other analogues, due to improved lipophilic properties, 
as well as balanced reduction potentials. In 2012, phase I clinical evaluation started through 
Cantella Therapeutics and Cancer Research UK.77 However, the selectivity and cytotoxicity 
levels were still below that of TPZ (38).  
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Figure 24. Compounds prepared by Denny which showed modest cell kill values and high 
cytotoxicity differentials.22,73,76 
In 2008 the Murphy group started to explore methods of releasing 38 into hypoxic 
cells using pro-drug technology.37 
 
Figure 25. CEN209. 
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1.8. Previous Work by the Murphy Group 
In conjunction with MORVUS technology, research was undertaken with the aim of 
using quinones such as 52 (page 17) an 104 to deliver nitrogen mustards and substituted 
guanidines selectively into hypoxic tumours.37 
1.8.1. Background to the Study  
Previous work37 on the benzoquinone pro-drug delivery system within the Murphy 
research group concentrated primarily on producing the quinone 105. In this analogue of 52 
the geminal methyl groups have been replaced by a benzene ring, giving a modified but still 
conformationally locked backbone. The rationale behind this modification was that by 
replacing the methyl groups with a six-membered aromatic ring, the release rates of various 
drugs could be tailored as desired. The release rates and activities of the pro-drugs derived 
from 105 could then be compared to those of 52.37  
Compound 105 was prepared in 6 steps from commercially available trimethyl 
hydroxyquinone 98 (Scheme 11). 
 
Scheme 11. (i) K2CO3, MEK, MeI, 65 °C, 72 h (ii) 2 % KOH, MeOH, <5 °C, 1 h, 1.6 A (iii) 
CH3CO2H (aq., 2 %) acetone, 0 °C, 25 min then r.t, 1.5 h (iv) 0.6 equiv., 1.5 equiv. n-BuLi, 
THF, -78 °C, 30 min then 0 °C, 1.5 h then -78 °C, 4 h (v) CF3CO2H, (CF3CO)2O, H2SO4, Δ, 4.5 h 
(vi) NBS, aqueous acetonitrile.37 
 Both quinones (50 and 104) were converted into guanidine derivatives. Three 
guanidine derivatives, 106-108, were prepared from 52 via reaction of the guanidine 
derivatives 109-111 with the activated ester 52a. Similarly, three analogous guanidine 
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derivatives 112-114 were prepared from the acid 105 via the activated ester 115 (scheme 
12). 
 
Scheme 12. Guanidine pro-drugs based on quinone acids. 
The previously studied aniline-mustard derivative 71 was also prepared using the 
methodology reported by Volpato,41 and an attempt was also made to prepare the analogous 
phenyl-substituted aniline mustard 116 (scheme 13). However, 117 was formed, in which 
the amine nucleophile has reacted with the imide carbonyl group, causing the succinimide 
to be ring-opened and to become incorporated into the final molecule instead of being 
displaced.37 
I the previous work, the release and cyclisation of 106 and 112 were studied with an 
enzymatic assay. It was found that the “phenyl” locked pro-drug 112 showed potential with 
very similar reaction rates to 106. The cyclisation of 106, occurring at 2.74 µM/min was 
similar to 112, which had a cyclisation rate of 2.26 µM/min.37 
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Scheme 13. Synthesis of mustards 71 and 117. 
 It was also postulated that benzoquinone drug delivery systems could be used to 
deliver the drug TPZ (38), increasing its selectivity and bioavailability. Subsequently, 
attempts were made to couple TPZ (38) to the benzoquinone 52 (scheme 14). Due to the 
poor solubility of TPZ, the reaction required the use of dimethylformamide, and after 72 
hours there was no evidence of reaction. In addition to the poor solubility, the two N-oxide 
groups deactivate the NH2 group of the 3-position, preventing nucleophilic substitution.
37  
  
31 
 
 
Scheme 14. A failed attempt to conjugate tirapazamine to activated ester 52a. 
1.9. Aims  
The primary aim of the first project is to investigate the preparation of a tirapazamine 
containing pro-drugs such as 118. The previous attempts by Martin1 using the NHS ester 
52a failed but changing the reaction conditions, for example by increasing the temperature 
or by varying solvent conditions will be explored. If unsuccessful, other coupling methods 
will be attempted, including EDC and HOBT at a range of temperatures. If a direct amide 
bond cannot be formed methodologies will be explored into the modification of TPZ itself 
to allow for coupling either at the benzotriazine core or on a functionalised linker. Once a 
successful method has been developed, analogues incorporating the newly-developed 
benzoic lock, for example 119, will be prepared from the carboxylic acid 105. The series of 
compounds prepared by Martin1 has not yet been completely evaluated in any biological 
trials. One major stumbling block was the inability to prepare the mustard derivative 116. 
Therefore a new method is required and other coupling methods will be explored. As with 
the preparation of 118, coupling agents such as HOBT will be used as an alternative coupling 
agent to NHS, as we can speculated that the HOBT will be displaced more easily and no 
ring-opening reaction is possible. Once completed, the whole range of compounds, including 
the guanidine derivatives 106 to 108 and 112 to 114, together with the mustards 71 and 116, 
will be submitted to the research group of Professor Roger Phillips at Huddersfield 
University for activity studies (Scheme 15). 
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Scheme 15. Aims of the current study (i) EDC, HOBT or DCC, PFP, THF. 
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2.0 Results and Discussion - Anticancer Pro-drugs 
 
2.1. An Effective Synthesis of the Phenyl Mustard Standard 115 
As mentioned in the introduction, the mustard pro-drug 116 is required in order to 
biologically evaluate the guanidine pro-drugs prepared by Martin37. However, attempts to 
couple the activated phenyl quinone 115 to the aromatic mustard 70 have proven 
unsuccessful, and produced the linked mustard 117 instead (Scheme 16). 
  
Scheme 16.  The unsuccessful coupling of 115 to 70. 
 The plan was to investigate other coupling methods for 105 to the mustard 70.  
The first method to be explored was to react 105 with 70 using EDC and HOBT to activate 
the acid. 
 
Scheme 17. The planned preparation of pro-drug 116 (i) 70, THF, r.t, 48 hrs. 
Before these experiments could be carried out, the preparation of fresh quinone 105 
and mustard 70 was required.  
  
34 
 
The preparation of 105 was carried out according to Martin’s37 method, as shown in 
scheme 18. The first step was the methylation of trimethyl hydroquinone 98, using 
iodomethane with 2-butanone as solvent and with potassium carbonate as a base, to give 99 
as a colourless oil which solidified on standing. The overall yield of the reaction was 65 %, 
which is comparable to the yield reported by Martin. Then dimethoxytrimethyl 
hydroquinone 99 was dissolved in 2% methanolic potassium hydroxide. Using a platinum 
anode and a reticulated carbon cathode, current of 1.0 A was passed through the solution for 
2 h (the power supply which was used by Martin was not available and the delivery of a 
current of 1.6 A not possible) while keeping the temperature below 5 ˚C with an ice bath. 
Within 2 h the solution became brown, and the solvent was removed by rotary evaporation. 
The residue was diluted with water and extracted with diethyl ether. Drying and evaporation 
of the solvent gave 100 as a yellow solid in 87 % yield. The product was used without further 
purification. 
Scheme 18. (i) K2CO3, MEK, MeI, 65 °C, 72 h (ii) 2% KOH, MeOH, <5 °C, 2 h, 1.0 Amp (iii) 
CH3CO2H (aq., 2%) acetone, 0 °C, 25 min then r.t, 1.5 h (iv) 0.6 equiv. N-phenylbenzamide, 0.95 
equiv. n-BuLi, THF, -78 °C, 30 min then 0 °C, 1.5 h then -78 °C, 4 h (v) CF3CO2H, (CF3CO)2O, 
H2SO4, Δ, 4.5 h (vi) 1.36 equiv. NBS, aqueous acetonitrile.37 
Treatment of 100 with chilled acetic acid, followed by aqueous work up with sodium 
hydrogen carbonate, gave 101 as a pale yellow solid with a 91 % yield. Again the product 
was used without further purification. Next the quinone 101 was converted into the lactone 
103. It had been found by Martin37 that residual N-phenylbenzamide 102 was impossible to 
separate from the lactone 103, and interfered with the subsequent rearrangement of 103 to 
104. Hence, 0.93 equivalents of phenylbenzamide were used with respect to the ketone 101 
to ensure that it would all be consumed. n-Butyllithium was added drop-wise to a cooled (-
78 ˚C) solution of N-phenylbenzamide in anhydrous THF, and the resulting mixture was 
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stirred at -78 ˚C for 30 min and then at 0 ˚C for 1 h. This solution was then cooled (-78 ˚C) 
before adding a solution of monoketal 101, and the reaction was allowed to reach r.t. 
overnight. An aqueous work up was carried out, involving the acidification of the reaction 
mixture by washing with 3M hydrochloric acid. This hydrolysed the remaining ketal-
protecting group and effected lactonisation. Purification by dissolving in hot diethyl ether 
and precipitation with methanol gave the lactone 103 as a white solid with a yield of 60 %. 
Lactone 103 was then rearranged by heating at reflux with a combination of trifluoroacetic 
acid, trifluoroacetic anhydride and sulfuric acid, to give 104. After work up, the crude 
product was recrystallized from dichloromethane and hexane to give lactone 104 as white 
crystals in a 99 % yield. Finally, a ring opening of 104 mediated by NBS in aqueous 
acetonitrile was carried out to give the quinone acid 105 in 81 % yield as a yellow oil after 
column chromatography. The yield compares well to the 77 % yield reported by Martin. 
It is worth noting that on scale –up, this reaction can be problematic, as appreciable 
amounts of the by-product 120 can form, which arises via an intramolecular 
bromolactonisation of the quinone acid. 
In all cases, the compounds 99-105 gave identical spectroscopic data to the 
previously prepared compounds.  
 
Scheme 19. By-product from the oxidation of 104 (i) 1.36 equiv. NBS, aqueous MeCN. 
Quantities of the mustard 70 were also required. The first step was prepared by the 
method provided by the partner company Morvus (Scheme 20), after which the preparation 
was continued according to the method reported by Martin.37  
The synthesis started with the reaction of 2,2-iminoethanol 122 with 
4-fluoro-1-nitrobenzene 121 in a sealed tube at 130 ˚C for 17 h, which gave a 73% yield of 
123 as yellow crystals, after recrystallization from ethyl acetate. Then the diol 123 was 
heated at reflux with thionyl chloride in dichloromethane and pyridine for 1h. After work 
up, the crude product was purified by column chromatography, to yield 124 as yellow 
crystals with a yield of 46% .37 Analysis of the 1H NMR data for 124 showed two triplets at 
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H 3.69 (4H, t, J = 6.8 Hz, 2 x CH2) and 3.87 (4H, t, J = 6.8 Hz, 2 x CH2). The product had 
a melting point of 91–94 ˚ C, which is in accordance with the literature value (lit. 95-96  °C).37 
However, the sample appeared to be contaminated with two lower running spots, and it was 
not possible to separate these by-products even on repeated chromatography. Martin had 
reported two by-products- the mono-chlorinated product 125 and the dioxathiazocane 2-
oxide 12637 (Figure 26). 
 
Scheme 20. Preparation of mustard 70. (i) Sealed tube 130 ˚C, 17 h (ii) pyridine, SOCl2, CH2Cl2, 
reflux (iii) 5% Pd/C, H2. 
 
Figure 26. Likely impurities in the mustard 70.37 
As these impurities did not seem to cause any problems for Martin, it was decided 
that the synthesis would be continued without further purification of 124. Hydrogenation of 
the nitro group with 5 % palladium on charcoal was carried out, followed by filtration 
through Celite©, and washing with methanol to ensure complete product recovery. 
Chromatography of the crude brown material gave an inseparable mixture of products, which 
was predominately (estimated 90%) the desired product 70 (by 1H NMR analysis), with a 
yield of 45 % compared to the yield of 68 % reported by Martin. Analysis by 1H NMR 
spectroscopy showed the appearance of a broad singlet at around δ 5.13, with an integral of 
2, indicating the formation of the aniline NH2. 
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Due to the poor quality of 70, a cleaner synthetic method was desired. It was decided 
that the thionyl chloride step was the initial cause of the presence of inseparable by-products. 
Thionyl chloride is highly reactive, and generates HCl as it reacts. In 2011, Wang78 reported 
a two stage chlorination of 123, where the diol is firstly mesylated then treated with sodium 
chloride to give 124 (Scheme 21). 
 
Scheme 21. (i) MeSO2Cl, NEt3 (ii) DMF, NaCl, reflux (iii) 5% Pd/C, H2. 
Thus, diol 123 was reacted with methane sulfonyl chloride in ethyl acetate with 
triethylamine to remove the HCl formed in the reaction. Filtration of the reaction product to 
remove precipitated triethylamine hydrochloride, followed by evaporation and 
recrystallization using hot ethanol with ethyl acetate, gave the product 127 in 68 % yield 
(Wang 89 %).78 Analysis by 1H NMR spectroscopy showed the disappearance of the 
resonance for the alcohol proton at H 3.28 (2H, b s, 2 x OH) ppm and the appearance of a 
singlet at 2.98 (6H, s, 2 x Me) ppm for the mesylate.78 The dimesylate 127 was then dissolved 
in anhydrous DMF with 3.3 equivalents of sodium chloride and heated at reflux for 15 
minutes. After work up and chromatography, 124 was obtained as a yellow crystalline solid, 
with a yield of 49 %. Comparison of the data with the previously prepared samples indicated 
that the impurities previously observed were not present in the new material. The overall 
yield of 36 % over two steps is lower than the 46 % yield from the thionyl chloride route, 
however, improved product purity is desirable for the continued synthesis. Finally 
hydrogenation of 124, using the previously employed method followed by column 
chromatography, gave pure mustard 70 in a 65 % yield.  
In order to circumvent the problems associated with the ring-opening of the 
succinimide ring in the 37, the in situ preparation of the HOBT ester 128 was carried out 
(scheme 22). HOBT and EDCI were added to the acid 105 in THF. After 3 h, the mustard 
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70 was added, and the reaction was stirred for an additional 48 hours. Purification by flash 
chromatography gave 116 in 33 % yield as a brown gum. Analysis of 116 by 13C NMR 
spectroscopy showed the required 26 carbons. Similarly, analysis by 1H NMR spectroscopy 
showed a triplet at δH 3.61 (4H, t, J = 6.5 Hz, 2 x CH2) ppm and a triplet at 3.70 (4H, t, J = 
6.5 Hz, 2 x CH2) ppm, corresponding to methylene signals of the mustard groups. Signals at 
δH 6.67 (2H, d, J = 8.6 Hz, CH) and 7.32 (2H, d, J = 8.6 Hz, 2 x CH) ppm were indicative 
of the para-disubstituted aromatic ring, whilst those at δH 7.16 (1H, dd, J = 1.2, 7.6 Hz, CH), 
, 7.47-7.56 (2H, m, 2 x CH, NH), and 7.70 (1H, b d, J = 7.7 Hz, CH) ppm corresponded to 
those of the phenyl locking ring. Final confirmation of the structure of 116 was obtained by 
high resolution mass spectrometry, with a mass of 485.1387 Da being observed for the 
[M+H+] ion. This is in good agreement with the required mass of 485.1399. 
 
Scheme 22. Synthesis of the phenyl mustard pro-drug 116. 
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2.2. Tirapazamine Based Pro-drugs  
 
As previously noted, initial attempts at the preparation of the pro-drug 118, in which 
tirapazamine (38) has been coupled to the pro-drug quinone system via the activated ester 
52a, proved unsuccessful37 (Scheme 23). As suggested by Martin, there appear to be two 
possible reasons for this. These are firstly that the presence of the two N-oxy groups may 
deactivate the NH2 on the 3-position towards nucleophilic substitution in the conjugation 
step, and secondly the poor solubility of tirapazamine 1 under the reaction conditions. 
Because of this, it was decided that these hypotheses should be investigated in the hope of 
developing a new synthetic strategy for 118. 
 
 
Scheme 23. (i) DMF, r.t. 118, 0 %.37The quinone acid 52 was prepared from trimethyl-
1,4-dihydroxyquinone (98) via a literature method (scheme 24).41 The first step was the 
reaction of trimethyl-1,4-dihydroxyquinone (98) with dimethylacrylate (129) in 
methanesulfonic acid, to give a brown semi-solid residue. Repeated recrystallisation from 
chloroform/petroleum ether gave the lactone 26 as a purple/gray solid in a yield of 88 %.41 
The lactone 26 was then converted into the quinone acid 52 using NBS in aqueous 
acetonitrile. After extraction with diethyl ether, the resulting orange/red solid was 
recrystallised from ethyl acetate, to give the quinone 52 as a bright yellow solid with a yield 
of 99 %.41 The activated ester 52a was then prepared by reacting the quinone with NHS and 
DCC in anhydrous THF. The resulting mixture was filtered repeatedly to remove 
precipitated DCU. Evaporation of the solvent gave a pale orange solid, which was 
recrystallised from ethyl acetate to give an amorphous solid 52a. This material still contained 
DCU, and was used without further purification.54 In all cases the compounds 98, 26, 52 and 
52a were found to have identical spectroscopic data to that reported in the literature (Scheme 
24).54  
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Scheme 24. (i) CH3SO3H, 3h, 70 ˚C; 88 %. (ii) NBS, MeCN, 99 %. (iii) DCC, NHS, THF, 0 ˚C.  
With the activated ester 52a in hand, attempts were made to prepare the pro-drug 118 
by coupling with tirapazamine (38). In the first attempt, the activated ester was stirred with 
117 in anhydrous DMF in the dark at varying temperatures of 40-80 ˚C. The reactions were 
checked by TLC on a regular basis, but no evidence of reaction was observed, as the starting 
ester 52a was still present and no other products were apparent. On work up, analysis of the 
crude material by NMR spectroscopy gave no evidence for formation of the amide 118, and 
only the parent acid 52 was isolated on purification. This is thought to have arisen from 
hydrolysis of 52a, but the possibility cannot be discounted that it might have arisen from the 
decomposition of 118.  
 
Scheme 25.  DMF, 40-80 ˚C. 
 
As was previously suggested, the NH2 group on the 2-position is deactivated due to 
the two N-oxide groups of the triazine core of 38, and as a result could be less nucleophilic. 
An alternative explanation might be that the product is unstable, and the product 118 
undergoes hydrolysis on work up and on silica during analysis by TLC.  
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Scheme 26. (i) DCC, HOBT, DMF, r.t., 12h (ii) 38, DMF, r.t. 
 
In order to investigate these theories, alternative coupling methods were explored. 
Firstly the NHS was substituted for HOBT. The HOBT ester of 52 was prepared by stirring 
the acid with DCC and HOBT in dry DMF for 12 h (scheme 26). The activated ester was not 
isolated, but on completion of the reaction, which was monitored by TLC, tirapazamine (38) 
was added dissolved in further DMF. This reaction proved to be unsuccessful, as evidenced 
by both TLC and NMR spectroscopy of the products. The reaction was repeated at 
temperatures of 40, 60 and 80 ˚C over 12-48 hours, and again no evidence for the formation 
of 118 was observed (Scheme 26). 
The coupling was also attempted using a mixed anhydride (Scheme 27), and the 
carboxylic acid 52 was converted into the carbonic acid anhydride 131 by reaction with 
isopropyl chloroformate in the presence of N-methyl piperidine. Once full consumption of 
52 had been observed via analysis by TLC, the anhydride 131 was stirred with tirapazamine 
(38) in anhydrous DMF at -15 ˚C and allowed to warm to r.t. overnight. Again, analysis by 
TLC indicated that no reaction had occurred, and the desired product 118 was not apparent 
from the analysis of the NMR spectroscopy data of the crude reaction product. 
 
Scheme 27. (i) iso-Propylchloroformate, N-methyl piperidine, DMF, 0˚C. 
The final attempt was carried out according to scheme 28, where the quinone acid 
was converted into the acid chloride 132 by heating under reflux with neat thionyl chloride 
for 30 minutes. Once the reaction was complete, excess thionyl chloride was removed under 
vacuum, and a solution of tirapazamine (38) in anhydrous DMF was added. The reaction 
was stirred at 0 ˚C for 1 hour, then at r.t. overnight. Again after work up, TLC analysis and 
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the crude NMR spectroscopy data indicated that the desired product 118 had not been 
formed. 
 
Scheme 28. Attempted acid chloride coupling of 52 to TPZ (38). 
 
 As this work was unsuccessful, it was decided that attempts would be made to couple 
the acid 52 to the N-oxide 3-amino-1,2,4-benzotriazine-1-oxide (77), to give the analogous 
structure 133 (Scheme 28). The use of 77 was considered to be useful as a pro-drug for 
several reasons. Firstly 77, which was found during biological trials and might in itself have 
useful activity, is a known metabolite of tirapazamine (38).80 Secondly it might be possible 
to convert 133 into 118 by chemical oxidation, either in situ or indeed in vivo. In addition, a 
practical consideration is that 77might show improved solubility over tirapazamine (38), 
allowing a wider range of solvents to be used in the coupling reactions. Also the lower 
oxidation level of 77 might lead to the amine at position 3- having a greater nucleophilicity 
than in 38. 
 
Scheme 29. Proposed preparation of 118 via 133. 
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The required triazine 77 was prepared via the heterocyclisation of 
2-aminonitrobenzene (134) and cyanamide (135), using a procedure described by Mason and 
Tenant which  afforded the desired product in a yield of 86 % (Scheme 30).81 
 
 
Scheme 30. (i) 100 ˚C then conc. HCl at 100 ˚C followed by 16 M NaOH at 100 ˚C, 86 %. 
 
The triazine 77 was found to be much more soluble at r.t. than TPZ (38) in a range 
of solvents, including pyridine and THF as well as DMF. With 77 in hand, an attempt was 
made to react it with the activated ester 52a in anhydrous DMF, but the product 133 was not 
formed, as evidenced by TLC and the NMR spectroscopy data of the crude reaction product.  
The preparation of 133 was also attempted by using the methods investigated in the 
coupling of acid 52 to TPZ (38). Unfortunately, none of these methods appeared to give any 
evidence for the formation of 133. 
 
Scheme 31. Attempts to couple 52a with 77 were unsuccessful. 
 
Similar couplings with unoxidised triazine 136 were next attempted. This,  again, is 
a known metabolite of TPZ (38) found to be formed in biological studies, and might have 
activity in itself.81 Again the reason behind this was that it was hoped that without the oxide 
groups present in TPZ, the amino group would show increased nucleophilicity and higher 
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solubility. An attempt was made to prepare 136 via a literature method that reported the 
reduction of 77 with sodium dithionite (Na2S2O4)(Scheme 32).
80 
 
Scheme 32. (i) Na2S2O4, EtOH, H2O, reflux, 67 %.80 
In the first attempt, 77 was dissolved in aqueous ethanol, along with 5 equivalents of 
sodium hydrosulfite, before heating at reflux for 1 hour, as described by Boyd80. On this 
occasion the desired product was not formed, with 86 % of the starting material recovered. 
 Another research group had prepared 13481 by adding sodium hydrosulfite 
portion-wise over 1 h or until 77 had disappeared by TLC. This method was also failed to 
produce 136, again with most of the starting material being recovered. It is known that 
heating sodium dithionite in aqueous conditions in the presence of dissolved oxygen leads 
to its decomposition to sodium bisulfate and sodium bisulfite.  
Therefore a third reaction was carried out, where a solution of 77 in aqueous ethanol 
was extensively degassed by bubbling argon through the solution, and the reaction was 
performed under a positive argon atmosphere. The solution was heated to reflux, and 
portions of dithionite (each 2 eqv.) were added every 30 minutes. After 2 additions there was 
no indication of the formation of the desired product, with a 91 % recovery of the starting 
material. 
The synthesis of 1,2,4-triazine systems such as 138 by the reaction of nitroaromatics 
with guanidine hydrochloride and lithium t-butoxide has been reported (Scheme 33).73  
 
  
Scheme 33. (i) Guanidine hydrochloride, THF, LiH, t-butanol (cat.), 60 ˚C.82 
  
Scheme 34. (i) Guanidine hydrochloride, DMSO, LiH, t-butanol (cat.), 100 ˚C. 
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Thus, attempts were made to produce 136 from nitrobenzene (139) using this 
method, but no product was isolated. It was assumed that nitrobenzene was less reactive 
towards nucleophilic substitution than 137 due to the absence of the electron-withdrawing 
fluorine substituent. Therefore the reaction solvent was changed from THF to DMSO, 
allowing the reaction to be heated at a higher temperature, and on repeating this reaction, 
TLC indicated the formation of a new spot, indicating the possible formation of 136. 
However, after an extractive work up, no product was obtained as evidenced by NMR 
spectroscopy. It was observed that during work up the aqueous phase became yellow in 
colour, which might suggest that the product was being transferred to the aqueous phase. 
The literature57 preparation of 138 suggested that the addition of the crude reaction mixture 
to saturated ammonium sulfate would result in the precipitation of the product. In practice 
the addition of the reaction mixture to 30 mL of ammonium sulfate solution caused a lumpy 
black precipitate to form, from which no product was obtained.82 
Next, the reaction conditions were modified by using potassium t-butoxide in 
anhydrous THF, instead of lithium hydride (which required an aqueous work up to 
decompose excess reagent). On completion, the crude residue was purified by column 
chromatography, which gave the desired product 136 in a low yield (~2 %), while the 
N-oxide 77 was formed in 48% yield. Unfortunately, both products co-eluted with a brown 
by-product which was inseparable even on repeated column chromatography. It was 
postulated that the red colour of the reaction is formed as a result of the basic nature of the 
reaction conditions, and it was thought that the crude reaction mixture could be neutralised 
by quenching with saturated ammonium hydrochloride solution. However, as mentioned 
earlier, aqueous work ups were problematic as the product appeared to be soluble in the 
aqueous phase. To counter this issue, saturated ammonium hydrochloride solution was added 
dropwise until the reaction mixture was neutral, and excess water was then removed by 
drying with magnesium sulfate followed by filtration washing with copious amounts of 
dichloromethane. These measures proved successful giving 136 in 30 % yield after 
chromatography, together with the N-oxide 77 in 52 % yield. The solubility of 136 in a range 
of solvents including tetrahydrofuran and ethyl acetate was much improved compared to 77 
and TPZ (38). 
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Scheme 35. (i) t-BuOK, guanidine hydrochloride, THF, 60 ˚C, 12 h. 
 
Attempts were made to form the quinone-conjugated derivative 140 by reacting 
triazine 136 with the activated ester 52a (scheme 36). However, this reaction was 
unsuccessful as evidenced by TLC and NMR spectroscopy of the crude reaction mixture. 
The preparation of 140 was also attempted from acid 52 and triazine 136 using all the 
methods investigated for the coupling of acid 52 to TPZ (38). The unchanged starting 
materials were identified in each case with no evidence of the formation of the coupling 
product 140. 
 
Scheme 36. (i) DMF, r.t., 48h (ii) mixed anhydride, HOBT activation. 
At this stage of the research, attempts had been made to couple tirapazamine (38) 
and its deoxy-analogues 77 and 136 to the quinone acid 52.  However, all of these attempts 
had failed. It is speculated that the amine present on the 3-position of the heterocycle is not 
nucleophilic enough to mediate this coupling. As this methodology had failed, an alternative 
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strategy for the incorporation of the TPZ moiety into a pro-drug delivery system was 
required.  
2.3. Preparation of N-alkylated Tirapazamine Derivatives  
The two main problems associated with the incorporation of tirapazamine (38) and 
its analogues into the quinone pro-drug delivery system were perceived to be low solubility 
of the reactants and poor nucleophilicity of the amino group. It was postulated that the 
addition of an alkyl chain to the amino group could help to improve solubility and might 
possibly improve the nucleophilic nature of the amino function.22,73 It is noteworthy that no 
simple N-alkyl TPZ analogues have been reported in the literature, although in 1959 Mueller 
reported the synthesis of the triazine 145 from 77 in 4 steps. No biological activity data has 
been reported for this compound (Scheme 37).83  
 
Scheme 37. (i) H2SO4, NaNO3, (ii) POCl3, (iii) ethylene glycol, DME, reflux, (iv) NH4Cl, Zn83. 
 
Therefore a test reaction was carried out in which nitrobenzene (139) was reacted 
with 1-octylguanidine hemisulfate (146) and t-BuOK in anhydrous THF for 20 hours. On 
completion, the reaction products were quenched with water and extracted with chloroform, 
to give 147 as a yellow solid in 30% yield after column chromatography. Analysis by NMR 
spectroscopy confirmed the structure of 147, with the 13C NMR data showing the required 
15 carbons and the presence of a characteristic NH signal at 6.00 ppm in the 1H NMR 
spectrum. Final confirmation of the structure of 147 was given by high resolution mass 
spectroscopy, with a mass of 259.1917 being observed for [M+H+], which is in agreement 
with the required mass. The alkylated derivative 147 was found to be soluble in a wide range 
of solvents including diethyl ether, THF, ethyl acetate and dichloromethane. 
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Scheme 38. (i) t-BuOK, PhNO2, THF, 65 ˚C, 30 %. 
Several attempts were made to couple the alkylated analogue 147 with the quinone 
52 to produce the pro-drug 148 (Scheme 39).  
In the first attempt the analogue 147 was stirred in anhydrous THF with the activated 
ester 52a. Analysis by TLC showed 52a to be consumed and new spots had formed. 
However, isolation of the new spots revealed them to be the starting quinone 52, which is a 
hydrolysis product of 52a and the activated quinone 50a itself. Multiple attempts using these 
reagents at a range of temperatures from ambient to 60 ˚C also proved unsuccessful, with no 
evidence for the formation of the desired product. Similar attempts at the coupling of 147 
with the previously-employed mixed anhydride 131 in the presence of methylpiperidine 
were also unsuccessful (Scheme 39).  
 
Scheme 39. (i) THF, r.t.-60 ˚C, 0%. (ii) Isopropyl chloroformate, NEt3, THF, -5 ˚C (iii) 147, MeCN, 
r.t., 16 hrs.  
There are two possible explanations as to why this reaction failed. Firstly, the octyl 
chain on the 3-position might make the amine too bulky and thus prevent the coupling 
occurring, and secondly the addition of the alkyl group might not have had an appreciable 
activating effect, leaving the system largely unreactive. 
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Although this approach proved unsuccessful as a method for direct conjugation at 
the three position, the preparation of 147 offered the possibility of incorporating a 
functionalised alkyl chain in which a pendant alcohol group is present. This could allow for 
esterification with the acid 52 to give a candidate pro-drug. For example, the reaction of 
nitrobenzene (139) with the guanidine alcohol 149 would give the analogue 150 which could 
then be linked to the quinone 52 via an ester bond to give the pro-drug 151 (Scheme 40). 
 
 
Scheme 40. Planned synthesis of 151 (i) t-BuOK, THF, 60 ˚C. (ii) HOBT, DMAP, THF,  
 
r.t.The desired guanidine 149 was prepared using a method reported by Nowak, 
which was by the reaction of 3-amino propan-1-ol (153) with 1H-pyrazole-1-
carboximidamide hydrochloride (152) (scheme 41).84 The reaction requires the presence of 
a mild base, and initially triethylamine was used and the reaction was carried out in DMF. It 
is possible to carry out the reaction in ethanol but reaction times are longer and the respective 
yields are lower.84 Due to the potentially very hygroscopic nature of the product, it was 
decided that an aqueous work up was not possible. Therefore on completion, the reaction 
products were cooled to r.t. and diethyl ether was added, which precipitated an oil. Analysis 
by NMR spectroscopy indicated that the product 149 had been formed, as evidenced by a 
signal at 159.7 ppm in the carbon spectrum corresponding to the guanidinium carbon. 
However, analysis by NMR spectroscopy also indicated that the product was contaminated 
by DMF and triethylamine hydrochloride, which was thought to have precipitated during the 
reaction. Attempts to remove these contaminants by trituration with further diethyl ether 
proved unsuccessful.  
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The reaction was repeated with DIPEA instead of triethylamine, and in this case the 
resulting solution was a clear golden yellow colour and no precipitate was formed. The 
solution was cooled and diluted with diethyl ether and the resulting oil was stirred 
mechanically with several portions of diethyl ether until 1H NMR spectroscopy indicated the 
removal of all traces of DMF, giving 149 as a viscous oil which was golden in colour. 
Compound 149 was used without further purification (Scheme 41). 
 
Scheme 41. (i) DIPEA, DMF, 60 ˚C. 
 
Analysis of 149 by NMR spectroscopy confirmed the structure, with the 13C data 
indicating the required 4 carbons and a signal at 158.9 ppm confirming the presence of a 
guanidinium species. The 1H NMR spectrum gave an apparent pentet at H 1.75 (2H, J  =  6.3 
Hz) ppm and two triplets at H 3.26 (2H, J = 6.7 Hz) and H 3.61 (2H, J = 6.0 Hz), confirming 
the presence of the alkyl chain. The structure of 149 was ultimately confirmed by high 
resolution mass spectrometry, with a mass of 118.0975 Da being observed for the [M+H+], 
which is in agreement with the required mass of the guanidinium ion.  
With 149 in hand, reaction with nitrobenzene 139 was attempted. However, 
guanidine 149 was found to be extremely difficult to dissolve in most solvents, and due to 
the possible instability of DMF under highly basic conditions, the only suitable solvent at 
this stage appeared to be DMSO.  
In the first attempt, nitrobenzene (139) was dissolved in anhydrous DMSO in the 
presence of t-BuOK before adding 149 dissolved in further DMSO. The reaction, which was 
red in colour, was heated at 60 ˚C overnight, and after an extractive work up no product was 
obtained. Analysis of the aqueous phase by TLC showed that several yellow compounds 
were present, suggesting that 150 was more soluble in water than in dichloromethane. Other 
extraction solvents were explored, including ethyl acetate, but no encouraging products were 
collected.  
In an attempt to avoid this aqueous solubility, the reaction was repeated in THF. 
Nitrobenzene (139) and t-BuOK were stirred together in THF to produce a red solution. This 
was then added via cannula to the guanidine 149, and the mixture was heated at reflux 
overnight. It was observed that the poorly soluble 149 had completely dissolved within an 
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hour of heating under reflux (scheme 42). Once the nitrobenzene (139) had been fully 
consumed (as indicated by TLC), the solution was carefully neutralised by adding just 
enough saturated ammonium chloride solution. The THF was then removed by rotary 
evaporation and the residue was dissolved in methanol before being filtered and dried. 
Analysis by NMR spectroscopy and mass spectrometry indicated that the desired compound 
150 had not been formed. 
 
Scheme 42. (i) t-BuOK, anhydrous THF, 60 ˚C. 
 
It was postulated that unprotected alcohol might be interfering with the reaction, and 
in an attempt to address this it was decided that the alcohol should be protected. Silyl 
protection was chosen due to the ease of its installation and removal, as well as its stability 
under highly basic conditions. Thus a new synthetic route was put forward, in which the 
protected guanidine 154 would be prepared before reacting with nitrobenzene (139). This 
would give 155, which after deprotection would give the target compound 150 (Scheme 43). 
  
Scheme 43. Planned synthesis of 150 via 155 (i) t-BuOK, THF, 60 ˚C. (ii) TBAF.  
The amine 156 was prepared by the reaction of 3-amino-1-propanol (153) with 
TBSCl and imidazole in dichloromethane, giving the amine in 75 % yield. The next stage 
was the guanylation of 156 using 152. It was realised that the silyl group would prevent the 
precipitation of 154 from DMF using diethyl ether. In order to overcome this obstacle, the 
reaction was carried out in ethanol. On work up, the ethanol was removed by rotary 
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evaporation to give a white solid, which on trituration with diethyl ether gave the previously- 
prepared unprotected guanidine 149, and not the desired product 154. 
 
Scheme 44. Attempted synthesis of protected guanidine 154. (i) CH2Cl2, imidazole, TBSCl, 0 ˚C 
(ii) DIPEA, ethanol, 65 ˚C.   
It is likely that the silyl group was hydrolysed, either during the reaction or on 
standing. Some evidence exists for the hydrolysis of silyl protecting groups by guanidinium 
residues via anchimeric assistance.85 This involves a hydrogen bonding interaction (157) 
between the lone pair of the oxygen atom and the NH group of the guanidinium group, 
increasing the susceptibility to nucleophilic attack and thus hydrolysis (Scheme 45). At this 
point, this route was abandoned. 
  
Scheme 45. Hydrogen bonding between the NH and the OTBS may cause the silyl group to be 
more susceptible to nucleophilic attack. 
2.4. The Direct Alkylation Approach 
Even though the amino group wasn’t sufficiently nucleophilic, Novellino86 reported the 
alkylation of a similar heterocycle 158 to give 160 in 54 % yield (Scheme 46). 
Alkylation at the 3-position of 77 might allow for the preparation of analogues which allow 
for the coupling to the quinone 52 via ester or amide bonds. 
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Scheme 46. K2CO3, KI (cat.), acetonitrile, reflux, 20 h.86 
The alkylation of 77 with 1.5 equivalents 1-iodoheptane was attempted under,86 using 
potassium carbonate and molecular sieves under reflux for 24 h (scheme 47, table entry 1). 
 
 Solvent K2CO3 eqv. 
Iodoheptane 
eqv. 
temperature 
˚C Time Yield 
1 Acetonitrile 1.5 1.5 82 24 h 2% 
2 Acetonitrile 1.5 1.5 82 7 d 3% 
3 Acetonitrile 1.5 1.5 130 24 h 11% 
4 DMF 1.5 1.5 135 24 h 30% 
5 DMF 1.5 1.5 125 24 h 27% 
6 DMF 1.5 1.5 120 24 h 24% 
7 DMF 1 1.5 120 24 h 25% 
8 DMF 0.5 1.5 120 24 h 9% 
9 Dioxane 1.5 1.5 120 24 h 0%  
10 DMF 1.5 1.2 120 24 h 22% 
11 DMF 1.5 1 120 24 h 18% 
Scheme 47. (i) Iodoheptane, K2CO3, reflux.  
The theory is that this approach may be advantageous over the method described in 
section 2.3, in which an alkyl guanidine was reacted with nitrobenzene (139). Under these 
conditions 161 was formed, but in a very low yield of 2 %. Increasing the reaction time did 
not improve the yield (entry 2). The reason for the low yield was thought to be due to the 
apparent lack of reactivity of the NH2 at the 3-position of 77.  Therefore, a range of different 
solvents and reaction conditions were trialled to allow the reaction to be carried out at a 
higher temperature.  
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The first of these reactions involved heating at reflux in acetonitrile in a Carius tube 
at 100 ˚C for 24 h, which resulted in an improved yield of 11 % (entry 3). It was found that 
the yield of 161 was increased to 30 % when changing the solvent to DMF and heating at 
135 °C for 24 h (entry 4). However, it was apparent that at this temperature other reaction 
products were being produced and unfortunately it was impossible to separate these products 
from the desired product 161, even with repeated chromatography.  
In order to counter this problem, the reaction temperature was lowered to 125 ˚C, in 
the hope that this would be high enough for the reaction to occur without the formation of 
the contaminants (entry 5). This gave the required product in 27 % yield, but again the 
product was contaminated with the unknown impurity. The reaction was repeated but at the 
lower temperature of 120 ˚ C, which gave pure 161 in 24 % yield after chromatography (entry 
6).  
Other attempts at improving the yield included lowering the amount of potassium 
carbonate, which seemed to have a marginal effect. The use of 0.5 equivalents of potassium 
carbonate decreased the yield to 9% (entries 7 and 8). The use of dioxane as a solvent was 
investigated but was unsuccessful (entry 9). Further reactions explored the use of less 
equivalents of iodoheptane, due to speculation that the excess of reagent might be leading to 
a doubly alkylated product. A reduction to 1.2 equivalents of iodoheptane and 1.5 
equivalents of potassium carbonate in DMF at 120 ˚C gave a similar yield of 22 % (entry 
10), where the use of 1.0 equivalent of iodoheptane gave a reduced yield of 18 % (entry 11). 
In all of these reactions, no evidence for a double alkylated product was observed.Analysis 
of 161 by NMR spectroscopy confirmed the structure, with the 13C data indicating the 
required 14 carbons. The 1H NMR spectrum indicated the presence of a triplet at H 0.81 
(3H, t, J = 6.6 Hz) ppm for the CH3 group, a multiplet at H 1.15-1.36 (8H, m, 4 x CH2) ppm, 
an apparent pentet at H 1.59 (2H, pentet, J = 7.2 Hz) and an apparent quartet at H 3.44 (2H, 
q, J = 6.9 Hz) ppm confirming the presence of the alkyl chain. A characteristic broad singlet 
at H 5.31 ppm was diagnostic for the presence of the NH proton on the ring system. 
Aromatic protons were also observed at H 7.20 (1H, ddd, J  = 1.1, 7.2, 8.3 Hz), 7.51 (1H, 
ddd, 1.1, 7.2, 8.3 Hz) and 8.25 (1H, bd, J = 8 Hz) ppm. Analysis of the IR spectrum gave a 
band at 3294 cm-1 corresponding to the N-H stretch. Final confirmation of the structure of 
161 was obtained from high resolution mass spectrometry, with a mass of 261.1711 being 
observed for the [M+H+], which is in good agreement with the required mass of 261.1710. 
It was also found that slow evaporation of a dichloromethane solution of 161 gave needle-
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like crystals which were suitable for X-ray analysis. This confirmed both the structure and 
the point of alkylation on the ring system. (Figure 27) 
 
Figure 27. Crystal structure of triazine 161. 
 
Scheme 48. Attempted Synthesis of 163 i) 77, DMF, K2CO3, KI, 3Å molecular sieves, 120 ˚C, 
24-48h. 
When compared to the nitrobenzene approach described in section 2.3., this 
methodology offers the potential to quickly produce a large catalogue of alkylated TPZ 
derivatives, as halo alkanes are more readily available and easier to prepare. It was also 
hoped that this method would allow for the preparation of functionalised derivative such as 
150, which would allow coupling to the quinone 52.  
Since pro-drug esters are more suitable, the use of a long chain bromoalcohol might 
be advantageous. The distance between the two linking functionalities might prevent the 
possible counterproductive anchimeric assistance. Thus 9-bromo-1-nonanol (162) was 
employed as the alkylating agent with 77, under the previously employed conditions (scheme 
49). 162 and 77 were dissolved in DMF with potassium carbonate and molecular sieves, 
together with potassium iodide as a catalyst, to effect an in situ Finkelstein modification, as 
suggested by Novellino86 The reaction was heated at 120 ˚C for 24 h. This reaction gave no 
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evidence for the formation of the desired product 163. A repeat of the reaction for 48 h also 
gave no product. The starting triazine 77 was recovered unchanged in each case.  
 
Scheme 49. (i) 48 % aq. HBr, PhMe, reflux, 16 h (ii) NaH, THF 0 ˚C, 1 h, then BnBr, reflux 16 h. 
 
The major difference between using iodoheptane and 9-bromo-1-nonanol is the 
presence of an unprotected alcohol, which appears to prevent the reaction from proceeding. 
As a result, the benzyl group was chosen as a robust protecting group. Unfortunately, by this 
point in the research the donated sample of 9-bromo-1-nonanol (162) had been used and no 
more was available. A large feedstock of decane-1,10-diol (164) was found and used instead 
for the next steps of this particular investigation. The desired protected compound 166 was 
prepared according to Huws87 (Scheme 49). Firstly decane-1,10-diol 164 was heated under 
reflux in 48 % aqueous HBr in toluene, and after column chromatography the pure 
bromoalcohol 165 was obtained in 32 % yield.87 Analytical data for 165 was in agreement 
with that reported by Huws.87 Alcohol 165 was then treated with sodium hydride and benzyl 
bromide in THF, to give benzyl ether 166 in 51 % yield. Evidence for the success of the 
reaction was the presence of signals at H 4.51 (2H, s, CH2), 7.36-7.35 and 7.31-7.29 (5H, 
m, Ph) ppm for the benzyl protecting group, which was in agreement with the literature 
data.87  
Alkylation of 77 with bromide 166 was carried out under the previously used 
conditions. This led to the formation of 167 as a yellow solid after chromatography (Scheme 
50). The presence of the compound was confirmed by high resolution mass spectrometry of 
the product, which gave a mass of 409.2598 being observed for [M+H+]. This is in exact 
agreement with the required mass. However, attempts to purify 167 were difficult, as the 
material co-ran with several minor impurities. Partial data for the compound was obtained. 
NMR spectroscopy of 167 confirmed the structure, with the 13C NMR data indicating the 
presence of 24 carbons, whilst signals in the 1H NMR spectrum at H  1.18-1.41 (12H, m, 6 
x CH2), 1.51-1.75 (4H, m, 2 x CH2), 3.46 (2H, t, J = 6.6 Hz, NH-CH2) and 3.50 (2H, app q, 
J = 7.0 Hz, CH2-OBn) ppm indicated the presence of the alkyl chain, and a singlet at 4.50, 
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(2H, s, CH2) ppm indicated the benzyl methylene group. A broad multiplet at H 7.32-7.35 
(5H, m, Ph) indicated the aromatic ring of the benzyl group while the presence of the triazine 
was confirmed by peaks at H, 7.25-7.30 (1H, m, CH), 7.59 (1H, b d, J = 8.4 Hz, CH), 7.69 
(1H, ddd, J = 1.4, 6.9, 8.5 Hz, CH) and 8.26 (1H, dd, J = 1.1, 8.7 Hz, CH). Analysis by 
infrared spectroscopy showed an NH peak at 3307 cm-1. 
 
Scheme 50. (i) K2CO3, KI (cat.), 77, DMF, 120 ˚C, 60%. 
The final stage of the synthesis was to deprotect 166 to provide alcohol 168 ready 
for coupling to the quinone 52. In the first instance, this was attempted under classical 
hydrogenation conditions using Pd/C and hydrogen gas. Analysis by TLC indicated the 
consumption of the starting material 167. However, the only triazine product that was 
isolated from the reaction appeared to be amine 77 in an amount which corresponded to 85 
% of the 167 used in the reaction. Benzyl alcohol was also identified in the crude reaction 
mixture using thin layer chromatography. Attempts were also made to deprotect the benzyl 
group in 167 using HBr in acetic acid.88 Unfortunately, on heating 167 at reflux with 33% 
HBr in acetic acid no reaction was observed, thus suggesting that the benzyl group was not 
susceptible to acid hydrolysis. 
 
Scheme 51. (i) H2, 5% Pd/C in methanol; or (ii) 33 % HBr in acetic acid. 
Although it was possible to prepare N-alkyl derivatives of TPZ (38), these derivatives 
could not successfully be attached to the quinone pro-drug delivery system. As a result, a 
new method was required for the preparation of substituted analogues of TPZ (38), 
incorporating a linker that would allow coupling to the quinone acid 52.  
 
2.5. Alkoxymethyl derivatives of tirapazamine 
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Scheme 52. Yongzhous preparation of 168: (i) (CH2O)n, BnOH, acetic acid, (ii) MCPBA, 
dichloromethane, NaHCO3.. 
Fortunately, in 2011 Yongzhou et al89 prepared a range of tirapazamine analogues 
by reacting 77 with paraformaldehyde and an alcohol. This produced alkoxymethyl 
derivatives such as 169. These derivatives were then oxidized using MCPBA to the 
corresponding 1,4-dioxides, for example 170 (scheme 52).  
  
Scheme 53. Proposed preparation of functionalised alkoxy methyl derivatives: (i) (CH2O)n, butane-
1,4-diol, acetic acid, (ii) 77, DMAP, EDC, THF, r.t.  
It was thus proposed that this method could be used to produce an analogue capable 
of being linked to the quinone 52. Reacting 77 with a large excess of a diol (for example 
butane-1,4-diol) should lead to the derivative 171, and ultimately to the pro-drug 172 
(Scheme 53).  
 
Scheme 54. (i) (CH2O)n, 1,4-butane-1,4-diol, acetic acid, 5 h, 55 %. 
In choosing butane-1,4-diol, it was also hoped that a 4-carbon chain would be long 
enough to prevent any anchimeric effects from occurring. Thus, reaction of 77 with a large 
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excess of 1,4-butanediol under the reported conditions gave the desired compound 171, 
contaminated with the excess unreacted butane-1,4-diol. Due to the high boiling point of 
butane-1,4-diol (235 ˚C)90 evaporation was not an option. Therefore, the crude mixture was 
poured into water and extracted with chloroform until the organic phase no longer turned 
yellow. This practice removed a great deal of the diol, giving a bright yellow semi-solid. 
Attempts were then made to purify 171 by column chromatography. However, the residual 
diol made this a very difficult process.  
Therefore on repeating this reaction, the crude product was dissolved in a minimum 
of hot chloroform and diethyl ether was added carefully until the solution became turbid. 
The flask was then stored at -17 ˚C overnight, during which time an amorphous yellow solid 
was precipitated. The solid was collected by vacuum filtration, then adsorbed onto silica and 
purified further by column chromatography, to give the target compound in 55 % yield. 
Analysis of the product 171 by NMR spectroscopy confirmed the structure, with the 13C data 
indicating the presence of 12 carbons, whilst signals in the 1H NMR spectrum at H 1.75-
1.62 (4H, m, 2 x CH2), 3.67 (4H, apparent bt, J = 6.0 Hz, 2 x CH2) and 1.93 (1H, b s, OH) 
ppm indicated the presence of the pendant 4-carbon chain. A broad doublet at H 5.07 (2H, 
d, J = 7.2 Hz, CH2) ppm and a broad triplet at H 6.18 (1H, b t, J = 7.2 Hz, NH) ppm are 
indicative of the methylene and NH groups respectively. Aromatic protons were observed at 
H 7.37 (1H, b t, J = 7.2 Hz, CH), 7.68 (1H, b d, J = 8.4 Hz, CH), 7.75 (1H, b t, J = 8.1 Hz, 
CH) and 8.28 (1H, b d, J = 8.5 Hz, CH) ppm. Analysis by infrared spectroscopy showed a 
broad OH peak at 3295 cm-1 and final confirmation of the structure of 171 was obtained 
from high resolution mass spectrometry, with a mass of 287.1109 being observed for 
[M+H+], which is in exact agreement with the required mass. 
 With the derivative 171 in hand, analogues such as 172 might be produced from it. 
However, an initial test reaction was performed using propanoic acid, largely due to the time 
and effort required to produce the quinone 52. Thus the alcohol 171 was reacted with 
propanoic acid in the presence of EDC and DMAP in anhydrous THF (scheme 55) to give 
the ester 173 as a yellow solid in 60 % yield. Analysis of 173 by NMR spectroscopy 
confirmed the structure, with the 13C data indicating the required 15 carbons. The 1H NMR 
spectrum indicated the presence of a triplet at H 1.03 (3H, t, J = 7.5 Hz, Me) ppm, and a 
quartet at H 2.19 (2H, q, 7.5 Hz, CH2) ppm indicated the presence of an ethyl group. Signals 
at H 1.67-1.55 (4H, m, 2 x CH2), 3.56 (2H, t, 6.0 Hz, CH2) and 4.02 (2H, t, J  = 6.4 Hz, 
CH2) ppm confirmed the presence of the pendant butyl chain, whilst a broad doublet at H 
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4.86 (2H, d, J = 7.1 Hz, CH2) and a broad triplet at H 6.84 (1H, b t,  NH) confirmed the 
presence of the methylene and NH groups. Four aromatic protons were observed at H 7.40 
(1H, ddd, J = 1.2, 7.0, 8.6 Hz, CH), 7.62 (1H, b d, J = 8.4 Hz, CH), 7.79 (1H, ddd, J = 1.2, 
7.0, 8.4 Hz, CH) and 8.21 (1H, dd, J = 1.2, 8.6, Hz, CH) ppm. Analysis using infrared 
spectroscopy gave bands at 3307 cm-1 for the NH stretch and at 1728 cm-1 for the ester 
carbonyl stretch. Final confirmation of structure was obtained by high resolution mass 
spectrometry, with a mass of 321.1561 being observed for [M+H+], which is in good 
agreement with the required mass of 321.1557.  
 
Scheme 55. (i) Propanoic acid, EDC, DMAP, anhydrous THF, r.t., 48 h. 
This reaction was then repeated using the quinone 52, and the analogue 171 (Scheme 
56) was successfully produced, with a yield of 39 % after chromatography. Confirmation of 
the presence of 172 was initially obtained by high resolution mass spectrometry with a mass 
of 497.2388 Da being observed for the [M+H+] ion, which is in good agreement with the 
required mass of 497.2386 Da. However, the mass spectrum was complex and it was 
apparent that a large number of masses were present, due to impurities and possible 
decomposition products. On analysis of 172 by NMR spectroscopy, it was apparent that the 
compound underwent decomposition in chloroform to give 171. This was also apparent by 
TLC, which suggested that the completed pro-drug was susceptible to acidic hydrolysis. A 
2-dimensional TLC study where the plate was immersed in chloroform for 15 minutes also 
indicated the formation of 171. The same TLC experiment was performed on 173, which 
appeared to be stable in chloroform. This result might suggest that the ester group in 172 is 
more easily hydrolysed, and this might be an effect related to the previously-observed 
anchimeric effect act in tandem with the gem-dimethyl effect reported by Levine.39 A 
conformer such as 174 might be proposed. 
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Scheme 56. EDC, DMAP, anhydrous THF, r.t. 48 hrs. 
Some improved stability was observed when performing NMR spectroscopy in 
CD3CN. However, hydrolysis was still apparent, despite being at a somewhat reduced rate, 
and it was difficult to obtain a convincing NMR spectrum of the compound.  
Given the propensity for 172 to be hydrolysed under mild conditions, there was a 
concern that the product was being lost during the aqueous work up and during purification 
by flash chromatography, so the reaction was repeated, using DCC instead of EDC as there 
would be no aqueous work up. Once the reaction was complete, the solvent was removed 
under reduced pressure, and the residue was dissolved in the minimum of ethyl acetate and 
cooled to 0 ˚C. The precipitated DCU was filtered off, and the process was repeated three 
times more. The crude product was then purified on triethylamine-deactivated silica gel, to 
give an improved yield of 54 %. Analysis by 1H NMR spectroscopy indicated the presence 
of 172. However, the product was contaminated with DCU, and again the 1H NMR spectrum 
was not convincing as to the formation of a pure product. The 1H NMR spectrum did indicate 
the presence of 4 singlets for the methyl groups of the quinone portion of the molecule at H 
1.46 (6H, s, 2 x Me), 1.98 (3H, s, Me), 1.99 (3H, s, Me) and 2.15 (3H, s, Me), as well as a 
singlet methylene signal at H 2.95 (2H, s, CH2) ppm. The signals at H 1.62-1.68 (4H, m, 2 
x CH2), 3.61 (2H, t, J = 5.9 Hz) and 4.01 (2H, t, J = 6.0 Hz) ppm are indicative of the 4-
carbon pendant chain, whilst signals at H 5.01 (2H, b d, J = 7.0 Hz, CH2) and at 7.03 (1H, 
b t, J = 7.0 Hz) confirm the presence of the methylene linker unit. Aromatic protons were 
also observed at 7.47 (1H, dt, J = 1.0, 7.3 Hz, CH), 7.68 (1H, b d, J  = 9.6 Hz, CH), 7.86 
(1H, dt, J = 1.2, 7.1 Hz, CH) and 8.27 (1H, dd, J = 0.7, 8.6 Hz, CH) ppm. Analysis of the 
sample by 13C-NMR spectroscopy in D6-DMSO gave a very complex spectrum, indicating 
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that the compound was not pure and had possibly undergone degradation during or post 
purification by chromatography. 
Following these results, it was speculated that a longer linker might reduce these 
proposed anchimeric interactions. The proposed study was to prepare the extended analogue 
175 from the intermediate alcohol 176 (Scheme 57). 
 
Scheme 57. Hexane-1,6-diol, (CH2O)n, CH3CO2H, 85 ˚C 16 hrs. (ii) 50, DMAP, DCC, THF, r.t. 
48 hrs. 
Thus, compound 77 was treated with hexane-1,6-diol in the presence of glacial acetic 
acid. The reaction was performed in neat hexane-1,6-diol (excess, 32 eqv), and as this solvent 
melts at 42 ˚C, the reaction was performed at 80 ˚C. Attempts to precipitate the product from 
the residual hexane-1,6-diol by cooling the mixture proved difficult. Attempts to remove the 
hexane-1,6-diol by dissolving in ethyl acetate solution and washing with water only removed 
some of the diol. It was possible to purify the compound by repeated flash chromatography, 
to give 175 in a yield of only 15 %. However, it was apparent that the final product was still 
contaminated with traces of diol. Analysis of the product 175 by NMR spectroscopy 
confirmed the structure, with the 13C data indicating the presence of 14 carbons, whilst 
signals in the 1H NMR spectrum at H 1.24-1.40 (4H, m, 2 x CH2), 1.47-1.61 (4H, m, 2 x 
CH2), 3.50-3.62 (4H, m, 2 x CH2), and H 2.07 (1H, b s, OH) ppm indicated the presence of 
the pendant 6-carbon chain. A broad doublet at H 5.04 (2H, b d, J = 7.1 Hz, CH2) ppm and 
a broad triplet at 6.68 (1H, b t, J = 7.1 Hz, NH) ppm are indicative of the methylene and NH 
groups respectively. Aromatic protons were observed at H 7.32 (1H, ddd, J = 1.2, 7.1, 8.3 
Hz, CH), 7.64 (1H, b d, J = 8.1 Hz, CH), 7.70 (1H, ddd, J = 1.2, 7.2, 8.0 Hz, CH) and 8.23 
(1H, b d, J = 8.0 Hz, CH) ppm. Analysis by infrared spectroscopy showed a broad OH peak 
  
63 
 
at 3295 cm,-1 and final confirmation of the structure of 175 was obtained from high resolution 
mass spectroscopy, with a mass of 293.1611 being observed for [M+H+], which is in exact 
agreement with the required mass. 
Pure 175 was then coupled to quinone 52 using DCC and DMAP (Scheme 57), to 
give the pro-drug 176, with a yield of 27 % after purification by flash chromatography. NMR 
data revealed the product 176 to be contaminated with DCU and easily hydrolysed on 
standing in chloroform. However, analysis of 176 by NMR spectroscopy in CD3CN 
confirmed the general structure, with the 13C data indicating the required 26 carbons. The 1H 
NMR spectrum indicated the presence of 3 singlets for the methyl groups of the quinone 
portion of the molecule at H 1.38 (6H, s, 2 x Me), 1.89 (3H, s, 2 x Me) and 2.07 (3H, s, Me) 
ppm, as well as a singlet methylene signal at H 2.86 (2H, s, CH2) ppm. The signals H 4.90 
(2H, d, J = 7.0 Hz, CH2) and at 6.89 (1H, b t, J = 7.0 Hz, 1H, NH) confirmed the presence 
of the methylene linker unit. Aromatic protons were also observed at 7.38 (1H, ddd, J = 1.1, 
7.0, 8.5 Hz, CH), 7.59 (1H, b d, J = 8.5 Hz, CH), 7.77 (1H, ddd, J = 1.4, 7.0, 8.5 Hz, CH) 
and 8.18 (1H, dd, J = 1.4, 8.5 Hz, CH) ppm. Analysis by infrared spectroscopy gave bands 
at 3294 cm-1 corresponding to the amine N-H stretch and at 1724 cm-1 for the ester carbonyl 
stretch. Analysis by high resolution mass spectrometry was unsuccessful, indicating the 
instability of the compound.  
In conclusion, a new method has been developed for producing analogues of 77, with a linker 
for conjugation, to release quinones such as 52. The methodology is simple, requiring few 
steps to the pro-drugs without the need of any protecting groups. However, modifications to 
the structure are required, as the conjugated esters may be hydrolysed, possibly due to 
anchimeric effects between the amine on the 3-position and the carbonyl of the ester linker. 
A further issue which had been foreseen with this approach is that it would probably be 
difficult to oxidise the final pro-drugs e.g. 172 and 176 due to their instability. Additionally, 
the pendant alcohol group might competitively oxidise. As a result it was envisaged that it 
would be preferable to form alkoxy-methyl derivatives directly by reacting tirapazamine (38) 
under the conditions reported by Yongzhou (Scheme 58).89 
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Scheme 58. n-Butanol, (CH2O)n, acetic acid (cat). 
Thus, a test reaction was set up where tirapazamine (38) was reacted with n-butanol 
and paraformaldehyde in the presence of glacial acetic acid (Scheme 58). It took two hours 
for TPZ (38) to dissolve fully, but after warming the reaction to 80 °C, the solution was 
bright red in colour. The reaction was monitored by TLC, and once complete the solvent was 
removed by rotary evaporation. The crude orange product was purified by column 
chromatography to give the TPZ analogue 177 as an orange powder in a yield of 63 %. 
Compound 177 had previously been prepared via a two-step method by Yongzhou89 with a 
yield of 51 %. Derivative 177 is considerably more soluble than TPZ (38), being soluble in 
solvents such as chloroform and ethyl acetate. This suggests that these analogues are likely 
to be much more workable than TPZ itself. This result shows that oxidised analogues of 172 
and 176 could be produced by this method, negating the need for a late stage oxidation, 
which may as mentioned prove problematic. 
 
Scheme 59. (i) Alkyl halide, K2CO3, DMF, 120 ˚C (ii) Butane-1,4-diol, (CH2O)n, acetic acid (cat). 
Further future work might involve the blocking of the remaining amine function at 
the 3-position, which would eliminate hydrogen bonding to the carbonyl of the ester. It is 
proposed that a methodology for achieving this would be first alkylation of the TPZ (38) 
using the methods described in section 2.4, following which the alkylated derivative 178 
would be treated with paraformaldehyde and diol as described in this chapter, to give 
analogues such as 179 (Scheme 59). Due to time constraints, this work could not be carried 
out during this study.  
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3.0. Conclusions and future work  
 The previously unprepared phenyl-locked mustard pro-drug 116 was successfully 
prepared using a HOBT-based coupling methodology. As part of this work, the quinone 105 
was prepared according to a known procedure37 in a comparable yield. However, an 
improved method91 was developed for the synthesis of the aniline mustard 70, which allowed 
synthesis without the formation of contaminant by-products (Scheme 60). 
 
 
Scheme 60. Synthesis of the pro-drug 116 (i) HOBT, EDCI, THF, r.t., 48 h. 
Now that the pro-drug 116 is available, together with a supply of the previously 
prepared guanidines  109-111 and 112-114 (prepared by Martin),1 as well as the mustard 71 
(also synthesised by Martin)37 they will be appraised as subjects for NQ01 and have their 
anticancer activity determined by the research group of Professor Roger Phillips at 
Huddersfield University.  
 
 
Figure 28. Guanidines and mustards submitted for biological evaluation. 
The first section of this thesis also focused on the preparation of several new analogues 
147, 161, 167, 171, 173 and 175 of tirapazamine (38) and 3-amino-benzotriazine-1-oxide 
  
66 
 
77. Attempts were made to couple 171 and 175 to the quinone 52 to give pro-drugs 172 and 
176 respectively. However, rapid hydrolysis of these compounds was observed to occur even 
in mildly acidic conditions, and therefore the absolute confirmation of structure for these 
was difficult. This undesired hydrolysis is a drawback in terms of suitability of these 
structures for pro-drug applications. However, by using the methodologies developed 
throughout the study, there is the potential to generate further, perhaps more stable, 
analogues of TPZ (38). The simplicity and robustness of these methods would also allow the 
rapid generation of a library of different TPZ analogues (Figure 29).  
Figure 29 Novel analogues of tirapazamine 1 prepared as part of this study. 
Currently none of these compounds have been appraised for activity. The partner 
company went bankrupt in 2012 and only recently an alternative method for evaluation has 
been identified.  
 As part of this work, two proposals have been put forward to overcome synthetic and 
stability problems. Firstly, the synthesis of TPZ analogues such as 177 directly from 38 by 
using the methods developed by Yongzhou89 negates the need for a late-stage oxidation. 
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Secondly, future work might involve the blocking of the remaining amine function at the 3-
position, which would eliminate hydrogen bonding to the carbonyl of the ester. Thus, starting 
with the alkylation of  TPZ (38) using the methods described in section 2.4, the alkylated 
product 178 would then be treated with paraformaldehyde and diol as described in section 
2.5, to give analogues such as 179 (Scheme 61). 
 
 
Scheme 61. Future developments of this work: (i) n-Butanol, (CH2O)n, acetic acid (cat). (ii) Alkyl 
halide, K2CO3, DMF, 120 ˚C. (iii) Butane-1,4-diol, (CH2O)n, acetic acid (cat). 
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Section B: 
The Synthesis of Natural Products from the 
Sea Sponge Monarca Arbuscula. 
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4.0 Introduction 
4.1 Leishmaniasis 
Leishmaniasis is a disease caused by a parasite of the order protozoa Leishmania, 
and is spread by various species of sandfly. The disease can present itself in three forms. 
These are Cutaneous (the least severe form presented as skin ulcers), mucotaneous 
(presenting as ulcers of the skin of the mouth and nose), and finally visceral (the most severe 
form, starting with skin ulcers which are followed by fever and in later stages low red blood 
cell count, the swelling of the spleen and liver, and death). The disease mostly affects the 
poorest regions of the world, but is widely spread. Annually, approximately 1.3 million new 
cases occur and 20,000 to 30,000 people die as a consequence of leishmaniasis (Figure 
30).60,61  
 Affected Areas 
 
Figure 30. Global Distribution of leishmaniasis.60 
The skin lesions are reminiscent of leprosy and in many regions the disease is 
misdiagnosed until it is in its later stages.  
Currently there are four main drugs in circulation for the treatment of leishmaniasis 
(Figure 31); Pentostam (180) (Fig 31.) is a pentavalent antimony compound which displays 
very good activity against visceral leishmaniasis. Unfortunately, the parasite has become 
resistant to the drug in areas such as India and the Mediterranean. The drug is also 
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phlebotoxic (toxic to veins), and after several doses of the drug, administration becomes 
difficult as viable veins become difficult to find.61 
Paromomycin (181) (Fig. 31) is an aminoglycoside antibiotic, and is currently used 
in Africa in conjuction with pentavalent antimonials. Although the side effects are much 
milder when compared to other anti-leishmanial drugs, it has shown poor activity as a sole 
agent.61 
 
Figure 31. Current anti-leishmanial drugs 
Miltefosine (182) (Fig. 31) is a phospholipid which is effective against both 
cutaneous and visceral leishmaniasis, and is the only leishmanial drug to date to be 
administered orally. Approximately 60 % of patients experience nausea and vomiting, with 
the effects being more severe towards women and children. The drug is also embryotoxic 
and has been linked with birth defects. As a consequence, contraception must be taken in 
conjuction with the drug.61 
Amphotericin B (183) (Fig. 31) was first extracted from the filamentous bacterium 
Streptomyces nodosus in 1955 and has been used extensively as a fungicide. It is effective 
against visceral leishmanisias in India, South America and the Mediterranean where the 
disease has become resistant to pentavalent antimonials. Unfortunately, amphotericin B is 
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well known for its severe side effects, which occur between 1 and 3 hours after infusion and 
include hypotension, low breathing, rapid breathing and often cardiac arrest and death.61 
The current treatments for leishmaniasis are far from ideal, displaying severe side 
effects or low activity and there is a need for a safe and effective treatment which can be 
administered orally. Controversially, cutaneous leishmaniasis is not a priority on the global 
agenda, and the development of new treatments is lagging behind.61 
4.2 The Role of Natural Products in Medicine 
Nature has been the source of pharmaceutical compounds on countless occasions 
throughout human history. Hippocrates (c. 460 – c. 377 BC) left records describing the 
prescription of powder made from the leaves and bark of the willow tree spirea to alleviate 
the symptoms of headaches, fevers and pains.62 However, with modern science allowing a 
deeper understanding into the pathology of several diseases, attention was shifted from 
natural products to synthetic targets, which could be created with a specific molecular target 
in mind. A synthetic approach in turn allowed for high throughput screening technologies 
supplying a large number of chemical libraries. In the past, combinatorial chemistry allowed 
the rapid generation of compounds. However, this methodology could only continue for so 
long, and by 2001 the number of new drugs discovered and licensed in this way had 
decreased dramatically. Since 2001 there has been a significant new drive to isolate new 
natural products that may have medicinal applications.63 
 
Figure 32. Paclitaxel (184) and artemisinin (185). 
The majority of current natural product derived therapies are of terrestrial origin, i.e. 
plants, bacterial and fungi. For example, both the cancer chemotherapy agent paclitaxel 
(184) (isolated from the bark of the pacific yew tree), and the anti-malarial agent artemisinin 
(185) (isolated from Artemisia anuua) are plant metabolites (Figure 32). 
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A natural product is a chemical compound or substance which is produced by a living 
organism such as plants, animals and microorganisms.96 Within the field of organic 
chemistry, the definition of natural products is usually restricted to mean purified organic 
compounds isolated from natural sources that are produced by the pathways of primary or 
secondary metabolism. Within the field of medicinal chemistry, the definition is often further 
restricted to secondary metabolites, Secondary metabolites are not usually biosynthesized 
by the primary metabolic pathways and have no apparent function in the growth, 
development or reproduction of the organism.97 However, they may play a role in many 
other ecological relationships, including defense against predation and competition for space 
and food. Compared to non-natural compounds, natural products show high chemical 
diversity, biochemical specificity, binding efficiency, and have the propensity to interact 
with biological targets, making them favourable lead structures for drug development. 98–100 
4.3. Marine Natural Products 
The ocean is a vast source of new species and, crucially, new natural products, which 
could hold the key to curing many diseases worldwide. The exploration of marine 
ecosystems only began in the mid-1970s with the advent of modern snorkelling and the 
introduction of scuba diving in 1970. Remotely operating vehicles came into use around 
1990, further increasing the potential for the exploration of the oceans.98 
 As a result of technical limitations, exploitation of marine organisms started with the 
collection of larger creatures such as red algae, sponges and soft corals.  This resulted in the 
isolation of many unique compounds.101 Marine natural products have shown a myriad of 
biological activity including anti-tumour, anti-microbial and anti-proliferative 
properties.100,102–106 
4.3.1. Guanidine Marine Natural Products 
Over the years, the work within the Murphy group at Bangor University has been 
focussed on the synthesis of guanidine-containing marine natural products.107–112 As a result 
of their biological properties, guanidine-containing natural products are gaining considerable  
interest from many research groups.113 Molecules containing the guanidine and guanidinium 
structural motif are capable of hydrogen bonding (from the guanidinium ion) with 
phosphate- and carboxylate-containing molecules. and possess a broad range of biological 
properties.108,109,112,114,115  
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 In 2013 Berlinck and co-workers at the university of Sao Paulo isolated two new 
guanidine-containing alkaloids from the sea sponge Monarca arbuscula, which were 
monalidine A (186) and arbusculidine A (187).116 From 360 g of dry sea sponge, only 1.2 mg 
of 186 and 0.9 mg of 187 were obtained after several extraction and HPLC purification 
stages.  
 
Figure 33. Two new natural products from the sea sponge Monarca Arbuscula.116 
4.4. The Crambine Alkaloids. 
 
 
Figure 34. Crambines A and B and ptilomycalin A. 
The structure of monalidine A (186) is very similar to the structures of the crambines 
A (188) and B (189) (figure 34), which were isolated from the Mediterranean sea sponge 
Crambe crambe by Berlinck in 1990.117,118 The bright red encrusting sea sponge is common 
along the coasts of the Mediterranean and is generally free from parasites and other epizoites. 
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Crambe crambe is also capable of causing tissue necrosis of other sponges which may be in 
physical contact with it.118  
Dried specimens were extracted with methanol to give a material with high toxicity 
against the fish Lebiste reticulatus, and which inhibited the re-aggregation of cells in other 
specimens such as the freshwater sponge Ephydiata fluviatillis. Berlinck identified 188 and 
189 as being bis-guandine alkaloids, and speculated that they were biogenetically related to 
ptilomycalin A (190), which was isolated from the Red sea sponges Ptilocaulis spiculifer 
and Hemimycale columella in 1989.118 
  
Figure 35. Crambines C1 and C2. 
 In 1992 Berlinck reported two further extracts from Crambe. The alkaloid crambine 
C1 (191) (Figure 35) was found in a specimen taken from Nice in France. It was also found 
as a minor component from specimens that were collected from Favignana (Italy), together 
with the second new alkaloid crambine C2 (192) (Figure 35). Structural elucidation revealed 
that crambine C1 (191) is an isomer of crambine B (1192). Furthermore, C1 (191) differs 
from C2 (192) only in the length of the alkyl chain between the ester group and the 
guanidine.119 
 
Scheme 62. Proposed Biosynthesis of crambines A and B.119 
  
75 
 
Berlinck speculated that both crambine A (188) and crambine B (189) are derived 
from the intermediate 193 (scheme 62), which could be formed by the condensation of fatty 
acids using a reduced form of γ-guanidinobutyric acid 194. Guanidine derivative 194 which 
is found in many marine invertebrates is a degradation product of arginine. Esterification of 
193 with a molecule of γ-guanadinobutanol 195 would give the chain found in crambines 
188, 189, 191 and 192. Cyclisation of this intermediate 193 leads to crambine A (188), whilst 
spirocyclisation would give the crambine B (189). Similarly crambine C1 (191) could arise 
from the esterification of 193 with γ-guanidinopentanol 196 respectively.80 
 
Scheme 63. (i) DMAP, benzene, Δ. (ii) C11H23CHO, piperidine. (iii) NH3, NH4OAc, MeOH, Δ. (iv) 
TBAF, THF. (v) a) MsCl, Et3N, CH2Cl2. b) Et3N, CHCl3, Δ. c) H2, Pd.120 
By 1993, both 188 and 189 had been synthesised from ethyl acetoacetate (195) in 
eight steps by Snider, according to scheme 623 (crambine A) and scheme 64 (crambine B).83 
Firstly the protected β-keto ester 197 underwent acyl transfer using DMAP, to give the 
guanylated ester 199 in a 53 % yield. The fatty acid chain was added by reacting 199 with 
dodecanal and piperidine to give 200 in 82 % yield. This then underwent condensation with 
O-methylisourea (201) to give the pyrimidine 202. This in turn was converted into the 
guanidine 203 using ammonia and ammonium acetate, giving a 94 % yield. Ring closure 
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was then carried out using methanesulfonyl chloride and triethylamine, before 
hydrogenation to deprotect the guanidine and give crambine A (188) in a 37 % yield.  
As an alternative method, 203 was cyclised on treatment with triethylamine to give 
205, which on hydrogenation gave crambine B (189) in 86 % yield.  
 
Scheme 64. (i) Et3N, CHCl3, Δ. (ii) H2, Pd/C, dichloromethane.120 
Biological studies performed by Rinehart121 found that crambines A (188) and B 
(189) were cytotoxic to L1210 cells with IC50 values of less than 1 µg/mL, showing identical 
activity to that of the naturally occurring material.  
4.5. The Batzelladine Alkaloids 
In 1994 Patil et al. isolated the batzelladines A-E 205-209 from the sea sponge 
Batzella spiculifer, along with the other previously isolated guanidine metabolites 
ptilomycaulin A (190), crambine A (188), crambescidine 900 (210), crambescidine 816 
(211) and ptilocaulin (212). Batzelladine A (205) and batzelladine B (206) were the 
first-known naturally occurring small molecules to be shown to inhibit the binding of 
HIVgp-120 to the CD4 receptor, and as a consequence were potential inhibitors of HIV.122 
 As previously noted, monalidine A (186) is very similar in structure to crambine A 
(188), and is also a similar structure to the “tethered” ester of batzelladine A (205) and 
batzelladine B (206), which share the same bicyclic motif. The major difference, however, 
is that 186 is devoid of the ester group at the 4-position, which might or might not have a 
profound effect on its biological activity.  
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Figure 36. The alkaloids isolated by Patil in 1994.122 
4.6. Arbusculidine A 
The structure of arbusculidine A (187) is very similar to those of the family of natural 
products of which ptilocaulin (212) was the first to be isolated, from the sponges Ptilocaulis 
aff. and P. spiculifer in 1981.121 
 
Figure 37. Arbusculidine A (187) and ptilocaulin (212). 
Both arbusculidine A (187) and ptilocaulin (212) have a tricyclic structure with 
aliphatic butyl chains on the 4-position and a methyl group on the 5 position. However, in 
arbusculidne, both 6-membered rings are aromatised and thus devoid of the stereochemistry 
present in ptilocaulin (212). The rings have been arbitrarily assigned A, B and C in order to 
aid discussion. Thus, arbusculidine A (187) appears to be a member of the ptilocaulin family, 
which is a range of compounds that have been shown to possess diverse biological activity, 
including anti-parasitic and anti-HIV activity.121–123 It also appears to be the first compound 
in the series which is aromatised in both the A- and C-rings.  
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4.6.1. The Ptilocaulin Family of Alkaloids 
 In 1981, Rinehart and co-workers isolated the two tricyclic guanidine- containing 
alkaloids, ptilocaulin (212) (Figure 37) and isoptilocaulin (215), from two samples of 
Ptilocaulis aff. P. Spiculifer which were collected from slightly different locations and 
depths.85 The two compounds were found to be biologically active, ptilocaulin (212) being 
the more active of the two, with an LD50 of 0.39 µg/mL (50 % inhibition of cell growth) 
against L1210 leukemia cells. It also showed strong activities against Streptococcus 
pyogenes, Pneumoniae faecalis, Staphylococcus aureus and Escherichia coli.121  
Between 1995 and 2008, 19 additional tricyclic alkaloids were isolated from a variety 
of other marine sponges. Braekman isolated 8b-hydroxyptilocaulin (226) from the sponge 
Monanchora arbuscula.124 In 1996 Capon et. al. isolated Mirabilins A-F 219-221, 231-232 
and 213-215 as their N-acetyl derivatives from the sponge Arenochalina mirabilis.123  
In 1997, Patil and Freyer isolated mirabilin B (220) along with 8α-hydroxymirabilin 
B (224) and compounds 216 and 217. Patil named compound 216  8a,8b-
dehydroptilocaulin.125 However, it was realised by Snider123 that 216 is in the same oxidation 
state as ptilocaulin (212), resulting in the dehydro-prefix being incorrect. Subsequently 216 
was renamed 7-epi-neoptilocaulin, using the neo-prefix to identify a double bond between 
8a and 8b as the iso-prefix was already in use. Similarly 217 was named 8a-hydroxy-7-epi-
neoptilocaulin.123  
In 2001, Capon reported the isolation of mirabilin G (214) from the sea sponge 
Claritha.126  It is worth noting that at this stage only ptilocaulin (212) and isoptilocaulin 
(215) had been evaluated for their biological activities.127  
In 2004 Hamann et al. isolated two further tricyclic guanidine alkaloids, 
8α-hydroxymirabilin B (224) and 8β-hydroxymirabilin B (225) as well as mirabilin B (220), 
from the Jamaican sea sponge Monanchora unguifera.127 They were unable to separate 224 
and 225, but managed to obtain 220 as a pure sample. The biological activities of the 
alkaloids were evaluated and it was found that mirabilin B (220) exhibits antifungal activity 
against Cryptococcus neoformams, with an IC50 value of 7 µg/mL, and antiprotozoal activity 
against Leishmania donovani with an IC50 value of 17 µg/mL. It was also found that a 
mixture of 224 and 225 was active against the malaria parasite Plasmodium falciparum with 
an IC50 of 3.8 µg/mL.
127 
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  In 2006 Kashman reported the isolation of netamines A-G 227-230, 218, 222 and 
223 from the marine sponge Beimna laboutei. Netamines C and D 229 and 230 showed 
biological activity (Table 2) against three human tumour cells lines: NSCL (A549), colon 
(HT29) and breast (MDA-MB-231).128  
 
Figure 38. The ptilocaulin family of alkaloids. 
Compound Cell lines/GI50 (µM) 
  A549 HT29 MDA-MB-231 
229 4.3 2.4 2.6 
230 6.6 5.3 6.3 
 
Table 2. Cytotoxicity of netamines C 229 and D 230.128 
Most of these tricyclic alkaloids show 7-epi stereochemistry, but mirabilin F (213), 
mirabilin G (214) and 8b-hydroxyptilocaulin (226) share the same C-7 stereochemistry as 
ptilocaulin (212).123 Mirabilins A (219), B (220) and C (221) and the netamines F (222) and 
G (223) are more oxidised and have aromatic 2-aminopyrimidine rings, whereas netamines 
A-D 227-230 are highly reduced, with a tetrahydro-2-aminopyrimidine ring. Hydroxylated 
metabolites 217, 226, 231 and 232 are at the dihydro-2-aminopyrimidine oxidation state 
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whereas 224 and 225 are at the aromatic 2-aminopyrimidine oxidation state. In the aromatic 
series or with the double bond between position 8a and position 8b as in the neoptilicaulins, 
two stereoisomers are possible at C-8. The side chains are in 7-epineoptilocaulin (216), 
mirabilin B (220) and mirabilin C (221).123    
It was postulated by Capon that the members of the ptilocaulin family are derived 
via the intramolecular cyclisation of guanidine-substituted polyketides.123,128 However, in 
2008, Snider123 proposed a biosynthetic pathway to ptilocaulin (212), 7-epi-neoptilocaulin 
(216) and the batzelladine alkaloids such as batzelladine K (240) in which they are 
biosynthetically related (Scheme 65). He proposed that the conjugate addition of guanidine 
to the bis-enone 234 results in the guanidinium enolate 235, which can then undergo an 
intramolecular Michael addition to give cyclopentane dione 236. There is considerable 
synthetic evidence to support conjugate additions leading to trans,trans-cyclopentane 
analogues of 236.129,130,117 An intramolecular aldol condensation and imine formation, 
followed by an epimerisation of H-8b, leads to the key tricyclic intermediate for the 
ptilocaulin metabolite, 237.  
The most critical step in the biosynthetic pathway for each metabolite is the reduction 
of 237, for example the 1,4-reduction of the -unsaturated imine in 237 at the α face gives 
ptilocaulin (212), whilst a 1,2-reduction of the imine at the less hindered β-face gives 
isoptilocaulin (215). In contrast the 1,4-reduction from the β-face followed by isomerisation 
of the enamine leads to 7-epi-neoptilocaulin (216).123 
Intermediate 235, once protonated, leads to the enone 238, which, on intramolecular 
conjugate addition of the guanidine, forms the pyrrolidine 239. After iminium ion formation 
and 1,2-reduction, this intermediate gives rise to batzelladine K 240.  
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Scheme 65. Hypothesis of the origins of the ptilocaulin alkaloids.123 
This proposed biosynthesis was put forward by Murphy in 1996, and formed the 
cornerstone of his synthetic methodology towards the batzelladine alkaloids and their 
analogues.110–112  
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4.6.2. The Synthesis of the Ptilocaulin Alkaloids 
  
Scheme 66. (i) Na, dioxane, n-BuI, 55 %. (ii) Crotonaldehyde, MeOH, -40 ˚C. 39 % (iii) 
CH3COOH, H2O, HCl 25 ˚C, 58 %.  (iv) 3-Butenylmagnesium bromide, CuBr.SMe2, 45 %. (v) O3, 
MeOH, -78 ˚C, then Me2S.  (vi) HCl, THF, 70 %. (vii) a) Guanidine, Benzene, azeotropic reflux. 
35 %. b) HNO3 1% aqueous.131 
In 1983, Snider first reported the synthesis of ptilocaulin (212) from the β-ketoester 
241, according to scheme 66.131 t-Butyl acetoacetate (241) was converted into 242 using 
sodium and iodobutane in dioxane. This was then reacted with crotonaldehyde to give 
Michael adduct 243. Acid-mediated cyclisation, ester hydrolysis and decarboxylation with 
acetic acid, water and HCl gave the enone 244 as a 1.7:1 mixture of trans:cis isomers. 
Conjugate addition of the cuprate prepared from 3-butenylmagnesium bromide and 
CuBr:S(CH3)2 to this enone gave 245, again as a 1.7:1 mixture of isomers. Ozonolysis of 
245 gave a quantitative yield of 246 which was cyclised using HCl in THF, to give enone 
247 in a 1:1 mixture of isomers in 70 % yield. This enone was heated with guanidine in 
benzene to bring about the azeotropic removal of water, and after quenching the reaction 
with nitric acid, ptilocaulin (212) was obtained as its nitrate in 35 % yield. 
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Scheme 67. Synthesis of ptilocaulin (212) and the co-crystallising isomer 248.132 
 Between 1983 and 1998, several syntheses and synthetic approaches to ptilocaulin 
(212) were reported.123,132 From these studies it was realised that the addition of guanidine 
to 247 results in the formation of multiple isomers. These minor stereo- or double bond 
positional isomers were not characterised until Schmalz reported132 that the compound 248 
co-crystallised with ptilocaulin (212), allowing its structure to be determined by X-ray 
crystallography. It is of particular interest that 248 appears to be formed by the presumed 
kinetic addition of guanidine to the less hindered top face of 247, while ptilocaulin (212) is 
formed by the thermodynamic addition of guanidine to the more hindered bottom face of 
247 (Scheme 67).132–137 
 
Scheme 68. Hassner’s proposed synthesis of 7-epi-ptilocaulin (250).123 
 In 1986, Hassner prepared the enone 249. This was treated with guanidine in benzene 
at reflux to give a compound which he characterized as 7-epi-ptilocaulin (250) (Scheme 68). 
The 1H and 13C NMR spectral data of 7-epi-ptilocaulin (250) in CDCl3 as obtained by 
Hassner123 are very similar to those reported in 1997 for 7-epi-neoptilocaulin (216) in 
CD3OD
125. This suggests that the proposed position of the double bond of Hassner’s product 
250 is incorrect. However, no definitive conclusions can be drawn because the spectra were 
recorded in different solvents.123   
  
Scheme 69. Hassner’s synthesis of mirabilin B.123 
Hassner also heated 249 with neat guanidine at >130 °C (Scheme 69), resulting in 
the formation of a disproportionated mixture of an aromatised compound. Snider123 
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concluded that this was most likely to be a mixture of mirabilin B (220) and a saturated 
compound 251 that was one of 16 possible stereoisomers. However, the NMR spectroscopic 
data for Hassner’s compounds were recorded in CDCl3 again, whereas those of natural 
mirabilin B (220) were recorded in CD3OD, making a direct comparison difficult.
123,125     
 
Scheme 70. (i) a) 0.25 eqv. t-BuOK, t-BuOH, 0°C. b) TsOH, PhMe, 80 °C. (ii) a) CH3Li/CeCl3 
(5 eqv.) THF, -78 °C, 30 min. b) PCC, CH2Cl2, 0.8 eqv. NaOAc. (iii) Li, NH3, t-BuOH, THF,          
-33 °C, 30 min. (iv) O3, -78 °C, CH2Cl2 then Ph3P. (v) 55 °C, 10 min microwave, 30:1 DME:6 M 
HCl.123 
In order to ascertain whether the addition of guanidine to 249 gave 7-epi-ptilocaulin 
(250), Snider developed a route to enone 249 with a defined relative stereochemistry at the 
methyl substituent. A six-step preparation gave indenone 249 as a 4:1 mixture of trans/cis 
isomers.123 The synthesis started with the Michael addition of 2E,6Z-nonadienal (cucumber 
aldehyde) (252) to the β-keto (253), followed by an intramolecular aldol condensation 
mediated by KOtBu in t-BuOH. The intermediate keto-ester was then hydrolysed and 
decarboxylated with TsOH in toluene, to provide cyclohexenone 254. Addition of MeLi in 
the presence of cerium chloride gave an intermediate tertiary allylic alcohol. This was then 
oxidised to the cyclohexanone 255 using PCC. Inspired by the work of House,138 the Birch 
reduction of 255 gave 256 as a 10:1 mixture of trans/cis-isomers at the butyl substituient. 
Ozonolysis of the side chain, followed by the microwave- mediated intramolecular aldol 
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condensation gave the indenone 249 as a 4:1 mixture of trans/cis isomers at the butyl 
substituient.123  
 
Scheme 71. Snider’s synthesis of 7-epineoptilocaulin and mirabilin B (i) MeOH, 24 h, 85 ˚C, then 
1 % HNO3. (ii) Neat, 130 ˚C-140˚C, then 1 % HNO3. (iii) MnO2, CH2Cl2 55˚C 24 h. 
Treatment of 249 with guanidine in methanol at 85 °C led to the formation of 
7-epineoptilocaulin (216) in 50% yield, together with the formation of the byproduct 
3a-bisepiptilocaulin (258) in a 10 % yield.123 This observation supports the proposition that 
Hassner’s original work had also led to the synthesis of 7-epineoptilocaulin (216), as NMR 
spectroscopic data for synthetic 216 in chloroform was identical to that previously reported. 
Similarly, heating 249 with guanidine in the absence of solvent gave mirabilin B (2220) in 
39 % yield as described by Hassner, as well as the tricyclic isomer identified as 259 in a 
31 % yield.123 Snider also reported that oxidation of 216 with activated manganese dioxide 
also gave mirabilin B (220) in an 80 % yield.  
In order to prepare the alkaloids ptilocaulin (212) and isoptilocaulin (215), Snider 
prepared the indenone 261, in which the cyclohexene double bond was installed by cyclizing 
the previously prepared 255 without carrying out the Birch reduction. This process gave the 
indenone 261 in 70% yield, which on treatment with guanidine in methanol gave the 
intermediate tricyclic iminium ion 237.  The reduction of 237 using sodium borohydride 
gave an inseparable 1:1 mixture of ptilocaulin (212) and isoptilocaulin (215) (Scheme 72). 
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Scheme 72. (i) O3, -78 ˚C, 99:1 CH2Cl2/pyridine. (ii) 55 ˚C, 5 min microwave, 30: 1 DME/6 M 
HCl. (iii) MeOH, 24 h, 85 ˚C. (iv) a) NaBH4, H2O, 25 ˚C b) 1 % HNO3.123 
Snider also reported the synthesis and structural reassignment of netamines E (218) 
and G (223) in an analogous manner, in which the methyl group in the previous synthesis is 
replaced by an n-propyl chain in the key intermediate 265.123 Addition of guanidine to 265 
under standard conditions led to netamine E (218) in 38% yield, whilst oxidation of this 
intermediate with MnO2 in dichloromethane led to Netamine G (223) in 25% yield over 2 
steps (Scheme 73). 
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Scheme 73. (i) a) 1: 1 PrMgCl/CeCl3 (5 eqv.) THF, 0 ˚C, 30 min. b) PCC, CH2Cl2, 0.8 eqv. NaOAc 
(ii) Li/NH3, t-BuOH, THF, -33 ˚C, 30 min. (iii) O3, -78 ˚C, CH2Cl2 then Ph3P (iv) 55 ˚C, 10 min 
microwave 30: 1 DME/ 6M aq. HCl. (v) MeOH, 24 h, 85 ˚C, 1 % HNO3 work up (vi) MnO2, 
CH2Cl2, 55 ˚C, 48 h.123 
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5.0. Results and Discussion 
5.1. Synthetic Approaches to Monalidine A (186) and Arbusculidine A (187).  
Berlinck reported the recent isolation of the bicyclic alkaloid monalidine A (186) and 
the tricyclic alkaloid arbusculidine A (187), which represents the newest member of the 
ptilocaulin family of alkaloids. This discovery offers the opportunity to embark upon a 
synthesis of these interesting metabolites. Monalidine A (186) is similar in structure to the 
crambines 188 and 189. The wide range of activity known for these compounds makes it an 
ideal target for synthesis.116–118 Likewise, arbusculidine A (187) is structurally similar to the 
mirabilins and netamine alkaloids, and it is the first of this class to exhibit a fully aromatised 
B ring, possessing a dihydrocyclopentaquinazoline skeleton. 
 
 
Figure 39. Monalidine A (186) and arbusculidine A (187). 
5.2. The Synthesis of Monalidine A 
5.2.1. Synthesis of Monalidine A 
The planned synthesis of monalidine A (186) is shown in scheme 74. The proposed 
synthesis (Scheme 74) is that diketone 268 would be produced via the Claisen condensation 
of commercially available 2-undecanone (266) with γ-butyrolactone (267), and then treated 
with guanidine to form the pyrimidine 269. The cyclisation of 269 could then be effected via 
the corresponding mesylate 270 by cyclisation under basic conditions,120 to give the target 
compound monalidine A (186). 
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Scheme 74. Proposed synthesis of monalidine A: (i) Claisen condensation. (ii) Guanidine. (iii) 
MsCl, base. (iv) NEt3, reflux. 
The diketone 268 was prepared by modification of a previously reported procedure 
by Detty et al., which was used to prepare structurally related compounds.102 He reported 
that the reaction of methyl ketones with -butyrolactone (267) under basic conditions gave 
the 1,3-diketone 268 in 61-95 % yields (Scheme 75). 
 
Scheme 75. (i) NaH, ethanol (cat.), diethyl ether, 15 ˚C. 
Therefore, the reaction of 2-undecanone (266) with γ-butyrolactone (267) was 
attempted under the conditions described by Detty, which gave 268 in a low 6 % yield (Table 
3, entry 1). It was found that the major product (48 %) was 271, which is formed by the 
dehydration of 268, presumably under basic conditions (Scheme 76). Attempts at an acid 
hydrolysis of 271 by heating under reflux with aqueous HCl proved unsuccessful. Therefore 
the original reaction was repeated, but the work up was modified by omitting the quench 
with ethanol, as it was felt that this might generate excess sodium ethoxide and promote the 
cyclisation. Work up with 10 % aqueous ammonium sulfate solution gave an improved yield 
of 20 % (entry 2).  
Next, the use of the less basic trifluoroethoxide ion (pKa ca 12.5) was investigated. 
Under these conditions it was found that yields in the range 28-36 % were obtained (entry 
3). At this point it was speculated that the solid reaction components not mixing sufficiently 
  
90 
 
might be a factor that could be causing lower yields. . A further attempt at the reaction in 
which mechanical stirring was used gave the diketone 268 over three attempts in yields of 
46-51 % (entry 4) (Scheme 76). 
 
Scheme 76. (i) NaH, EtOH or CF3CH2OH (cat.), diethyl ether, 15 ˚C. 
 
Quench 
  
Catalytic 
alcohol 
Highest 
obtained 
yield % 
1 EtOH EtOH 6 
2 No EtOH 20 
3 No CF3CH2OH 36 
4* No CF3CH2OH 51 
 
Table 3. Varying conditions for the synthesis of diketone 268 (*mechanically stirred). 
 Despite the moderate yield, the reaction was easily performed and, after flash 
chromatography followed by one recrystallisation from diethyl ether and hexane, the 
diketone 268 could be prepared in multi-gram quantities. The diketone 268 proved to be 
highly unstable under acid conditions, forming the elimination product 271. It was also found 
that the use of chloroform as an NMR solvent resulted in a slow conversion to 271, possibly 
due to the trace acidity of the solvent. The use of DMSO as an NMR solvent suppressed the 
cyclisation. However, it was apparent that the pure compound exists as a 50:50 mixture of 
the diketone 268 and its enol 268b. Analysis of 268 by NMR spectroscopy confirmed the 
structure, with the 13C NMR data indicating the required 18 carbons including 3 carbonyl 
shifts in the 13C NMR spectrum at 205.3, 194.6 and 193.8 ppm. The 1H NMR spectrum 
indicated the presence of two OH protons as broad triplets at H 4.44 (0.5H, t, J = 4.5 Hz, 
OH) and 4.49 (0.5H, t, J = 4.5 Hz, OH) ppm as well as an enol proton present as a broad 
singlet at H 15.61 (0.5H, b s, OH) ppm with an integral of 0.5. The alkene of the enol was 
present at H 5.68 (0.5H, s, CH) ppm with the corresponding CH2 of the keto tautomer 
appearing as a singlet at H 3.66 (1H, s, CH2). The structure of 268 was finally confirmed by 
high resolution mass spectrometry, with a mass of 257.2107 Da being observed for the 
[M+H+]. This is in close agreement with the required mass of 257.2111 Da. 
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Figure 40. Keto-enol tautomerism observed in 268. 
With 268 in hand, the next step was the synthesis of the pyrimidine 269 by the 
addition of guanidine (Scheme 77, Table 4). The first conditions attempted involved heating 
268 under reflux with guanidine hydrochloride in absolute ethanol solution. The reaction 
was observed to gradually turn yellow over a period of 4 hours. On work up, 1H NMR 
spectroscopic analysis of the reaction indicated that 268 had been completely converted into 
the previously observed ketone 271 (entry 1). This conversion might be as a result of the 
slight acidity of guanidine hydrochloride. As a literature120 report suggested that 
triethylamine could be added to the reaction leading to weakly basic conditions, the reaction 
was repeated with one equivalent of triethylamine (entry 2). After being heated under reflux 
for 12 h, complete consumption of starting material 268 was observed, and product 269 was 
obtained in an 11 % yield.  
It was anticipated that this yield might be improved by replacing the guanidine with 
free guanidine. Free guanidine can be generated by the treatment of guanidine salts with a 
stronger base such potassium t-butoxide. A possible consideration was that the increased 
basicity caused by adding potassium t-butoxide might promote the formation of the 
elimination product 271, and prevent the formation of the desired product 269. To avoid this, 
a slight excess (1.1 eqv.) of guanidine hydrochloride was always employed in these 
reactions. This was treated with one equivalent of potassium t-butoxide for 1 h at r.t. to 
ensure the full consumption of the alkoxide. A solution of 1,3-diketone 268 was then added 
and the mixture heated under reflux overnight. The reaction gradually turned yellow, which 
was indicative of the formation of the elimination product 271. However on work up, the 
product 269 was isolated in an improved 22 % yield. The reaction was repeated by stirring 
at r.t. for 12 hours in an attempt to minimise formation of 271, however the yield was low 
(18 %) and again considerable formation of 271 was observed (entry 4). 
 In order to improve the yield, the effect of using other alcohols as the reaction 
solvent was then explored. The use of t-butanol did not improve the overall yield of the 
reaction, which was conducted at 30 ˚C to ensure that the reaction mixture did not solidify 
(entry 5). The reaction was next attempted in trifluoroethanol (entry 6) and a small but 
reproducible improvement in yield was seen, to 25-28 % over 6 separate reactions. However, 
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elimination product 271 was again formed as a major by-product in up to 52 % yield.  The 
reasons for this improvement in yield are unclear. Further reactions were conducted at r.t. 
for 48 and 72 h but no appreciable improvement in yield was noted. However, due to the 
ease of preparation of 268 this yield was considered workable, and on scale up, it was 
possible to perform this reaction on a 23 mmol (~6 g) scale and to obtain gram quantities of 
the pyrimidine 269. 
 
Scheme 77 (i) Base, guanidine HCl, CF3CH2OH, r.t. 
 
  Solvent Base Temperature Time 
Yield 
(266) 
 
 
1 Ethanol none Reflux 48 h 0% 
 
 
2 Ethanol NEt3 Reflux 12 h 11% 
 
 
3 Ethanol KOtBu Reflux 12 h 22% 
 
 
4 Ethanol KotBu r.t. 12 h 18% 
 
 
5 t-butanol KotBu 30 ˚C 12 h 19% 
 
 
6 trifluoroethanol KotBu r.t. 12 h 28% 
 
        
Table 4. Guanylation of 268. 
The structure of 269 was confirmed by the disappearance of the carbonyl peaks in 
the 13C NMR spectrum.  This contained the required 14 carbon signals, including four signals 
at C 172.8 I. 170.9 (C), 162.7 (C) and 109.7 (CH) ppm, for the pyrimidine ring system. The 
1H NMR spectrum displayed a signal for the pyrimidine CH, which was observed at H 6.38 
(s, 1H, CH) ppm, whilst the NH2 of the pyrimidine was observed at H 5.21 (2H, b s, NH2) 
ppm. This, together with signals at H 3.69 (2H, t, J = 6.0 Hz, CH2), 2.69 (2H, t, J = 8.0 Hz, 
CH2), 2.51 (2H, t, J = 8.0 Hz, CH2), 1.92 (2H, app. pentet, J = 7.0 Hz, CH2), 1.64 (2H, app. 
pentet, J = 7.0 Hz, CH2), 1.26 (12H, m, 6 x CH2) and 0.87 (2H, t, J = 8 Hz, CH3) were 
confirmation of the structure of 269, with the singlet at H 5.02 (1H, s, OH) corresponding 
to the alcohol proton. Final confirmation of the structure was obtained from high resolution 
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mass spectrometry, giving a mass of 280.2384 Da for [M+H],+ which was in good agreement 
with the expected mass of 280.2383 Da for compound 269. 
The next stage of the synthesis was the formation of the dihydropyrrole ring. As 
inspiration, the work of Snider was taken,120 who reported a similar cyclisation in his 
synthesis of crambine A (188) via a mesylate intermediate. Thus, the pyrimidine 269 was 
reacted with methanesulfonyl chloride in the presence of triethylamine to give the crude 
mesylate 270. This was taken on to the next step immediately.  
 
 
Scheme 78. (i) CH3SO2Cl, NEt3, CH2Cl2, 0˚C. 
A solution of 270 in dichloromethane was heated at reflux with triethylamine for 
16 h and, pleasingly, a new product was obtained after purification. NMR spectroscopy 
signals indicated the presence of the expected product 186. But astonishingly, it was found 
that the product isolated still contained a signal corresponding to the methylsufonyl residue. 
It was thought that this might be the methansulfonic acid salt of the natural product. 
However, high resolution mass spectrometry demonstrated that the mesyl fragment was part 
of the structure, as a mass of 362.1872 Da was obtained, corresponding to the [M+Na]+ ion 
of structure 273. Additionally, the IR spectrum of the product lacked bands corresponding 
to either an amine or an alcohol function. It was thus speculated that the structure obtained 
273, was the mesylation product of 186, which was obtained in 11 % yield. In this structure 
the mesylate group has transferred to the amine function. A possible explanation might be 
the poor nucleophilicity of the amidine nitrogen in the pyrimidine ring. It is speculated that 
the NH2 becomes mesylated on prolonged heating by transfer from another molecule of 270. 
This mesylate group helps stabilise the formation of a negative charge by deprotonation at 
the sulfonamide, and this facilitates cyclisation. Support for this mechanism is that the 
alcohol 269 was obtained in 15 % yield following flash chromatography of the reaction 
products.  
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Scheme 79. Proposed mechanism for the formation of 273 (i) NEt3, CH2Cl2, reflux.  
A suggested alternative method is the Appel modification of the Mitsunobu reaction 
using iodine, triphenylphosphine and imidazole. This has been used successfully in the group 
in other related cyclisations.107,114,140,141  Thus, 269 was dissolved in dichloromethane and 
cooled to -18 ˚C. Triphenylphosphine, imidazole and iodine were then added sequentially 
and the reaction was stirred to r.t. over 6h. After work up and column chromatography the 
product was treated with 1 M HCl, to give the desired alkaloid 186 in 67 % yield as its 
hydrochloride salt. 
 
Scheme 80. (i) PPh3, imidazole, I2, CH2Cl2. 
The 13C NMR spectrum of 186 contained the required 14 carbon signals, including 
four signals at C 179.5 (C). 164.8 (C), 154.9 (C) and 107.0 (CH) ppm for the pyrimidine 
ring system. The 1H NMR spectroscopy in DMSO displayed two broad singlets at H 8.99 
(1H, s, NH) and 8.33 (1H, s, NH) ppm for the two NH protons, and a signal for the pyrimidine 
CH was observed at H 7.03 (1H, s, CH) ppm. This together with signals at H 4.14 (2H, t, J 
= 8.0 Hz, CH2), 3.32 (1H, s, CH), 3.21 (2H, t, J = 8.0 Hz, CH2), 2.69 (2H, t, J = 8.0 Hz, 
CH2), 2.26 (2H, app. pentet, J = 8.0 Hz, CH2), 1.65 (2H, m, CH2), 1.29 (12H, m, 6 x CH2) 
and 0.86 (3H, t, J = 8Hz, CH3) ppm was confirmation of the structure of 186. Final 
confirmation of the structure was obtained from high resolution mass spectrometry, which 
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gave a mass of 262.2271 Da for [M+H],+ being in exact agreement with the expected mass 
of monalidine A (186). 
5.2.2. Conclusion and biological studies of monalidine A (186) 
In conclusion, the metabolite monalidine A (186) has been prepared in three steps 
from cheap, readily available starting materials. The completed synthesis is shown in scheme 
81, and it is worth noting that it was achieved without the need for protecting groups. The 
atom efficiency of the synthesis is good, with all the carbon atoms of the starting materials 
being found in the product. The overall yield for the synthesis is 9 %. Whilst this is not an 
overly high yield, the ease of the first 2 steps makes the pathway applicable for the synthesis 
of gram quantities of the intermediates and indeed the natural metabolite 186. The final 
product was indistinguishable from samples of the natural product, and the availability of 
186 enables biological studies to be performed. This synthesis was essential to these studies, 
as only 1.2 mg of natural monalidine was isolated from the sponge Monanchora arbuscula, 
which is insufficient to perform detailed studies. 
 
Scheme 81. (i) γ-butyrolactone, NaH, TFE, diethyl ether, r.t.. (ii) t-BuOK, guanidine 
hydrochloride, TFE, r.t.. (iii) PPh3, imidazole, I2, CH2Cl2, -18 ˚C. 
The biological evaluation of synthetic monalidine A (186) and the intermediates 
pyrimidine 269 (noting its close structural similarity to crambine C1 (1191)) and crambine 
C2 (192) were performed in the laboratories of R. Berlinck and A. Tempone at the University 
of Sao Paulo, Brazil. The anti-parasitic activity was also determined against Trypanosoma 
cruzi (T. cruzi), the parasite responsible for both Chagas disease in South America and 
sleeping sickness in Africa, and Leishmania infantum (L. infantum), which is the parasite 
responsible for visceral leishmaniasis. This latter was studied in both its promastigote and 
amastigote forms, which relate to the different morphological forms found in the life cycle 
of the parasite. (Figure 41, table 5)  
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Figure 41. Monalidine A (186) and the intermediate 269. 
 T. cruzi 
L.infantum 
(promastigote) 
L. infantum 
(amastigote) 
Cytotoxicity 
186 8.09 2.45 no activity 26.27a 
269 8.07 41.68 5.18 8.15b 
182 ND 16 17 122a, 241b 
Table 5. IC50 values for monalidine A hydrochloride (186) and pyrimidine 269 compared to 
miltefosine (182) (μM). ND = not determined, a = monkey kidney LLC Mk2, b = NCTC cells. 
 Both 186 and 269 displayed very similar levels of activity against T. cruzi, with IC50 
value of 8.09 μM and 8.07 μM respectively. In studies with L. infantum, monalidine A (186) 
displayed a high activity against the promastigote form of the parasite at a concentration of 
2.45 µM, compared to 269 which required a much higher concentration of 41.68 µM. For 
the parasite in its amastigote form, monalidine A (186) displayed no activity, while 269 gave 
a much higher activity at lower concentrations, with an IC50 value of 5.18 µM showing 
higher activity than the drug miltefosine (182), which was used as a standard and gave an 
IC50 concentration of 17 µM. Interestingly, the synthetic monalidine A (186) and 269 were 
much more toxic towards the NCTC and LLC Mk2 (cancerous monkey kidney) mammalian 
cell lines than the standard miltefosine (182), with  concentrations of 26.27 μM compared to 
122 μM in the case of 186 and 8.15 μM compared to 241 μM  in the case of 269.116 
It is obvious that the two compounds behave very differently towards L. infantum, 
and possible explanations for these differences is that they may be due to the difference in 
receptor properties or metabolic differences between the leishamanial promastigote and 
amastigote forms. The observed difference in activity could also be due to a difference in 
the lipophilic properties of 186 and 269. It is also possible that the degree of protonation of 
the guanidine function in the two molecules might differ in vivo, especially as the pyrimidine 
is aromatic in nature in 269, whilst it is not in structure 186.  
Overall these results are very promising. Studies are continuing on the synthetic 
material and there is considerable interest in the compound.  
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5.3. Approaches to the Synthesis of Arbusculidine A (187) 
Attention was next turned to the synthesis of the metabolite arbusculidine A (187). 
As pointed out previously, the related metabolites ptilocaulin (212), isoptilocaulin (215), 
netamine E (218), 3a-bis-epiptilocaulin (258), and mirabilin B (220) are similar to 
arbusculidine A (187), only differing in the degree of unsaturated oxidation level of the 
various rings (Figure 41). A comparison of these metabolites indicates that 3a-bis-
epiptilocaulin (258) has only one degree of unsaturation in the two 6-membered rings, whilst 
the metabolites ptilocaulin (212), isoptilocaulin (215), 7-epineoptilocaulin (216) and 
netamine E (218) have two degrees of unsaturation. Before the isolation of arbusculidine A 
(187), the most unsaturated metabolite isolated to date was mirabilin B (220) (Figure 42). 
  
Figure 42. Arbuscilidine A (187) and the structurally related ptilocaulin alkaloids. 
Snider’s biomimetic hypothesis123 suggests that the more saturated metabolites might 
have arisen from a common biomimetic precursor 237. This molecule has three degrees of 
unsaturation via a reductive pathway, with the possibility of rearrangement. It might be 
speculated that mirabilin B (220) has arisen from the aromatisation of a metabolite such as 
7-epineoptilocaulin (216) by an oxidative process. This would imply that the target molecule 
187 might also have arisen from an intermediate such as 237 via oxidation (Scheme 82). 
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Scheme 82. Proposed biosynthesis of mirabilin B (220) and arbusculidine A (187). 
 As previously discussed, in 2008 Snider reported123 the synthesis of several 
ptilocaulin metabolites in a biomimetic manner and had as his key intermediates the 
indenones 249 and 261. The proposal is that it might be possible to prepare arbusculidine A 
(187) from one of these indenones, via the addition of guanidine and the subsequent 
oxidation of the intermediate addition products such as 7-epineoptilocaulin (216) or 237 
(Scheme 83). 
 
Scheme 83. Proposed synthesis of arbusculidine A: (i) Methanol, 85 ˚C, 24 h (ii) MnO2 CH2Cl2, 55 
˚C, 24 h. 
Therefore, a synthesis of the intermediate enone 249 (Scheme 84) was embarked 
upon. This is prepared by the condensation of the known aldehyde 252 with the β-ketoester 
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253. Intermediate 253 was prepared by alkylation of the dianion of tert-butyl 3-oxobutanoate 
(241) following a literature procedure.142 Due to availability, iodobutane was utilised as an 
alkylating agent in place of the bromobutane that was used in the literature preparation. The 
reaction was carried out on six occasions, each achieving similar yields from 59-65 %, which 
is comparable to the reported yield of 75 %.104 The product was then reacted with cucumber 
aldehyde (252) in the presence of potassium t-butoxide, to give a crude intermediate as a 
yellow oil. This oil was then dissolved in toluene, p-toluene sulfonic acid was added and the 
reaction was heated at 80 ˚C overnight to give the cyclohexanone 254 as a racemic mixture. 
The reaction was performed a total of five times, with yields of 48-61 %. It is speculated that 
the use of fresh potassium t-butoxide would result in yields which are more in line with that 
of Snider.123 The 1H NMR spectrum for 253 and 254 was in very close agreement with the 
literature in both cases (Scheme 85). Enone 254 was then treated with methyl lithium to give 
an intermediate alcohol, which was subsequently oxidised with PCC without purification to 
give the cyclohexanone 255 in 52- 56 % yield over 3 attempts.  
 
Scheme 84. (i) NaH, n-BuLi, then C4H9I, THF. (ii) a) t-BuOK, then p-TsOH, PhMe, 80 ˚C (iii) a) 
MeLi, Ce(III)Cl3, THF, -78 ˚C. b) PCC, CH2Cl2, r.t.. (iv) Li, N-propylamine, ethylenediamine, 0 
˚C, 1.5 h.123 
For the next step, Snider reports the reduction of the enone double bond using 
classical Birch reduction conditions.123 However, liquid ammonia was unavailable and an 
alternative method was required. In 2000, Garst et al. had modified the Birch reduction by 
substituting liquid ammonia for short chain amines (N-propylamine and ethylenediamine), 
giving results comparable to those obtained when  using liquid ammonia but with a much 
simpler and safer reaction procedure.105 This reaction was attempted on the cylclohexanone 
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255, which led smoothly to the formation of 256 as a mixture of isomers in yields of 46-54 % 
over 4 attempts. Although this is a lower range of yields than the 73 % reported by Snider,123 
it is worth noting that the reaction procedure was much simpler and safer than a conventional 
Birch reduction.  
Ozonolysis was used to convert alkene 256 into aldehyde 257 (Scheme 85) as a 5:1 
mixture of isomers in 74 % yield. Aldehyde 257 was then converted into the indenone 249 
as a 6:4 mixture of isomers in 74 % yield by heating with 6M HCl in diethyl ether. The 1H 
and 13C NMR data obtained was in very close agreement with that reported by Snider.123 
Confirmation of structure of 249 was obtained by high resolution mass spectrometry, with a 
mass of 251.2369 Da being observed for the [M+H]+ ion. This is in exact agreement with 
the required mass (scheme 85). It is worth noting that the relative stereochemistry is not an 
issue in these reactions, as the planned oxidation of the guanidine intermediates to give 
arbusculidine A (187) will result in a removal of these stereocenters.  
 
Scheme 85. (i) a) O3, CH2Cl2, -78 ˚C; b) PPh3. (ii) 6M HCl, DME, 55 ˚C microwave, 10 min. 
Indenone 249 was reacted with guanidine in methanol, which was generated by 
reaction of guanidine hydrochloride with sodium methoxide at r.t. for 30 minutes. This 
mixture was heated in a sealed tube at 85 ˚C for 24 hrs - conditions which were reported to 
give 7-epineoptilocaulin (216) by Snider.110 
 
Scheme 86. (i) Guanidine, MeOH, 85 ˚C, 24 h. 
After work up, the product subjected to purification by column chromatography. 
However, only a complex mixture of products was evident, and not the formation of 216. 
The reaction was repeated a further 3 times on the same scale, and the products obtained 
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were combined to give a sufficient sample for analysis and for subsequent reactions. 
Analysis of the 1H NMR spectrum of this crude compound gave a complex spectrum. 
However, analysis of the 13C spectrum gave signals at c 154.7, 126.4, 119.4 ppm, which are 
indicative of (±)7-epineoptilocaulin (216), as well as signals at 157.8/153.6, 126.4/123.2 and 
121.2/118.2 ppm, which indicate the presence of either isomeric compounds or oxidised 
analogues of 216. Analysis by high resolution mass spectrometry indicated the presence of 
the desired compound with a m/z found at 248.2122 ([M+H]+), with C15H26N3
+ requiring 
248.2121 Da. Other masses at 246.1966 ([M+H]+) corresponded to C15H24N3
+  mirabilin B 
(220), which requires 246.1966 Da, and at 244.1810 ([M+H]+) corresponding to C15H22N3,
+ 
which requires 244.1810 Da, are evident of the oxidised species 274. A mass at 250.2278 
([M+H]+) corresponds to C15H28N3,
+ which requires 225.2278 Daltons, corresponding to the 
reduced compound 275 (Figure 43). 
 
 
Figure 43. Structures 216, 2220, 274 and 275 and the mass spectrum obtained from addition of 
guanidine to indenone 249. 
Whilst the inability to purify 216 is a problem, the presence of the other isomers in 
the mixture is not overly worrying, as for the proposed synthesis of arbusculidine A (187) 
oxidative aromatisation of both the A- and C-ring of 216 is required, and the other 
compounds are intermediates in this process. In Snider’s preparation of mirabilin B (220), 
the crude reaction mixture from the preparation of 7-epineoptilocaulin (216) was aromatised 
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in the A-ring by treatment with manganese dioxide in dichloromethane at 55 ˚C for 24 h. It 
was speculated that an increased reaction time, in addition to the use of an increased amount 
of oxidant, might allow the further aromatisation of mirabilin B (220) to give arbusculidine 
A (187) (Scheme 87). 
 
Scheme 87. Proposed synthesis of arbusculidine A (187). 
Several methods are available for the preparation of activated manganese dioxide, 
and it was decided that the method reported by Carpino106 in which the manganese dioxide 
is dispersed upon activated charcoal should be used. This method was reported to give better 
results in a range of oxidations. Thus, activated carbon was added to an aqueous solution of 
potassium permanganate, and after 16 h, the solid formed filtered and washed with water to 
give the manganese dioxide-coated carbon. The activity of the product was tested by 
oxidising a sample of N-propanol in deuterated chloroform, which resulted in the formation 
of propanal as evidenced by 1H NMR spectroscopy after 1 h. The activity of the reagent was 
determined by treatment with excess ammonium iron(II) sulfate, followed by back titration 
of the excess iron(II) with potassium permanganate. From these calculations it was found 
that 1.0 g of the oxidant contained 2.06 mmol of manganese(II).  
Using the method described by Snider, a solution of the crude product 216 in 
dichloromethane was treated with 10.7 equivalents of manganese dioxide on charcoal, and 
the mixture was heated in a sealed tube at 55 ˚C for 48 h. This was twice as much oxidising 
agent and double the reaction time to that reported by Snider. After 48 h the reaction was 
cooled to r.t. and filtered through a pad of Celite©, washing with copious quantities of 
methanol. The reaction was carried out on 36.0 mg of the crude product from the previous 
guanylation (crude 7-epineoptilocaulin (216)), but only 7.0 mg of the crude material was 
obtained after washing. Analysis of this sample by high resolution mass spectrometry 
interestingly demonstrated that only the reduced compound 275 was present in the crude 
product, as a mass at m/z 250.2279 (100%, [M+H]+) Da was observed. This corresponds 
closely to the required mass of 250.2278 Da. 
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Scheme 88. (i) MnO2 on carbon, CH2Cl2, 55 ˚C, 24 h. 
This result suggested that 216 and the part aromatised compounds were undergoing 
an oxidation reaction, but that the reduced compound 275 was not. In addition, the conditions 
of the reaction are in some way removing or decomposing the oxidised compounds, or that 
they were being lost on purification. It was decided that alternative oxidation processes 
would be investigated, such as the palladium catalysed oxidation of the crude 216 using a 
method described by Labinger.145  
 
Scheme 89. Attempted oxidation of 216: (i) Pd(O2CCF3)2, O2, acetone, r.t., 16 h. 
Thus, crude 216 was dissolved in acetone with a catalytic quantity of palladium 
trifluoroacetate. A positive atmosphere of oxygen was maintained using balloons. The 
balloons were replenished until the consumption of oxygen appeared to cease, indicating 
that the reaction had finished. After stirring for 16 h, removal of solvent, and analysis by 1H 
NMR spectroscopy suggested that no reaction had occurred. 
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Scheme 90. Attempted oxidation of 216: (i) IBX, MeCN, reflux, 48 h. 
Finally, the oxidising agent IBX (276) was employed. Thus, guanidine 216 was 
heated under reflux in the absence of light with six equivalents of IBX in anhydrous 
acetonitrile. On monitoring the reaction by TLC, the rapid production of a new spot, thought 
to be mirabilin B (220), was apparent, and the reaction was continued until this spot 
disappeared. After aqueous work up, an off-white solid was obtained, which was found to 
be composed mostly of residual IBX and IBX by-products. Unfortunately, it proved difficult 
to separate any potential products from this material, and analysis by mass spectrometry 
indicated that no ions corresponding to arbusculidine A (187) were present. However, mass 
spectrometry did indicated the presence of the starting material at m/z 248.2125 ([M+H]+) 
with C15H26N3
+ requiring 248.2121 Daltons, as well as masses at 246.1969 ([M+H]+) 
C15H24N3
+ requiring 246.1966 for mirabilin B (220), and 250.2281 ([M+H]+) C15H28N3
+ 
requiring 250.2278 for (275) (Scheme 91). 
 
Scheme 91. (i) MnO2, Pd(OOCCF3)2, IBX. 
In conclusion, at this stage of the research the indenone 249 had successfully been 
prepared and guanylated to form 7-epineoptilocaulin (216), which unfortunately was not 
easily oxidised to arbusculidine A (187), and under the conditions employed gave only the 
previously prepared110 mirabilin B (220). It was thus concluded that either manganese 
dioxide is not a sufficiently powerful oxidising agent to convert 216 into 187, or that this 
transformation is not possible under oxidative conditions. This work might suggest that once 
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the A-ring is aromatised, the B ring is highly deactivated towards further oxidation, and an 
alternative route to arbusculidine A (187) was required (Scheme 92). 
As was noted previously, Snider85 reported the synthesis of ptilocaulin (212) and 
isoptilocaulin (215) via the addition of guanidine to the enone 261, followed by reduction of 
the proposed intermediate guanidine 237. If this intermediate could be accessed, then 
oxidation of this intermedate might be an easier process than the oxidation of the reduced 
intermediate 7-epineoptilocaulin (216) used in the previous oxidations (Scheme 92). 
Therefore the double bond in the enone 255 was selectively ozonolysed -78 ˚C in 
pyridine and dichloromethane, to give the aldehyde 260 in 50 % yield together with 50 % of 
recovered starting material. The cyclisation of 260 was achieved by microwave-mediated 
cyclisation, using aqueous 6M HCl in dimethoxyethane. This resulted in a 54 % yield of 
261. The 1H NMR spectrum of 261 was identical to that reported by Snider, and gave key 
diagnostic signals at H 9.79 (1H, s) for the aldehyde proton and at H 6.66 (1H, d, J = 4.0 
Hz, CH) ppm for the enone CH. Next, the reaction was performed as reported by Snider,123 
and the enone 261 was added to a methanolic solution of guanidine. After heating the mixture 
in a sealed tube at 85 ˚C for 24 h, the solution was evaporated to give a crude sample of the 
presumed structure 237 as a brown gum (Scheme 92). 
Scheme 92. (i) O3, CH2Cl2, pyridine, PPh3, -78 ˚C (ii) 6M HCl, 55 ˚C microwave (iii) guanidine, 
methanol, 85 ˚C, 24 h. 
Snider did not isolate 237, instead reduced it immediately with sodium borohydride 
to form ptilocaulin (212) and isoptilocaulin (215).123 It was desired that its structure was 
investigated in more detail, so the crude mixture was analysed by high resolution mass 
spectrometry. It was apparent from this analysis that there were at least three and possibly 
four structures present in the mass spectrum corresponding to [M+H]+ ions of 242.1653, 
244.1809, 246.1966 and 248.2122 Daltons. The mass of the desired product is 246.1965 
  
106 
 
Daltons and the other three appear to differ by approximately 2 mass units and might suggest 
that a disproportionation-like process is occurring in the mixture, as was suggested by Snider 
in his one–pot synthesis of mirabilin B (220)110 (Figure 44). 
 
Figure 44. The mass spectrum of the crude product from the preparation of 237. 
 
Scheme 93.  Proposed structures for the ions observed in the mass spectrum (fig 43). 
It is possible to speculate that these masses correspond to the ions 274, 277, 278 and 
279. Ion 277 corresponds to the proposed intermediate form Snider’s work, which could 
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disproportionate to the ions 274 and 277, and further that 274 undergoes oxidative 
aromatisation to give 279, which is the protonated form of the desired product arbusculidine 
A (187). 
The intensity of the ion corresponding to 187 is very low, but this is persuasive 
evidence that this is the desired compound and that in nature its formation involves an 
oxidative process. Indeed, this observation might also suggest that 187 is an artefact from 
the isolation process from the native sponge due to aerial oxidation. 
To determine whether the iminium ion 237 would be oxidised to arbusculidine A 
(187) on exposure to molecular oxygen, the remaining mass spectrum sample was dissolved 
in methanol before being stirred in the presence of atmospheric oxygen until completely 
evaporated. This was repeated, and the dissolution- evaporation process repeated once more, 
the experiment lasting a total of three days. It was hoped that further analysis by mass 
spectroscopy would show an increase in the peak intensity at 242.1653 Da and a decrease in 
the intensity of the other three ions. The sample was resubmitted for analysis by mass 
spectrometry and surprisingly, it was observed that the desired ions between 242 and 248 
Daltons were not observed, but there was an intense ion at around 306.2176 Daltons. (Figure 
45)   
 
Figure 45. Mass spectrum showing the ion for methanolic addition of arbusculidine A. 
This appears to correspond to a structure in which two molecules of methanol have 
added to arbusculidine A (188). It is possible to speculate as to the nature of this [M+H]+ 
ion, and structures such as 280-282 might be suggested, all of which have a mass of 306.2176 
(Figure 46). 
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Figure 46. Possible structures corresponding to the exact mass of 306.2176 Daltons. 
During preparation for mass spectrometry, the sample had been dissolved in 
methanol and ammonium acetate was added. Ammonium acetate can act as a proton source 
under the correct conditions, and it is conceivable that in this case it acted as a catalyst for 
the addition of two molecules of methanol. Although this is a disappointing result, it does 
seem to indicate that all of the species which were detected in the previous mass spectrum 
had possibly oxidised in the air to give arbusculidine A (187) or a related intermediate. 
It had been speculated that the iminium ion 237 would be highly unstable, and it was 
desirable to further oxidise it immediately. While waiting to receive the mass spectrometry 
data for it, the further oxidation of the crude iminium ion 237 was carried out. The oxidation 
was to be carried out in duplicate in dichloromethane with manganese dioxide in a sealed 
tube, as described by Snider123 for the oxidation of 7-epineoptilocaulin (216). However, it 
was found that the crude iminium ion 237 would not dissolve completely in dichloromethane 
and therefore, three different oxidation reactions were carried out.  
Firstly, the crude iminium ion was triturated with dichloromethane and transferred 
to a Carius tube and oxidised with ten equivalents of manganese dioxide at 55 ˚C for 24 h. 
Secondly, the remaining undissolved residue was dissolved in methanol and transferred to a 
Carius tube before removing the methanol under vacuum. Dichloromethane was then added 
and the oxidation reaction performed using ten equivalents of manganese dioxide at 55 ˚C 
for 24 h. It was speculated that as the reaction proceeded, the reactants would dissolve. 
Finally, a sample of crude 237 was dissolved in methanol and transferred to a separate sealed 
tube, and again the methanol was removed under vacuum before adding dichloromethane 
and 10 equivalents of manganese dioxide on carbon and heating at 55 ˚C for 24 h. On 
working up, each reaction was passed through a pad of Celite©, washing with copious 
quantities of methanol. Evaporation of the solvent yielded a brown gum in each case and a 
sample of each was submitted for analysis by accurate mass spectrometry. Unfortunately, no 
ions indicated the formation of 187 or any partially oxidised intermediates of 187.  
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Scheme 94. (i) Guanidine, methanol, 85 ˚C, 24 h. (ii) Activated MnO2 on carbon, dichloromethane, 
Carius tube, 55 ˚C for 24 h. 
One observation from these reactions was that the mass balance of these reactions 
was very poor, and considerably less material was recovered from each reaction when 
compared to the amount originally put into the reaction. For example in one case where 40.0 
mg of the indenone 237 was guanylated to give 67.0 mg of 237, only 10.0 mg of crude 
product was obtained after the oxidation stage, and it was  thus speculated that the activated 
charcoal used in the oxidation might be retaining much of the aromatised compound. In order 
to isolate further products, the activated charcoal was washed again but using methanol with 
a few drops of aqueous 1M HCl added, as it was speculated that as a hydrochloride salt, the 
product may have less affinity for the activated carbon. The solvent was removed and the 
residue triturated with dichloromethane to give a further 48.0 mg of crude product. Analysis 
of this residue by high resolution mass spectrometry did not indicate the presence of 187 or 
any intermediates relating to 187. However, the fact that more material was recovered led us 
to reconsider the oxidation process used.  
Activated charcoal is often used as a decolourising agent and to remove trace 
impurities form organic compounds during recrystallization. It was though possible that a 
planar aromatic compound such as arbusculidine A (187) would show a high affinity to the 
activated charcoal, which might explain why the desired product was not isolated after 
washing with dichloromethane or methanol alone. 
 Following this assumption, a sample of activated manganese dioxide was 
precipitated from manganese sulfate and potassium permanganate at 60 ˚C under aqueous 
conditions. The chocolate brown solid was oven dried (120 ˚C) over 2 days then ground to 
a powder in a pestle and mortar before use.  
At this stage two separate reactions were attempted. Firstly the iminium ion 237 was 
prepared from the indenone 261. Following guanidine addition, the sample was transferred 
to a tube where care was taken to thoroughly remove all traces of methanol (under vacuum) 
before suspending the residue in dichloromethane and adding 6.5 equivalents of activated 
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manganese dioxide. The reaction was then heated at 55 ˚C for three days, before being 
filtered and the solvent removed under reduced pressure to give a brown gum (Scheme 95). 
A sample was submitted for analysis by mass spectrometry, which revealed that 
(M+H) ions at 246.1967 and 248.2124 Daltons which were prevalent in the starting material 
had considerably diminished, and ions at 242.1656 (arbusculidine A (187)) and 244.1811 
Daltons were present at much higher intensity (Figure 47).  
 
Figure 47. Mass spectrum of the product formed from the oxidation of 237 with activated 
manganese dioxide. 
 Attempts were made to purify this mixture by preparative TLC. Unfortunately, no 
pure compound was obtained from this endeavour and analysis by NMR spectroscopy gave 
no positive indication for the formation of 187. Comparisons of the crude samples by NMR 
spectroscopy in DMSO were attempted but it was apparent that 187 was not present, as 
considerable contamination was a problem in the reaction. 
 
Scheme 95. (i) Activated MnO2 (6.5 eqv.), dichloromethane, Carius tube, 55 ˚C, 3 days.  
 
In parallel with this experiment, a small sample of the iminium ion 237 was stirred 
in chloroform in contact with the air until evaporation of the solvent occurred (ca 3 days), at 
which point further chloroform was added, and this stirring and evaporation repeated a 
second time. Analysis of the sample by mass spectrometry indicated that a similar 
transformation of the imine 237, which gave ions at 246.1967 and 248.2124 Daltons into 
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ions at 242.1656 (arbusculidine A (187)) and 244.1811 Daltons, had occurred. This might 
suggest that 187 occurs as a consequence of post-isolation oxidation of another related 
natural product (Scheme 96). 
 
 
Scheme 96 (i) Air 6 days. 
 In an attempt to prepare a larger sample of 187 from 237, the manganese dioxide 
oxidation reaction was repeated on a larger scale with more equivalents of the oxidising 
agent and a longer reaction time (7 days). A modified work up was employed, to give a 
chloroform extract of the oxidation alongside the methanol extract (Scheme 97). 
 
Scheme 97. (i) Activated MnO2 (8 eqv), dichloromethane, Carius tube, 55 ˚C, 7 days. 
Analysis of the chloroform extract by high resolution mass spectrometry indicated a 
large abundance of the ion at 242.1656 Daltons, corresponding to arbusculidine A (187), 
with small peaks at 244.1812 and 246.1969 Daltons for the intermediate species (Figure 48). 
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Figure 48. Mass spectrum of the chloroform extracts of the oxidation of imine 237 with MnO2. 
The methanol extract showed considerable amounts of an ion at 242.1654 Daltons, 
corresponding to arbusculidine A (187), with more significant peaks at 244.1812 and 
246.1969 Daltons (Figure 49). The presence of these intermediates suggests that the reaction 
might need further time or more equivalents of oxidant to effect a complete conversion. 
Additionally, the mixing of the solid oxidant with the reagent in the Carius tube might not 
be very efficient and this might be reflected in this incomplete oxidation. 
 
Figure 49. Mass spectrum of the methanol extracts of the oxidation of imine 237 with MnO2. 
The crude products from this reaction are currently undergoing purification using 
preparative HPLC by the project’s collaborator Professor Roberto Berlinck (Sao Paulo, 
Brazil).  
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6.0 Conclusions  
 The bicyclic natural product monalidine A (187) was successfully synthesised via an 
efficient procedure, with the novel use of trifluoroethanol negating the need for protecting 
groups. Biological testing of monalidine A (187) showed it to be highly active against L. 
infantum amastigotes (non-infectious form), but no activity was observed against L. 
infantum promastigotes (infectious form). The intermediate 269 showed good activity 
against L. infantum promastigotes, indicating that monalidine A (186) shows poor activity 
due to its relative charge and poor cell uptake.  
Extensive research has been conducted towards the synthesis of the tricyclic alkaloid 
arbusculidine A (187), but multiple attempts to synthesize it by oxidising mirabilin B (220) 
failed. The alternative oxidation of the iminium ion 237 with manganese dioxide to give the 
target compound arbusculidne A (187) was attempted with mixed results. Mass spectrometry 
appeared to give conclusive evidence for the formation of 187 during these reactions, 
however, NMR spectroscopy evidence was not conclusive. A larger sample of crude 187 has 
been prepared and is currently being purified and investigated by the project’s collaborators 
in Brazil.  
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7.0 Experimental  
7.1. General experimental synthesis procedures.  
Reactions were magnetically stirred and monitored by TLC using Kieselgel 60 F254 
silica coated plates, which were visualised using either I2, phosphomolybdic acid, vanillin 
reagents or under UV light. General chemicals were obtained from Sigma Aldrich or Alfa 
Aesar. All anhydrous reactions were carried out in oven dried glassware and under a static 
argon atmosphere. Anhydrous Et2O and CH2Cl2 were obtained from an Innovative 
Technology Pure Solv MD-3 solvent purification system. Trifluoroethanol (TFE) was dried 
over activated molecular sieves (3 Å powder). Flash chromatography was carried out on 
Davisil® 60A silica gel with the eluting solvent (chloroform, dichloromethane, diethyl ether, 
ethyl acetate, hexane, methanol, petroleum ether, THF or toluene) stated in each case. 1H 
and 13C NMR spectra of reaction products were obtained using a Bruker Ultrashield Plus 
400 MHz spectrometer in CDCl3 unless otherwise stated, and are reported as ppm referenced 
to the solvent internal standard at 7.26 and 77.16 ppm respectively. Infrared spectra were 
obtained using a Perkin Elmer FTIR spectrometer as either a thin film or as a KBr Disc. 
Ionisation (CI) and Electrospray Ionisation (ESI) mass spectra were recorded on a 
Micromass Quattro II spectrometer, and high resolution mass spectra were recorded on either 
a Finnigan MAT 900 XLT or a Finnigan MAT 95 XP at the EPSRC National Mass 
Spectrometry Service Centre based in Swansea, UK. All non-aqueous reactions were 
performed in a static atmosphere of dry argon or nitrogen unless otherwise stated. 
Microwave reactions were carried out using a CEM Discover SP-D closed vessel microwave 
reactor. 
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7.2. Preparative Methods 
Preparation of deactivated silica 
Silica gel (50 g) was stirred in methanol (100 mL) and triethylamine (10 mL) for 30 minutes 
before being filtered under vacuum and washing with further methanol. The silica was then 
air dried before use. 
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Preparation of activated manganese dioxide on carbon106 
A solution of potassium permanganate (10.0 g, 63 mmol) in water (125 mL) in a 
beaker was heated to boiling point before removing from the heat and adding activated 
carbon (3.12 g) portion wise over 5 minutes, allowing the frothing to subside between 
additions. The solution was then boiled until the purple colour was discharged. The solution 
was allowed to stand at r.t. for 10/15 minutes before being filtered on a Buchner funnel and 
washing the filtrate with water (4 x 25 mL), and allowed to air dry before leaving in an oven 
at 115 ˚C for 24 h, to give activated manganese dioxide on carbon (7.91 g). The amount of 
absorbed manganese was calculated by the treatment of 0.50 g of the sample with aqueous 
ammonium iron(II) sulfate (0.2 M, 25 mL, 5 mmol) and aqueous H2SO4 (1 M, 20 mL, 20 
mmol), followed by back titration of the excess iron(II) with acidified potassium 
permanganate (0.008 M) to a persistent pink colour. From these calculations it was found 
that 22 mL of permanganate solution (0.176 mmol) was required, which equates to 0.88 
mmol of excess iron(II). Thus the original permanganate consumed 4.12 mmol of iron (II), 
equating to 2.06 mmol of MnO2 per gram. 
Reduction of Mn4+   MnO2 + 2Fe
2+ + 4H+ → Mn2+ + 2Fe3+ + H2O 
Quantification of excess Fe2+  MnO4
- + 5 Fe2+ + 8H+ → Mn2+ + 5 Fe3+ + 4 H2O 
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Preparation of activated manganese dioxide. 
A solution of manganese sulfate monohydrate (25 g) in water (480 mL) was heated 
to 60 ˚C and added in portion to a heated (60 ˚C) solution of potassium permanganate 
(17.4 g) in water (330 mL). The suspension formed was stirred at this temperature for 1 h 
then cooled, filtered and washed with water (100 mL). The solid obtained was dried in an 
oven at 120 ˚C for 48 h to give activated manganese dioxide (9.0 g) in 70% yield. 
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Preparation of 6-hydroxy-4,4,5,7,8-pentamethylchroman-2-one (26)37 
 
A mixture of 2,3,5-trimethyl-1,4-hydroquinone (98) (5.07 g, 33.3 mmol), methyl 3,3-
dimethylacrylate (5.0 mL, 41.0 mmol, 1.23 eqv.) was dissolved in methanesulfonic acid 
(50 mL) and this was heated at 70 ˚C for 3 h. After cooling and stirring at r.t. overnight, the 
reaction mixture was cautiously added to water (200 mL) and extracted with ethyl acetate (3 
x 150 mL). The combined organic layers were washed in turn with water (100 mL), saturated 
sodium carbonate (100 mL), and brine (100 mL). They were then dried (MgSO4), filtered 
and the solvent removed under reduced pressure to give a grey/purple solid. The crude 
product was recrystallized from chloroform/hexane to yield the lactone 26 (6.88 g, 29.4 
mmol, 88 % yield) as a white solid. Data was in accordance with the literature.  
Rf = 0.39 (50:50 diethyl ether:petroleum ether); δH 4.52 (1H, s, OH), 2.55 (2H, s, 
CH2), 2.36 (3H, s, Me), 2.22 (3H, s, Me), 2.18 (3H, s, Me), 1.46 (6H, s, 2 x Me); δC 168.8, 
148.8, 143.5, 128.2, 123.4, 121.8, 118.9, 46.1, 35.5, 27.7, 14.4, 12.5, 12.3. 
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Preparation of 3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic 
acid 5237 
 
The lactone 26 (6.25 g, 26.68 mmol) was suspended in acetonitrile (15 % aq. v/v, 
270 mL), and a solution of NBS (6.41 g, 36.01 mmol, 1.35 eqv.) in acetonitrile (40 % aq. 
v/v, 120 mL) was added drop wise over 1 h to the suspension. The resulting mixture was 
stirred for a further 30 min, diluted with water (500 mL) and extracted with dichloromethane 
(3 x 100 mL). The combined organic layer was washed with water (2 x 100 mL) and brine 
(100 mL).  It was then dried (MgSO4), filtered and the solvent was removed under reduced 
pressure to give a bright yellow solid. The crude product was re-dissolved in diethyl ether 
and petroleum ether was added to the cloud point. The solution was then cooled (0 ˚C) 
overnight. The supernatant liquid was decanted from the crystals formed to give the quinone 
52 as a yellow solid (6.60 g, 26.37 mmol, 99 % yield). Data was in accordance with the 
literature. 
Rf = 0.17 (50:50 diethyl ether:petroleum ether); δH 10.06 (1H, b s, OH), 3.02 (2H, s, 
CH2), 2.14 (3H, s, Me), 1.95 (3H, s, Me), 1.93 (3H, s, Me), 1.44 (6H, s, 2 x Me); δC 190.8, 
187.4, 178.4, 152.0, 143.0, 139.0, 138.4, 47.2, 37.9, 28.8, 14.3, 12.5, 12.1. 
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Preparation of 2,5-dioxopyrrolidin-1-yl 3-methyl-3-(2,4,5-trimethyl-3,6-
dioxocyclohexa-1,4-dien-1-yl)butanoate 52a37 
 
DCC (1.80 g, 8.72 mmol, 1.2 eqv.) was added to a cooled (0 ˚C) solution of quinone 
52 (1.80 g, 7.19 mmol, and N-hydroxysuccinimide (0.91 g, 7.91 mmol, 1.1 eqv.) in 
anhydrous THF (60 mL). After stirring for 18 h at r.t., the mixture was filtered to remove 
DCU and evaporated under reduced pressure. The residue was triturated with ethyl acetate 
(30 mL) and filtered again. The filtrate was evaporated under reduced pressure to give a 
yellow solid. This solid was then dissolved in hot ethyl acetate (11 mL) then cooled to 0 ˚C. 
A crystalline mass formed, and the supernatant solvent was decanted from this, after which 
it was dried under vacuum to give the crude activated ester 52a (2.79 g) as a yellow solid, 
which was used without further purification. 
Rf = 0.09 (25:75 EtOAc:hexane), δH 3.22 (2H, s, CH2); 2.71 (4H, s, 2 x CH2), 2.11 
(3H, s, Me), 1.96 (6H, s, 2 x Me), 1.46 (6H, s, 2 x Me); δC 190.4, 187.5, 169.0, 167.8, 150.1, 
143.0, 140.6, 139.0, 44.3, 39.0, 29.3, 25.7, 14.4, 12.7, 12.4.  
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Preparation of N,N’-bis(2-Chloroethyl)benzene-1,4-diamine (70)37 
  
Pd/C (5 %, 0.40 g) was added to a solution of N,N-bis(2-chloroethyl)-4-nitroaniline 
(124) (0.40 g, 1.52 mmol) dissolved in EtOH (35 mL), and this mixture was stirred under an 
atmosphere of hydrogen gas (balloons) for 17 h. After filtration through a Celite© pad, which 
was washed with a 2:1 mixture of EtOAc and hexane (ca 100 mL), the red/brown filtrate 
was concentrated in vacuo to give a brown solid (0.99 g). The crude product was then 
adsorbed onto silica and purified by flash chromatography (50:50 EtOAc:hexane) to give 70 
(0.24 g, 1.03 mmol, 68 % yield) as a brown solid. The data was in agreement with the 
literature.  
Rf = 0.16 (33:67 EtOAc:hexane); δH 7.02 (2H, b s, NH2), 6.79 (2H, d, J = 3.6 Hz, 2 
x CH), 6.70 (2H, d, J = 3.6 Hz, 2 x CH), 3.58-3.70 (8H, m, 4 x CH2); δC 135.7, 126.0, 116.3, 
114.0, 54.1, 14.8. 
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Preparation of 3-amino-1,2,4-benzotriazine-1-oxide (77) 81 
 
From 2-nitroaniline (134): 2-Nitroaniline (5.00 g, 36.2 mmol) and cyanamide 
(7.60 g, 181 mmol, 5 eqv.) were heated at 100 ˚C with stirring until a deep red melt formed. 
The reaction was then cooled to 40 ˚C, and concentrated hydrochloric acid (15 mL) was 
cautiously added in a drop wise fashion.  The resulting exothermic reaction was allowed to 
subside, and this was followed by heating at 100 ˚C for 2 hrs. The reaction was then allowed 
to cool to 40 ˚C, and NaOH solution (50 mL, 16 M) was added cautiously in a drop wise 
fashion, before heating the now bright orange solution at 100 ˚C for 2 hrs. The reaction was 
then cooled to room temperature and water (50 mL) was added and the mixture was stirred 
for 30 minutes. The yellow suspension was then filtered and washed with water (10 mL) 
followed by diethyl ether (2 x 5 mL), collected and dried in a vacuum desiccator over P2O5. 
The product 75 (5.05 g, 31.17 mmol, 86 % yield) was obtained as a bright yellow solid and 
was used without further purification. Data was in agreement with the literature. 
 
From nitrobenzene (139): Potassium t-butoxide (6.52 g, 58.23 mmol, 8.3 eqv.) was 
stirred in anhydrous THF (30 mL) under a positive argon atmosphere at 25 ˚ C for 30 minutes. 
Guanidine hydrochloride (4.23 g, 13.70 mmol, 2.0 eqv.) was then added, followed by 
nitrobenzene (1 g, 6.85 mmol) in anhydrous THF (10 mL), and the suspension formed was 
stirred at 65 ˚C overnight. The progress of the reaction was monitored by TLC and once the 
starting material had disappeared, water (1.2 mL) was added. After stirring for 15 mins, the 
reaction was dried (MgSO4) and filtered, washing the filter pad with copious quantities of 
ethyl acetate. Evaporation of the filtrate gave a brown/black residue which was purified by 
column chromatography (25-40 THF:petroleum ether in 5 % increments). This gave 77 as a 
bright yellow solid (0.53 g, 3.3 mmol, 48 % yield).  
Rf = 0.60 (100 % ethyl acetate); δH (DMSO) 8.12 (1H, dd, J = 0.9, 8.6 Hz, CH), 7.78 
(1H, ddd, J = 1.4, 7.0, 8.3 Hz), 7.53 (1H, dd, J = 0.8, 8.3 Hz), 7.30-7.36 (3H, m, CH, NH2); 
δC 160.3, 148.8, 135.8, 129.9, 125.9, 124.7, 119.9. 
  
123 
 
Preparation of 3,6-Dimethoxy-1,2,4-trimethylcyclohexa-1,4-diene (99)37 
 
2,3,5-Trimethyl-1,4-hydroquinone (10.02 g, 65.83 mmol) was dissolved in methyl 
ethyl ketone (150 mL), and potassium carbonate (45.0 g, 325.6 mmol, 4 eqv.) was added. 
The mixture was stirred at r.t. for 30 minutes and iodomethane (16.2 mL, 260.67 mmol, 
4 eqv.) was added. The mixture was stirred for 16 h at 65 ˚C. The reaction mixture was then 
cooled to r.t. and the solvent was removed under reduced pressure. The solid residue was 
triturated with diethyl ether (2 x 100 mL). The filtered triturates were evaporated under 
reduced pressure to give a brown oil, which was purified by column chromatography (5:95 
diethyl ether:hexane) to give 99 as a colourless oil (7.70 g, 42.79 mmol, 65 % yield). Data 
was in agreement with the literature. 
Rf = 0.33 (5:95 diethyl ether:hexane); δH 6.53 (1H, s, CH), 3.78 (3H, s, Me), 3.65 
(3H, s, Me), 2.28 (3H, s, Me) 2.20 (3H, s, Me); 2.11 (3H, s, Me). 
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Preparation of 3,3,6,6-tetramethoxy-1,2,4-trimethylcyclohexa-1,4-diene (100)37 
 
1,4-Dimethoxy-2,3,5-trimethyl-benzene (99) (7.35 g, 40.78 mmol) was dissolved in 
cooled (5 ˚C) methanolic potassium hydroxide (2 % (w/v), 250 mL) in an electrolysis cell 
(See appendix p191) , and a current of 1.0 Amp was passed through the solution for 3.5 h. 
The solvent was then removed in vacuo to yield a brown solid which was dissolved in water 
(200 mL), and the mixture was extracted with ether (3 x 100 mL). The combined organic 
layers were washed with brine (2 x 100 mL), dried (MgSO4), filtered, and the solvent was 
removed under reduced pressure to give 100 (8.60 g, 35.48 mmol, 87 % yield) as a pale 
yellow solid, which was used without further purification. Data was in agreement with the 
literature. 
Rf = 0.21 (40:60 diethyl ether:hexane); δH 6.02 (1H, b q, J = 1.4 Hz, CH), 3.19 (6H, 
s, 2 x Me), 2.98 (6H, s, 2 x Me), 1.77 (3H, d, J = 1.4 Hz, Me), 1.75 (3H, d, J = 0.7 Hz, Me), 
1.68 (3H, d, J = 0.7 Hz, Me). 
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Preparation of 4,4-dimethoxy-2,3,5-trimethylcyclohexa-2,5-dien-1-one (101)37 
 
A solution of 3,3,6,6-tetramethoxy-1,2,4-trimethyl-cyclohexa-1,4-diene (100) 
(10.94 g, 45.15 mmol) in acetone (50 mL) was cooled (0 ˚C) and stirred vigorously, 
whereupon a cooled (ca 5 ˚C) acetic acid solution (2 % v/v, 55 mL) was added drop wise 
over 10 min. The resulting mixture was stirred at 0 ˚C for 25 min, then at r.t. for 3 h. The 
mixture was poured into sodium hydrogen carbonate solution (5 %, 260 mL) and then 
extracted with diethyl ether (4 x 100 mL). The combined extracts were washed with water 
(2 x 100 mL) and brine (100 mL), dried (MgSO4), filtered and evaporated under reduced 
pressure to give 101 (8.06 g, 41.09 mmol, 91 % yield) as a yellow solid which was used 
without further purification. Data was in agreement with the literature. 
Rf = 0.21 (40:60 diethyl ether:hexane); δH  6.33 (1H, q, J = 1.4 Hz, CH), 3.00 (6H, 
s, 2 x Me), 1.92 (3H, b s, Me), 1.90 (3H, d, J = 1.4 Hz, Me), 1.89 (3H, b s, Me).  
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Preparation of 2,3,5-trimethyl-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-2,5-diene-
3',4-dione (103)37  
 
A solution of n-butyllithium (12.6 mL, 2.2 M, 27.63 mmol, 2 eqv.) was added drop 
wise to a cooled (-78 ˚C) solution of N-phenylbenzamide (102) (2.73 g, 13.82 mmol) in THF 
(33 mL), and the resulting mixture was stirred at -78 ˚C for 30 min and then at 0 ˚C for 1 h. 
This solution was then re-cooled (-78 ˚C) and a solution of monoketal 101 (2.92 g, 14.86 
mmol, 1.08 eqv.) in THF (10 mL) was added drop wise. The resulting bright green solution 
was stirred for 4h then allowed to warm to  r.t. overnight. The reaction mixture was diluted 
with diethyl ether (100 mL) and vigorously washed with 3 M hydrochloric acid (3 x 100 mL) 
and separated. The combined aqueous layers were further extracted with diethyl ether (3 x 
50 mL), and the combined organic layers were then washed with brine (100 mL), dried 
(MgSO4), filtered and evaporated under reduced pressure to give a dark brown solid. This 
solid was recrystallized by dissolving in hot diethyl ether and diluting this with methanol, to 
give on standing the spirolactone 103 (2.10 g, 8.27 mmol, 60 % yield) as white crystals after 
filtration. 1H NMR data were in agreement with the literature. 
δH 7.97 (1H, d, J = 7.6 Hz, CH), 7.66 (1H, ddd, J = 1.0, 7.4, 7.6 Hz, CH), 7.58 (1H, 
ddd, J = 0.8, 7.4, 7.7 Hz, CH), 7.15 (1H, d, J = 7.7 Hz, CH), 6.35 (1H, q, J = 1.4 Hz Me), 
1.98 (3H, q, 0.7 Hz, Me), 1.96 (3H, d, 1.4 Hz, Me), 1.55 (3H, q, 0.7 Hz, Me). 
  
  
127 
 
Preparation of 2-hydroxy-1,3,4-trimethyl-6H-benzo[c]chromen-6-one (104)37 
 
A mixture of the spirolactone 103 (0.50 g, 1.97 mmol), trifluoroacetic acid (5 mL), 
trifluoroacetic anhydride (10 mL) and concentrated sulfuric acid (10 drops) was heated at 
reflux for 7 h. The solvent was removed under reduced pressure and the residue was 
dissolved in methanol (25 mL), before being partitioned between dichloromethane (100 mL) 
and water (200 mL). The layers were separated and the aqueous phase further extracted with 
dichloromethane (3 x 50 mL). The combined organic extracts were then dried (MgSO4) and 
the solvent was removed under reduced pressure to give a pale yellow solid. The crude 
product was recrystallized from dichloromethane/hexane to give lactone 104 (0.50 g, 1.95 
mmol, 99 % yield) as white crystals. Data was in agreement with the literature. 
 Rf = 0.21 (dichloromethane); Mp. 198-199 ˚C (lit.37 200-201 ˚C); δH 8.46 (1H, dd, J 
= 1.5, 7.9 Hz, CH), 8.26 (1H, b d, J = 8.3 Hz, CH), 7.78 (1H, dt, J = 1.5, 8.2, 8.3 Hz, CH), 
7.55 (1H, b dd, J = 7.9, 8.2 Hz, CH), 4.75 (1H, b s, OH), 2.72 (3H, s, Me), 2.43 (3H, s, Me), 
2.32 (3H, s, Me); δC 161.7, 148.9, 144.4, 136.4, 133.7, 130.5, 127.6, 126.5, 125.3, 123.5, 
122.2, 117.4, 116.0, 16.2, 12.9, 12.4. 
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Preparation of 3',4',6'-trimethyl-2',5'-dioxo-2',5'-dihydro-[1,1'-biphenyl]-2-carboxylic 
acid (105)37 
 
Lactone 104 (0.82 g, 3.22 mmol) was suspended in a water/acetonitrile mixture 
(15 %: v/v, 40 mL), and a solution of NBS (0.78 g, 4.38 mmol, 1.36 eqv.) in 
water/acetonitrile (40 %: v/v, 12 mL) was added drop wise over 1h. The resulting mixture 
was stirred for a further 30 min, then diluted with water (120 mL) and extracted with 
dichloromethane (3 x 50 mL). The combined organic layers were washed with water (2 x 50 
mL) and brine (50 mL), then dried (MgSO4) and evaporated under reduced pressure to give 
a crude yellow oil. The crude product was purified by column chromatography 
(dichloromethane then 20:80 EtOAc:petroleum ether) to give 105 (0.70 g, 2.61 mmol, 81 % 
yield) as a waxy yellow solid. Data was in agreement to that reported previously.1 
Rf = 0.59 (5:95 MeOH:EtOAc); Mp. 154-156 ˚C (lit.37 155-157 ˚C); δH 9.50 (1H, s, 
OH), 8.16 (1H, d, J = 7.6 Hz CH), 7.61 (1H, t, J = 7.6 Hz, CH), 7.48 (1H, t, J  = 7.6 Hz), 
7.14 (1H, d, J = 7.6 Hz), 2.08 (3H, s, Me), 2.01 (3H, s, Me), 1.82 (3H, s, Me); δC 188.0, 
186.4, 170.9, 145.1, 141.0, 140.9, 138.8, 136.4, 133.4, 131.6, 130.5, 128.8, 128.6, 13.8, 12.6, 
12.5. 
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Preparation of N-(4-(bis(2-chloroethyl)amino)phenyl)-3',4',6'-trimethyl-2',5'-dioxo-
2',5'-dihydro-[1,1'-biphenyl]-2-carboxamide (116) 
 
Carboxylic acid 105 (51.0 mg, 0.19 mmol), EDC (35.7 mg, 0.23 mmol, 1.2 eqv.) and 
HOBT (30.8 mg, 0.23 mmol, 1.2 eqv.) were dissolved in THF (5 mL) and stirred for 2 h. A 
solution of the mustard 99 (53.7 mg, 0.23 mmol, 1.2. eqv.) dissolved in THF (2 mL) was 
then added, and the mixture was stirred at r.t. for 48 h. After completion of the reaction 
(TLC), the product was diluted with EtOAc (50 mL), and the mixture was washed with water 
(3 x 100 mL), dried (MgSO4) and evaporated under reduced pressure to give the crude 
product as a brown gum. This was purified via flash chromatography (1:5 EtOAc in 
petroleum ether) to give 116 as a brown gum (30.0 mg, 0.062 mmol, 33 % yield). 
Rf = 0.22 (20:80 EtOAc:petroleum ether); δH (CDCl3) 7.70 (1H, b d, J = 7.7 Hz, CH), 
7.47-7.56 (2H, m, 2 x CH, NH), 7.32 (2H, d, J = 8.6 Hz, 2 x CH), 7.16 (1H, dd, J = 1.2, 7.6 
Hz, CH), 6.67 (2H, d, J = 8.6 Hz, CH), 3.70 (4H, t, J = 6.5 Hz, 2 x CH2), 3.61 (4H, t, J = 6.5 
Hz, 2 x CH2), 2.05 (3H, q , J = 0.7 Hz, CH3), 1.99 (3H, b q , J = 0.7 Hz, CH3), 1.90 (3H, s, 
CH3); δC 188.4, 187.8, 187.1, 143.8, 141.4, 141.2, 140.4, 133.9, 133.3, 130.9, 130.6, 130.5, 
127.9, 127.8, 127.1, 126.7, 122.7, 55.1, 39.5, 14.2, 12.7, 12.6; LRCIMS m/z 485.1 (100 %, 
[M+H]+), 487.1 (65 %) 489.1 (10 %); HRCIMS m/z found 485.1387 ([M+H]+), 
C26H27
35Cl2N2O3 requires 485.1399. 
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Attempted coupling of quinone 52a with Tirapazamine (38), 77, 147 and 161 
 
i) From the activated ester 52a: Tirapazamine 38 (102.0 mg, 0.58 mmol. 1.5 eqv.) 
was suspended in acetonitrile (10 mL), and the activated ester 52a was added after dissolving 
in anhydrous acetonitrile (5 mL). The reaction mixture was stirred at r.t. for 48 h and 
monitored by TLC with 100 % ethyl acetate. Once the starting material 52a had been fully 
consumed, the solvent was removed by rotary evaporation. Analysis by NMR spectroscopy 
and TLC suggested the presence of only tirapazamine (38) and the quinone acid 52. This 
reaction was repeated at 40 ˚C and 60 ˚C with similar results.  
An identical series of reaction were performed on the same scale using 
3-amino-1,2,4-benzotriazine-1-oxide (77), N-octylbenzo[1,2,4]triazin-3-amine (147) and 
3-(heptylamino)benzo[1,2,4]triazine 1-oxide (161) at r.t., 40 ˚C and 60 ˚C, with only the 
recovery of starting materials being observed.  
(ii) Using HOBT activation: Quinone 52 (100.0 mg, 0.40 mmol), was dissolved in 
anhydrous acetonitrile (10 mL). DCC (69.0 mg, 0.33 mmol, 1.2 eqv.) was then added 
followed by HOBT (80.0 mg, 0.52 mmol, 1.3 eqv.). The reaction was stirred at r.t. for 1 hour 
whereupon a solution of tirapazamine (38) (102.0 mg, 0.58 mmol, 1.5 eqv.) in acetonitrile 
(15 mL) was added. The reaction was stirred at r.t. for 48 h, and then evaporated under 
reduced pressure. After this, ethyl acetate (10 mL) was added and the mixture was cooled (0 
˚C) with stirring. After filtering through a cotton wool plug to remove undissolved DCU, the 
filtrate was evaporated, and this procedure was repeated twice more with ethyl acetate (5 
mL) to give a crude gum (115.6 mg). Analysis of the product and the precipitated DCU 
residues by NMR spectroscopy and TLC suggested only the presence of tirapazamine (38) 
and the quinone acid 52. 
An identical series of reaction were performed on the same scale using 
3-amino-1,2,4-benzotriazine-1-oxide  (77), N-octylbenzo[1,2,4]triazin-3-amine  (147) and 
3-(heptylamino)benzo[1,2,4]triazine 1-oxide  (161) at r.t., 40 ˚C and 60 ˚C, with only the 
recovery of starting materials being observed.  
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 iii) Via an acid chloride: Quinone acid 52 (100.0 mg, 0.40 mmol) was dissolved in 
thionyl chloride (3 mL) and heated under reflux for 30 minutes. Excess thionyl chloride was 
removed under reduced pressure, and a solution of tirapazamine (38) (102.0 mg, 0.58 mmol, 
1.5 eqv.) in anhydrous pyridine (20 mL) was added. The reaction was stirred at r.t for 4 hrs, 
and the solvent was removed under reduced pressure to give a brown semi-solid. Analysis 
by NMR spectroscopy showed the resulting product to be unchanged tirapazamine and 
quinone acid 52. 
 iv) Via a mixed anhydride: Quinone 52 (100.0 mg, 0.40 mmol) was dissolved in THF 
(10 mL) and cooled (-5 ˚C), whereupon a solution of isopropylchloroformate (1 M, 0.4 mL, 
0.40 mmol, 1.0 eqv.) in toluene was added. Triethylamine (0.055 mL, 0.40 mmol, 1.0 eqv.) 
was then added and the reaction stirred at -5 °C for 30 minutes. A solution of tirapazamine 
(102.0 mg, 0.58 mmol, 1.5 eqv.) dissolved in acetonitrile (10 mL) was then added, and after 
stirring to r.t. over 24 hrs, the solvent was evaporated under reduced pressure. Analysis by 
NMR spectroscopy and TLC suggested the presence of only tirapazamine (38) and the 
quinone acid 52. 
An identical series of reactions were performed on the same scale using 
3-amino-1,2,4-benzotriazine-1-oxide (77), N-octylbenzo[1,2,4]triazin-3-amine (147), and 3-
heptylamino)benzo[1,2,4]triazine 1-oxide (161) at r.t., 40 ˚C and 60 ˚C with only the 
recovery of starting materials being observed. 
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Preparation of 2,2'-((4-nitrophenyl)azanediyl)bis(ethan-1-ol) (123)82 
 
A mixture of 1-fluoro-4-nitrobenzene (8.8 mL, 11.69 g, 82.9 mmol) and 
2,2-iminoethanol (8.0 mL, 8.76 g, 83.5 mmol, 1.1 eqv.) were heated (130 ºC) in a sealed 
tube for 19 h. After cooling to r.t., NaOH solution (aq, 0.6 % w/v, 50 mL) was added and 
the suspension formed was heated to 60 ºC for 30 min.  It was then filtered and the solid 
obtained was air dried. The residue was recrystallised from EtOAc to give the product 123 
(13.68 g, 73% yield) as yellow crystals. Data was in accordance with the literature.91 
Rf = 0.69 (50:50 MeOH:EtOAc); Mp. 101-103C (lit.91 100-102 ˚C); δH 8.11 (2H, 
d, J = 8.2 Hz, 2 x CH), 6.67 (2H, d, J = 8.2 Hz, 2 x CH), 3.95 (4H, t, J = 5.0 Hz, 2 x CH2) 
3.73 (4H, t, J = 5.0 Hz, 2 x CH2), 2.82 (2H, b s, 2 x OH); δC 152.7, 137.5, 126.3, 111.3, 60.5, 
55.2. 
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Preparation of N,N-bis(2-chloroethyl)-4-nitroaniline (124)37,91 
 
 From 123: Diol 123 (0.80 g, 3.53 mmol) was suspended in anhydrous 
dichloromethane (8 mL) and pyridine (1 mL, 12.36 mmol), and the mixture was cooled to 0 
˚C. Thionyl chloride (1.2 mL, 16.45, 4.7 eqv.) was added slowly, and the mixture was heated 
under reflux for 7 h. After cooling to r.t., the mixture was then extracted with 
dichloromethane (2 x 100 mL), the organic layer was washed with water (2 x 100 mL), dried 
and filtered, and the solvent was removed under reduced pressure to give a yellow solid. The 
crude product was then purified via flash chromatography (20:80 EtOAc:petroleum ether) 
to give the target compound as a yellow crystalline solid (0.74 g, 2.83 mmol, 80 % yield), 
which was contaminated with ca. 10 % of an inseparable impurity. 
 
From 127: Mesylate 127 (2.13 g, 6.01 mmol) and sodium chloride (1.15 g, 
19.68 mmol, 3.3 eqv,) were dissolved in anhydrous DMF (10 mL) and heated at 160 ˚C for 
15 minutes. The reaction was then cooled to r.t. and stirred overnight. The solvent was 
removed under reduced pressure (toluene azeotrope) and the residue dissolved in ethyl 
acetate (100 mL) and washed with water (500 mL) followed by brine (300 mL). After drying 
(MgSO4), filtration and evaporation under reduced pressure gave a crude brown solid, which 
was purified by flash chromatography (20:80 EtOAc:hexane) to give the product as yellow 
crystals (0.77 g, 2.93 mmol, 49 % yield). Data were in agreement with the literature.91  
Rf = 0.15 (10:90 EtOAc:petroleum ether), 88-91°C (lit.
91 92-93 °C), δH 8.14 (2H, d, 
J = 9.1 Hz, 2 x CH), 6.68 (2H, d, J = 9.1 Hz, 2 x CH), 3.87 (4H, t, J = 6.8 Hz, 2 x CH2), 3.69 
(4H, t, J = 6.8 Hz, 2 x CH2); δC 151.3, 138.6, 126.6, 110.9, 53.5, 40.0  
Preparation of ((4-Nitrophenyl)azanediyl)bis(methylene) dimethanesulfonate (127)91 
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Diol 123 (2.00 g, 8.8 mmol) was suspended in EtOAc (30 mL) and the mixture was 
gently heated until full dissolution occurred. MeSO2Cl (1.9 mL, 2.87 g, 25.2 mmol, 2.9 eqv.) 
was then added drop wise over 10 minutes, followed by the drop wise addition of 
triethylamine (3.9 mL, 2.84g, 28.16 mmol, 3.2 eqv.). After 5 minutes, the reaction mixture 
was filtered, the filter pad washed with acetone (ca. 50 mL) and the combined filtrate and 
acetone washings evaporated under reduced pressure to give an orange residue. 
Recrystallisation from ethanol/EtOAc gave 127 (2.13 g, 6.01 mmol, 68 % yield) as 
yellow/orange crystals. Data was in accordance with the literature.91 
Mp. 90-93 °C (lit.91 94-95 ˚C); δH 8.17 (2H, d, J = 9.4 Hz, 2 x CH), 6.72 (2H, d, J = 
9.4 Hz, 2 x CH), 4.42 (4H, t, J = 5.7 Hz, 2 x CH2), 3.91 (4H, t, J = 5.7 Hz, 2 x CH2), 3.02 
(6H, s, 2 x Me); δC 168.6, 151.5, 126.6, 111.2, 65.6, 51.0, 37.9.  
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Preparation of 3-(octylamino)benzo[1,2,4]triazine 1-oxide (147) 
 
 Potassium t-butoxide (2.72 g, 24.33 mmol, 8.3 eqv.) was stirred in anhydrous THF 
(20 mL) under a positive argon atmosphere at 25 ˚C for 30 minutes. Octyl guanidine 
hemisulfate (1.29 g, 5.86 mmol, 2 eqv.) was then added, followed by nitrobenzene (0.36 mL, 
2.93 mmol) in anhydrous THF (5 mL). The resulting suspension was stirred at 65 ˚C for 20 
h and monitored by TLC (50:50 EtOAc:petroleum ether) until the nitrobenzene had been 
consumed. The reaction was cooled to r.t. and water (10 mL) was added before stirring for 
15 minutes. The aqueous reaction mixture was extracted with chloroform (4 x 50 mL), and 
the combined organic extracts were dried (MgSO4) and filtered, and the solvent was removed 
by rotary evaporation to give a brown/black residue. This was purified by column 
chromatography (30:70 diethyl ether:petroleum ether) to give the product as a bright yellow 
solid (321 mg, 1.2 mmol, 30 % yield) which was of ca 90-95% purity.  
Rf = 0.30 (30:70 diethyl ether:petroleum ether); Mp. 66-69 ˚C; δH 8.22 (1H, b d, 
J  = 8.2 Hz, CH), 7.77 (1H, ddd, J = 1.4, 7.0, 8.4 Hz, CH), 7.61 (1H, b d, J = 8.4 Hz, CH), 
7.41 (1H, ddd, J = 1.0, 7.0, 8.2 Hz), 6.18 (1H, b s, NH), 3.58 (2H, b s, CH2), 1.72 (2H, 
apparent pentet, J = 7.3 Hz, CH2), 1.20-1.48 (12H, m, 6 x CH2), 0.88 (3H, t, J = 6.7 Hz, 
CH3); δC 14.2, 22.8, 27.1, 29.4, 29.4, 29.8, 31.9, 41.5, 125.2, 125.6, 128.9, 139.1, 130.1 (2 x 
C), 136.1; vmax (film) 3249, 3061, 2954, 2924, 2852, 2223, 1674, 1586, 1563, 1499, 1466, 
1487, 1446, 1377, 1235, 758, 718, 693 cm-1; LRCIMS m/z 259.2 (100%); HRCIMS m/z 
found 259.1917 ([M+H]+), C15H23N4 required 259.1923.  
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Preparation of 1-(3-hydroxypropyl)guanidine hydrochloride (149)84 
 
1H-Pyrazole-1-carboxamidine hydrochloride (5 g, 34.2 mmol) was stirred in 
anhydrous DMF together with 3-amino-1-propanol (2.87 mL, 37.62 mmol, 1.10 eqv.) and 
DIPEA (5.25 mL, 37.6 mmol, 1.10 eqv.) for 16 h. The reaction was checked for completion 
by TLC (1% methanol in chloroform), after which anhydrous diethyl ether (300 mL) was 
added, precipitating a yellow oil. The cloudy diethyl ether layer was then carefully decanted 
from the yellow oil before adding a further portion of anhydrous diethyl ether (300 mL) and 
stirring with an overhead stirrer overnight. The diethyl ether layer was again decanted from 
the yellow oil, and any residual ether was removed under vacuum, before checking for 
residual DMF by using NMR spectroscopy. Fresh anhydrous diethyl ether (300 mL) was 
added and the mixture was stirred overnight. The solvent was decanted and pure product was 
obtained as a brown/yellow oil (4.80 g, 31.37 mmol, 91 % yield) after the removal of residual 
traces of solvent by rotary evaporation. 
δH (CD3OD) 3.61 (2H, t, J = 6.0 Hz, CH2), 3.26 (2H, t, J = 6.7 Hz, CH2), 1.75 (2H, 
apparent pentet, J = 6.3 Hz); δC (CD3OD) 158.9, 59.7, 39.7, 32.4; LRCIMS m/z 118 (100 %, 
([M+H]+); HRCIMS m/z found 118.0975 ([M+H]+), C4H11N3O requires 118.0975.  
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Attempted preparation of 3-(benzo[e][1,2,4]triazin-3-ylamino)propan-1-ol (150) 
 
Potassium t-butoxide (10.45 g, 93 mmol, 9.3 eqv.) was added to THF (40 mL) and 
the mixture was stirred to ensure dissolution. At this point, the solution was transferred via 
cannula to a flask containing 1-(3-hydroxypropyl)guanidine hydrochloride (149) (3.06 g, 
20.0 mmol, 2.0 eqv.), and the mixture was stirred for 5 mins. Nitrobenzene (1.00 g, 
10.0 mmol) dissolved in THF (10 mL) was added, and the solution (which darkened 
considerably within 1 min) was heated at 65 ˚C for 20 h. The progress of the reaction was 
monitored by TLC (20:80 THF:petroleum ether), and once the nitrobenzene had been 
consumed, the reaction was cooled to r.t. and quenched with water (2 mL). The reaction 
mixture was then dried (MgSO4) and filtered. Removal of the solvent gave a brown oil. 
Attempts at purification by column chromatography (20-100% EtOAc:petroleum ether) 
proved unsuccessful and no product was isolated. 
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Preparation of 3-((tert-butyldimethylsilyl)oxy)propan-1-amine (156) 
 
Imidazole (0.65 g, 8.89 mmol, 1.3 eqv.) was added in portions to a stirred solution 
of 3-amino-1-propanol (1.0 g, 6.84 mmol) and TBSCl (1.34 g, 8.89 mmol, 1.3 eqv.) 
dissolved in dichloromethane (10 mL). After 16 h, water (15 mL) was added and the mixture 
separated and the organic phase was washed with water (3 x 5 mL) followed by brine 
(10 mL). The organic phase was dried (MgSO4), filtered the solvent removed by rotary 
evaporation to give a light yellow oil (1.33 g, 5.12 mmol, 75 % yield), which was used 
without further purification. 
δH 3.70 (2H, t, J = 6.1 Hz, CH2), 2.80 (2H, t, J = 6.8 Hz, CH2), 1.66 (2H, app pentet, 
J = 6.5 Hz, CH2), 1.46 (2H, b s, NH2), 0.89 (9H, s, 3 x Me), 0.05 (6H, s, 2 x Me); δC 61.6, 
39.4, 36.3, 25.9, 18.3, -5.4.  
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Preparation of 3-(heptylamino)benz(1,2,4)triazine 1-oxide (161) 
 
Potassium carbonate (140 mg, 1.01 mmol, 1.5 eqv.) was added to a suspension of 3-
amino-1,2,4-benzotriazine-1-oxide (77) (100 mg, 0.62 mmol) in anhydrous DMF (15 mL) 
containing powdered molecular sieves (3 Å, ca. 0.2 g). 1-Iodoheptane (224 mg, 0.99 mmol, 
1.5 eqv.) was added, and the reaction was heated at 120 °C for 20 h. The solution changed 
from yellow to orange in colour, and the reaction was checked for completion by TLC before 
cooling and filtering the product. The solvent was then removed by co-evaporation with 
toluene, until a solid residue formed. This crude material was purified by column 
chromatography (25:75 diethyl ether:petroleum ether), to give the product as a bright yellow 
solid (41.0 mg, 0.16 mmol, 25 % yield).  
This reaction was repeated on nine occasions  
i) Using 77 (536 mg, 3.3 mmol) in acetonitrile (40 mL) with 1-iodoheptane (1.12 g, 
4.96 mmol, 1.5 eqv.) and potassium carbonate (0.7 g, 4.96 mmol, 1.5 eqv.), with heating 
under reflux for 24 h to give 161 (18.6 mg, 0.072 mmol, 2 % yield). 
ii) Using 77 (108 mg, 0.67 mmol) in acetonitrile (10 mL) with 1-iodoheptane (224 mg, 
1.01 mmol, 1.5 eqv.) and potassium carbonate (140 mg, 1.01 mmol, 1.5 eqv.), heating under 
reflux for 7 d to give 161 (5.23 mg, 0.02 mmol, 3 % yield) 
iii) 77 (108 mg, 0.67 mmol) in acetonitrile (10 mL) with 1-iodoheptane (224 mg, 1.01 mmol, 
1.5 eqv.) and potassium carbonate (140 mg, 1.01 mmol, 1.5 eqv.), heating at 130 ˚C in a 
sealed tube for 20 hours to give 161 (19.8 mg, 0.08 mmol, 11 % yield). 
iv), 77 (100 mg, 0.62 mmol) in anhydrous DMF (13 mL) with 1-iodoheptane (224 mg, 
1.01 mmol, 1.5 eqv.) and potassium carbonate (140 mg, 1.01 mmol, 1.5 eqv.), heating at 135 
˚C to give 161 (48.4 mg, 0.19 mmol, 30 % yield), which eluted with an inseparable impurity. 
iv) 77 (100 mg, 0.62 mmol) in anhydrous DMF (13 mL) with 1-iodoheptane (224 mg, 
1.01 mmol, 1.5 eqv.) and potassium carbonate (140 mg, 1.01 mmol, 1.5 eqv.), heating at 125 
˚C to give 161 (38.7 mg, 0.15 mmol, 24 % yield), which eluted with an inseparable impurity. 
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v) Using 77 (100 mg, 0.62 mmol) in anhydrous DMF (13 mL) with 1-iodoheptane (224 mg, 
1.01 mmol, 1.5 eqv.) and potassium carbonate (85.6 mg, 0.62 mmol, 1.0 eqv.), heating at 
120 ˚C to give 161 (40.3 mg, 0.16 mmol, 25 % yield). 
vi) Using 77 (100 mg, 0.62 mmol) in anhydrous DMF (13 mL) with 1-iodoheptane (224 mg, 
1.01 mmol, 1.5 eqv.) and potassium carbonate (42.8 mg, 0.31 mmol, 0.5 eqv.), heating at 
120 ˚C to give 161 (14.5 mg, 0.06 mmol, 9 % yield) 
vii) Using 77 (100 mg, 0.62 mmol) in anhydrous DMF (13 mL) with 1-iodoheptane (168 mg, 
0.74 mmol, 1.2 eqv.) and potassium carbonate (140 mg, 1.01 mmol, 1.5 eqv.), heating at 120 
˚C to give 161 (35.5 mg, 0.14 mmol, 22 % yield) 
viii) Using 77 (100 mg, 0.62 mmol) in anhydrous DMF (13 mL) with 1-iodoheptane 
(140 mg, 0.62 mmol, 1.0 eqv.) and potassium carbonate (140 mg, 1.01 mmol, 1.5 eqv.), 
heating at 120 ˚C to give 161 (29.0 mg, 0.11 mmol, 18 % yield) 
ix) Using 77 (100 mg, 0.62 mmol) in anhydrous dioxane (20 mL) with 1-iodoheptane 
(224 mg, 1.01 mmol, 1.5 eqv.) and potassium carbonate (140 mg, 1.01 mmol, 1.5 eqv.), heat 
under reflux for 4 days. 161 was not isolated.  
Rf = 0.29 (30:70 diethyl ether:petroleum ether); Mp. 130-132 ˚C; δH 8.25 (1H, dd, 
J = 0.6, 8.3 Hz, CH), 7.61 (1H, ddd, J = 1.1, 7.2, 8.3 Hz, CH), 7.51 (1H, b d, J = 8.3 Hz, 
CH),  7.20 (1H, ddd, 1.1, 7.2, 8.3 Hz, CH), 5.31 (1H, b s, NH), 3.44 (2H, apparent q, J = 6.9 
Hz, CH2), 1.59 (2H, apparent pentet, J = 7.2 Hz, CH2), 1.15-1.36 (8H, m, 4 x CH2), 0.81 
(3H, t, 6.6 Hz, Me); δC 158.9, 148.6, 135.5, 130.8, 129.8, 126.3, 124.8, 120.4, 41.4, 29.3, 
28.9, 26.8, 22.6, 14.0; vmax (film) 3294, 2952, 2850, 1732, 1586, 1570, 1494, 1418, 759, 
673, 647 cm-1; LRCIMS m/z 261.17 (100 %, ([M+H]+)), 283.2 (50 %, ([M+Na]+)), 543.3 
(55 %, ([2M+Na]+); HRCIMS m/z found 261.1711 ([M+H]+) C14H21O1N4 required 
261.1710; for X-ray structure see appendix. 
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Attempted preparation of 3-((9-hydroxynonyl)amino)-1,4-benzo[1,2,4]triazin-1-olate 
(163). 
  
Potassium carbonate (140.0 mg, 1.01 mmol, 1.5 eqv.) was added to a suspension of 
3-amino-1,2,4-benzotriazine-1-oxide 77 (100.0 mg, 0.62 mmol) in anhydrous DMF (15 mL) 
containing potassium iodide (10.0 mg, 0.06 mmol, 0.1 eqv.) and powdered molecular sieves 
(3 Å, ca 0.2 g). 9-Brononon-1-ol (221.0 mg, 0.99 mmol, 1.5 eqv.) was then added and the 
reaction was heated at 120 °C for 92 h. Analysis by NMR spectroscopy  indicated that no 
reaction had occurred, as the major product recovered was 77. A repeat of this reaction with 
fresh potassium iodide was also unsuccessful. 
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Preparation of 10-bromodecan-1-ol (165)87 
 
Decane-1,10-diol (5.0 g, 33.8 mmol) was dissolved in toluene (90 mL), and HBr (48 
% aqueous, 3.88 mL, 34.17 mmol, 1.01 eqv.) was added. The mixture was heated under 
reflux overnight. After cooling to r.t., the organic layer was separated. The organic extract 
was dried (MgSO4), filtered and the solvent was removed under reduced pressure to give the 
crude product as a yellow oil. Purification by column chromatography (50:50 diethyl 
ether:hexane) gave the product as a pale yellow oil (2.55 g, 10.75 mmol, 32 % yield). Data 
was in agreement with the literature.  
Rf = 0.33 (15:85 EtOAc:petroleum ether) δH 3.64 (2H, t, J = 6.6 Hz, CH2), 3.41 (2H, 
t, J = 6.9 Hz, CH2), 1.81 (2H, apparent pentet, J = 7.2 Hz, CH2), 1.57 (2H, apparent pentet, 
J = 7.0 Hz, CH2), 1.45 -1.24 (13H, m, 7 x CH2, OH), δC, 63.1, 34.1, 32.8, 32.8, 29.5, 29.4 (2 
x CH2), 28.7, 28.2, 25.7.  
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Preparation of (10-bromodecyl)oxy)methyl)benzene (166)146 
 
 10-Bromodecan-1-ol (1.00 g, 3.94 mmol) was added to a cooled (0 °C) suspension 
of sodium hydride (60% in oil, 0.23 g, 9.45 mmol, 1.8 eqv.) in THF (20 mL), and the mixture 
was stirred for 1 h. Benzyl bromide (1.47 mL, 2.12 g, 3.98 mmol, 1.01 eqv.) was added, and 
the creamy white suspension was heated under reflux for 16 h. The reaction was cooled to 0 
°C before carefully adding saturated ammonium chloride solution (30 mL). The reaction 
mixture was then extracted with diethyl ether (3 x 50 mL), and the combined organic extracts 
were washed with brine (100 mL) then dried (MgSO4), and the solvent was removed under 
reduced pressure, to give a crude yellow oil. This was purified by column chromatography 
(40:60 dichloromethane:hexane) to give the product as a colourless oil (0.66 g, 2.01 mmol, 
51 % yield). Data was in agreement with the literature. 
δH 7.37-7.27 (5H, m, 5 x CH), 4.50 (2H, s, CH2), 3.46 (2H, t, J = 6.6 Hz, CH2), 3.40 
(2H, t, J = 6.9 Hz, CH2), 1.85 (2H, apparent pentet, J = 7.2 Hz, CH2), 1.66-1.58 (2H, m, 
CH2), 1.43-1.28 (12H, m, 6 x CH2); δC 138.9, 128.5, 127.8, 127.6, 73.0, 70.6, 34.2, 33.0, 
29.9, 29.6, 29.6, 29.5, 28.9, 28.3, 26.3.  
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Preparation of 3-((10-(benzyloxy)decyl)amino)benzo[1,2,4]triazine 1-oxide (167) 
 
 Potassium carbonate (279.0 mg, 2.02 mmol, 1.5 eqv.) was added to a solution of 3-
amino-1,2,4-benzotriazine-1-oxide (77) (218.0 mg, 1.35 mmol) in anhydrous DMF (15 mL) 
containing powdered molecular sieves (3 Å, ca 0.2 g) and potassium iodide (30 mg, 0.18 
mmol, 0.1 eqv.) Bromide 166 (660.0 mg, 2.02 mmol, 1.5 eqv.) was then added, and the 
reaction was heated at 120 °C for 20 h. The resulting solution, which changed from yellow 
to orange in colour, was cooled and filtered, and the solvent was then removed by co-
evaporation with toluene to give a crude solid residue. This was purified by column 
chromatography (40:60 diethyl ether:petroleum ether) to give the product as a bright yellow 
solid (334 mg, 0.81 mmol, 60 % yield), which was contaminated with impurities. 
Rf = 0.29 (40:60 diethyl ether:petroleum ether); Mp. 60-63 ˚C; δH 8.26 (1H, dd, J = 
1.1, 8.7 Hz, CH), 7.69 (1H, ddd, J = 1.4, 6.9, 8.5 Hz, CH) 7.59 (1H, b d, J = 8.4 Hz, CH), 
7.32-7.35 (5H, m, Ph) 7.25-7.30 (1H, m, CH), 5.19 (1H, b s, NH), 4.50, (2H, s, CH2), 3.50 
(2H, app q, J = 7.0 Hz, CH2), 3.46 (2H, t, J = 6.6 Hz, CH2), 1.51-1.75 (4H, m, 2 x CH2), 
1.18-1.41 (12H, m, 6 x CH2); δC 159.0, 139.0, 135.8, 129.1, 129.0 128.6, 128.2, 127.9, 127.8, 
127.8, ,125.15, 125.1, 120.8, 73.2, 70.8, 30.1, 30.0, 29.8, 29.8, 29.7, 29.7, 29.6, 27.1, 26.5; 
vmax (film) 3307, 2921, 2851, 1716, 1569, 1494, 1464, 1416, 1358, 1274, 1113, 760, 713, 
693 cm-1; LRCIMS m/z 409.3 (100%, ([M+H]+)), 431.2 (75%, ([M+Na]+); HRCIMS m/z 
found 409.2598 ([M+H]+) C24H33N4O2 requires 409.2598. 
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Attempted Preparation of 3-((10-hydroxydecyl)amino)-1,4-benzo[e][1,2,4]triazin-1-
olate (168).  
 
 
i) Via hydrogenation of 167: Palladium on charcoal (5 %, 330.0 mg) was added to 3-
((10-(Benzyloxy)decyl)amino)benzo[1,2,4]triazine-1-oxide (167) (330.0 mg, 0.81 mmol) 
dissolved in ethanol (5 mL), and the mixture was stirred under a hydrogen atmosphere. After 
30 hrs, TLC (EtOAc) indicated the disappearance of the starting material, and the mixture 
was filtered through a Celite© pad and evaporated to give a brown gum. This was purified 
by column chromatography (20-50 % EtOAc: Hexane) to give 3-amino-1,2,4-benzotriazine-
1-oxide (77) (111 mg, 85 %  yield). 
 ii) Via HBr mediated debenzylation of 167: HBr (33 % in acetic acid, 10 mL) was 
added to 3-((10-(benzyloxy)decyl)amino)benzo[1,2,4]triazine 1-oxide 167 (169.0 mg, 
0.41 mmol), and the mixture was stirred at r.t. for 2 hours, at which point the reaction mixture 
had turned orange. The reaction mixture was poured into water (50 mL) and extracted with 
dichloromethane (3 x 100 mL). The organic extracts were then collected, washed with brine 
(50 mL), dried (MgSO4), filtered and the solvent was removed under reduced pressure to 
give the crude product (213.0 mg). Analysis by TLC and NMR spectroscopy indicated only 
the presence of the starting material 167. 
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Preparation of 3-(((4-hydroxybutoxy)methyl)amino)benzo[1,2,4]triazine 1-oxide (171) 
 
3-Amino-1,2,4-benzotriazine-1-oxide (77) (178 mg, 1.10 mmol) and 
paraformaldehyde (141 mg, 4.7 mmol, 4.2 eqv.) were suspended in butane-1,4-diol (10 mL, 
10.2 g, 112.0, 103 eqv.) with gentle warming (~25 ˚C) to keep the mixture fluid. A catalytic 
quantity of glacial acetic acid (5-10 drops) was added, and the resulting suspension was 
heated (80 ˚ C) for 5 h, by which point all the solid components had dissolved to give a yellow 
solution. This was cooled to r.t. and poured into water (100 mL) before extracting with 
chloroform (3 x 100 mL). The combined organic extracts were dried (MgSO4) and the 
solvent was removed under reduced pressure to give a viscous yellow oil. This crude product 
was dissolved in a minimum (>5 mL) of chloroform, and diethyl ether was added until the 
solution clouded, at which point the solution was placed in a freezer for 3 hours. This 
precipitated a crude yellow solid, which was purified by flash chromatography (60:40 
EtOAc:hexane) to give the product as a bright yellow solid (160 mg, 0.60 mmol, 55 % yield). 
Rf = 0.31 (60:40 EtOAc:Hexane); Mp. 161-165 ˚C; δH 8.28 (1H, b d, J = 8.5 Hz, 
CH), 7.75 (1H, b t, J = 8.1 Hz, CH), 7.68 (1H, b d, J = 8.4 Hz, CH), 7.37 (1H, b t, J = 7.2 Hz, 
CH), 6.18 (1H, b t, J = 7.2 Hz, NH), 5.07 (2H, d, J = 7.2 Hz, CH2), 3.67 (4H, b t, J = 6.0 Hz, 
2 x CH2), 1.93 (1H, b s, OH), 1.75-1.62 (4H, m, 2 x CH2); δC 158.9, 148.8, 136.1, 136.0, 
135.9, 126.1, 120.7, 72.5, 68.4, 63.1, 30.0, 26.6; vmax (film) 3432, 3295, 2923, 2853, 1561, 
1459, 1419, 1327, 1328, 919 cm-1; LRCIMS m/z 287.1 (100 %, ([M+Na]+)), 461.2 (30 %), 
551.2 (40 %, ([2M+Na]+)); HRCIMS m/z found 287.1109 ([M+Na]+), C12H16N4O3Na 
requires 287.1109. 
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Preparation of 3-(((4-((3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-
yl)butanoyl)oxy)butoxy)methyl)amino)benzo[e][1,2,4]triazine 1-oxide (172) 
 
Quinone acid 52 (600 mg, 2.40 mmol, 2 eq.) was stirred with DCC (247.6 mg, 
1.20 mmol, 1 eqv.) and DMAP (1.47 g, 12 mmol, 10 eqv.) in THF (30 mL) for 45 minutes. 
Triazine 171 (317 mg, 1.20 mmol) was then added, and the mixture was stirred for 48 h. On 
completion (TLC), the reaction mixture was filtered and the solvent was removed under 
reduced pressure. The crude residue was then dissolved in a minimum volume of EtOAc, 
cooled (0 ˚C) and filtered to remove precipitated DCU. This process was repeated twice 
more, and after evaporation of the remaining solvent, the crude product was purified by flash 
chromatography on triethylamine-deactivated silica (40:60 diethyl ether:hexane). This gave 
172 as an unstable bright yellow oil (232 mg, 0.47 mmol, 39 % yield), which was 
contaminated with DCCU. 
Rf = 0.32 (40:60 diethyl ether:hexane); δH (DMSO) 8.27 (1H, dd, J = 0.7, 8.6 Hz, 
CH), 7.86 (1H, dt, J = 1.2, 7.1 Hz, CH), 7.68 (1H, b d, J = 9.6 Hz, CH), 7.47 (1H, dt, J = 1.0, 
7.3 Hz, CH), 7.03 (1H, b t, NH), 5.01 (2H, b d, J = 7.0 Hz, CH2), 4.01 (2H, t, J = 6.0 Hz, 
CH2), 3.61 (2H, t, 5.9 Hz, CH2) 2.95 (2H, s, CH2), 2.15 (3H, s, Me), 1.99 (3H, s, Me), 1.98 
(3H, s, Me), 1.68-1.62 (4H, m, 2 x CH2), 1.46 (6H. s, 2 x Me); vmax (film) 3329,  2958, 2872, 
1793, 1714, 1242 cm-1; LRCIMS m/z 497.2 (100 %, ([M+H]+)); HRCIMS m/z found 
497.2388 ([M+H]+), for C26H33N4O6 requires 497.2395. 
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Preparation of 3-(((4-(propionyloxy)butoxy)methyl)amino)benzo[1,2,4]triazine 
1-oxide (173) 
 
Propionic acid (29.0 mg, 0.38 mmol, 2.0 eq.) was stirred with DCC (37.0 mg, 
0.18 mmol, 1.0 eqv.) and DMAP (220.0 mg, 1.8 mmol, 10 eqv.) in anhydrous THF (10 mL) 
under a positive argon atmosphere for 30 minutes. Triazine 171 (50.0 mg, 0.18 mmol) was 
then added, and the reaction mixture was stirred for 48 hours and monitored by TLC (60:40 
EtOAc:hexane, starting material Rf = 0.31). On completion, the mixture was filtered through 
a sinter, then poured into water (100 mL). The aqueous mixture was then extracted with 
diethyl ether (3 x 20 mL), and the organic extracts were dried, filtered, and the solvent was 
removed by rotary evaporation. The crude product was then purified by column 
chromatography (30:70 EtOAc:hexane) to give the product as a bright yellow oil which 
solidified on standing (35.0 mg, 0.11 mmol, 60 % yield). 
Rf = 0.33 (30:70 EtOAc:hexane); Mp. 75-78 ˚C; δH (CD3CN) 8.21 (1H, dd, J = 1.2, 
8.6, Hz, CH), 7.79 (1H, ddd, J = 1.2, 7.0, 8.4 Hz, CH), 7.62 (1H, b d, J = 8.4 Hz, CH), 7.40 
(1H, ddd, J = 1.2, 7.0, 8.6 Hz, CH), 6.84 (1H, t,  NH), 4.86 (2H, d, J = 7.1 Hz, CH2), 4.02 
(2H, t, J = 6.4 Hz, CH2), 3.56 (2H, t, 6.0 Hz, CH2) 2.19 (2H, q, 7.5 Hz, CH2), 1.67-1.55 (4H, 
m, 2 x CH2), 1.03 (3H, t, J = 7.5 Hz, Me); δC (CD3CN) 175.1, 160.0, 149.4, 136.7, 132.4, 
127.5, 126.5, 120.9, 72.5, 68.2, 64.7, 28.0, 26.9, 26.3, 9.4; vmax (film) 3307, 3092, 3072, 
2977, 2925, 2872, 1728, 1567, 1558, 1497, 1417, 1361, 1328, 1201, 1120, 1112, 1080, 764, 
675, 653 cm-1; LRCIMS m/z 175.1 (100 %), 321.2 (55 %, [M+H]+), 343.1 (90 %, [M+Na]+); 
HRCIMS m/z found 321.1561 ([M+H]+), C15H21N4O4 requires 321.1557. 
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Preparation of 3-((((5-hydroxypentyl)oxy)methyl)amino)benzo[1,2,4]triazine 1-oxide 
(175) 
  
A mixture of 3-amino-1,2,4-benzotriazine-1-oxide (77) (500 mg, 3.09 mmol), 
paraformaldehyde (435 mg, 14.5 mmol, 4.7 eqv), and hexane-1,6-diol (16.0 g, 135.4 mmol, 
44.0 eqv) was heated with stirring at 60 ˚C until the diol melted and a yellow suspension 
formed. A catalytic amount of glacial acetic acid (5-10 drops) was then added, and the 
mixture was heated (85 ˚C) for 16 h. The resulting yellow solution was poured into water 
(150 mL) and extracted with chloroform (4 x 50 mL). The combined organic extracts were 
dried (MgSO4) and the solvent was removed under reduced pressure to give a viscous yellow 
oil. This was purified by repeated column chromatography (20:80 EtOAc:hexane), to give 
175 as a bright yellow solid (138 mg, 0.47 mmol, 15 % yield) which contained trace amounts 
(ca. 5-10%) of hexane-1,6-diol. 
 Rf = 0.29 (20:80 EtOAc:hexane); Mp. 76-78 ˚C; δH 8.23 (1H, b d, J = 8.0 Hz, CH), 
7.70 (1H, ddd, J = 1.2, 7.2, 8.0 Hz, CH), 7.64 (1H, b d, 8.1 Hz, CH), 7.32 (1H, ddd, J = 1.2, 
7.1, 8.3 Hz, CH), 6.68 (1H, b t, J = 7.1 Hz, NH), 5.04 (2H, d, J = 7.1 Hz, CH2), 3.62-3.50 
(4H, m, 2 x CH2), 2.07 (1H, b s, OH), 1.61-1.47 (4H, m, 2 x CH2), 1.40-1.24 (4H, m, 2 x 
CH2); δC 158.8, 148.7, 135.8, 127.1, 126.0, 120.5, 72.4, 68.5, 63.1, 32.8, 29.7, 26.0, 25.7, 1 
x quaternary not observed; vmax (film) 3308, 2931, 2859, 1722, 1560, 1495, 1418, 1356, 
1319, 1241, 1069, 760 cm-1; LRCIMS m/z 175.1 (100 %), 293.2 (75 %, ([M+H]+)); 
HRCIMS m/z found 293.1611 ([M+H]+), C14H21N4O3 requires 293.1608. 
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Preparation of 3-((((6-((3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-
yl)butanoyl)oxy)hexyl)oxy)methyl)amino)benzo[e][1,2,4]triazine 1-oxide (176) 
 
 
Quinone acid 52 (112.5 mg, 0.45 mmol, 2 eq.) was stirred with DCC (45.9 mg, 0.22 
mmol, 1.0 eqv.) and DMAP (268.4 g, 2.2 mmol, 10 eqv.) in THF (10 mL) under a positive 
argon atmosphere for 45 minutes. Triazine 175 (112.5 mg, 0.45 mmol, 2.0 eqv.) was then 
added and the reaction mixture stirred for 48 hours. On completion (TLC), the reaction 
mixture was filtered and the solvent was removed under reduced pressure. The crude 
reaction residue was then dissolved in a minimum volume of EtOAc, cooled (0 ˚C) and 
filtered to remove precipitated DCU. This process was repeated twice more. After 
evaporation of the solvent, the crude product was then purified by flash chromatography on 
triethylamine-deactivated silica (40:60 diethyl ether:hexane) to give the product as an 
unstable yellow oil (64.0 mg, 0.12 mmol, 27 % yield), which was contaminated with DCU. 
Rf = 0.35 (40:60 diethyl ether:hexane); δH 8.18 (1H, dd, J = 1.4, 8.5 Hz, CH), 7.77 
(1H, ddd, J = 1.4, 7.0, 8.5 Hz, CH), 7.59 (1H, b d, J = 8.5 Hz, CH), 7.38 (1H, ddd, J = 1.1, 
7.0, 8.5 Hz, CH), 6.89 (1H, b t, J = 7.0 Hz, 1H, NH), 4.90 (2H, d, J = 7.0 Hz, CH2), 3.88 
(2H, t, J = 6.5 Hz, CH2), 3.50 (2H, t, J = 6.6 Hz, CH2), 2.86 (2H, s, CH2), 2.07 (3H, s, Me), 
1.89 (3H, s, 2 x Me), 1.40-1.55 (4H, m, 2 x CH2) 1.38 (6H, s, 2 x Me), 1.18-1.30 (4H, m, 2 
x CH2); δC 191.7, 188.2, 173.2, 160.0, 153.6, 149.4, 143.9, 139.6, 139.6, 139.1, 136.7, 127.5, 
126.6, 121.0, 72.6, 68.6, 65.0, 48.4, 39.0, 30.3, 29.3, 29.1, 29.0, 26.5, 26.4, 14.5, 12.8, 12.2; 
vmax (film) 3369, 2935, 1794, 1717, 1555, 1493, 1464, 1419, 1358, 1240, 766 cm-1; Mass 
data not obtained due to instability. 
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Preparation of 3-((butoxymethyl)amino)benzo[1,2,4]triazine-1,4-dioxide (177) 
  
Tirapazamine (38) (100.0 mg, 0.56 mmol) and paraformaldehyde (71.0 mg, 
2.4 mmol, 4.2 eqv.) were suspended in n-butanol (5 mL). Glacial acetic acid (1 mL) was 
then added and the suspension was heated at 80 ˚C for 5 h, by which point all the solid 
components had dissolved to give a red solution. After cooling to r.t., the reaction mixture 
was poured into water (100 mL), extracted with chloroform (3 x 100 mL) and the organic 
extracts dried (MgSO4). The solvent was removed by rotary evaporation to give a crude red 
solid. Purification by flash chromatography (75:25 EtOAc;dichloromethane) gave the 
product as a bright red solid (93.0 mg, 0.35 mmol) in 63 % yield. Data was in accordance 
with the literature.89 
Rf = 0.21 (50:50 EtOAc:dichloromethane); Mp. 154-156 ˚C (lit.89 158-160 ˚C); δH 
8.36 (2H, m, 2 x CH), 7.91 (1H, t, J = 7.2 Hz, CH), 7.72 (1H, b s, CH), 7.58 (1H, t, J = 
8.0 Hz, CH), 5.10 (2H, d, J = 5.6 Hz, CH2), 3.58 (2H, t, J = 6.6 Hz, CH2), 1.57 (2H, m, CH2), 
1.36 (2H, m, CH2), 0.90 (3H, t, J = 7.4 Hz, CH3); δC 149.8, 138.4, 135.9, 131.3, 127.9, 121.7, 
117.8, 72.0, 68.7, 31.6, 19.3, 13.9; LRCIMS m/z 191 (90 %), 265.1 (100 %, [M+H]+), 287.1 
(65 %, [M+Na]+), 529.3 (30 %, [2M+H]+), 551.2 (40 %, [2M+Na]+); HRCIMS m/z found 
265.1297, ([M+H]+), C12H17N4O3 requires 265.1295. 
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Preparation of monalidine A hydrochloride (186)116 
 
A solution of 269 (905.0 mg, 3.24 mmol) in anhydrous dichloromethane (80 mL) 
was cooled to -18˚C, and triphenylphosphine (1.96 g, 7.47 mmol, 2.31 eqv.), imidazole 
(823.0 mg, 12.09 mmol, 3.73 eqv.) and iodine (820.0 mg, 3.23 mmol, 1.00 eqv.) were added 
sequentially. The reaction was stirred to r.t over 6 h. On completion, flash silica (7.0 g) was 
added and the solvent was removed under reduced pressure to give a free flowing solid, 
which was loaded onto a flash column. The column was eluted with ethyl acetate until the 
triphenylphosphine oxide by-product had been eluted, and then with 15:85 MeOH:EtOAc. 
The product-containing fractions were evaporated, dissolved in chloroform (50 mL) and 
washed with aqueous HCl (1M, 2 x 10 mL), and the organic phase was dried (MgSO4). The 
solvent was then removed to give 186 (652 mg, 2.18 mmol, 68 % yield) as an amorphous 
yellow gum. 
Rf = 0.33 (15:85 MeOH:chloroform); δH (DMSO-d6) δ 8.96 (1H, s, NH), 8.45 (1H, 
s, NH), 7.03 (1H, s, CH), 4.16 (2H, t, J = 7.5 Hz, CH2), 3.21 (2H, t, J = 7.9 Hz, CH2), 2.67 
(2H, t, J = 7.1 Hz, CH2), 2.26 (2H, apparent pentet, J = 7.7 Hz, CH2), 1.63 (2H, apparent 
pentet, J = 7.3 Hz, CH2), 1.15-1.36 (12H, m, 6 x CH2), 0.84 (3H, t, J = 6.8 Hz, CH3); δC  
(DMSO-d6) δ 179.5, 164.8, 154.9, 107.0, 80.1, 59.6, 38.3, 32.2, 32,1, 29.8, 29.7, 29.4, 28.5, 
23.0, 20.9, 14.9; vmax (film) 3469 (NH), 3402 (NH) and 3307 (NH), 2957 (CH), 2730 
(aromatic CH), 1662, 1579 cm-1; LRCIMS m/z 262.2 (100 %, [M+H]+); HRCIMS m/z 
found 262.2271 ([M+H]+), C16H28N3 requires 262.2278. 
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Attempted synthesis of arbusculidine A (187) 
 
Attempted synthesis from ±7-epineoptilocaulin nitrate (216) with manganese dioxide 
on charcoal: preparation of 187. Crude 216 (36.0 mg, ca. 0.144 mmol) was dissolved in 
anhydrous dichloromethane (5 mL) and placed in a Carius tube. Activated manganese 
dioxide on charcoal (750 mg, 1.55 mmol, 10.7 eqv.) was then added, and the tube was sealed 
and heated (55 ˚C) with stirring for 48 h. The reaction was cooled and then filtered through 
a pad of Celite©, and the solvent was removed under reduced pressure to give a brown semi- 
solid (7.0 mg), which from mass spectrometry appeared to be the reduced compound 275 
(For a full discussion of MS data please see the discussion section (page 105). HRMS m/z 
250.2279 (100%, [M+H]+), C15H28N3
+ requires 250.2278. 
Attempted synthesis with palladium trifluoroacetate and molecular oxygen: Crude 
216 (92.0 mg, 0.3 mmol) was dissolved in acetone (5 mL) and palladium trifluoroacetate (5 
mg, 0.015 mmol, 0.05 eqv.) was added. The reaction mixture was degassed under vacuum/N2 
over three cycles. On the final cycle oxygen gas was added and the mixture was stirred for 
16 hrs. Evaporation gave a crude product (124.0 mg) as an orange gum. Analysis by NMR 
spectroscopy  indicated largely unchanged starting material.  
Attempted oxidation using IBX: Crude 216 (10.0 mg, 0.032 mmol) was dissolved in 
anhydrous acetonitrile (2 mL) under an argon atmosphere. IBX (44.1 mg, 0.194 mmol, 
6.0 eqv.) was then added and the reaction was stirred in the dark at r.t. for 20 h. The reaction 
was then heated under reflux for a further 20 h. The reaction mixture was filtered and diluted 
with dichloromethane (50 mL), after which it was washed with water (2 x 20 mL) and 
saturated sodium carbonate solution (20 mL). The combined aqueous fractions were then 
back extracted with dichloromethane (3 x 20 mL), and the combined organic fractions were 
dried (MgSO4) and the solvent was removed under reduced pressure to give a brown semi-
solid (70 mg). Attempted purification by precipitation/filtration in chloroform was 
unsuccessful. Analysis by high resolution mass spectrometry indicated the presence of the 
starting material at m/z 248.2125 ([M+H]+) with C15H26N3
+ requiring 248.2121 Daltons as 
well as other masses at 246.1969 ([M+H]+) C15H24N3
+ requiring 246.1966 for mirabilin B 
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220 and 250.2281 ([M+H]+) C15H28N3
+ requiring 250.2278 for 275. (For a full discussion of 
MS date please see the discussion section (page 106)).  
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Putative synthesis of arbusculidine A (187) from imine 237. 
 
i) With 6 eqv. activated MnO2: A solution of crude imine 237 (61.0 mg, 0.30 mmol) 
dissolved in methanol was transferred to a Carius tube and the methanol was removed under 
vacuum. Once evaporated to dryness, dichloromethane (5 mL) was added together with 
activated manganese dioxide (170.0 mg, 1.02 mmol, 6.5 eqv.), and the tube was sealed and 
heated (55 ˚C) for 4 days. After cooling, the mixture was filtered through Celite©, washed 
with chloroform and the solvent was removed to give a brown gum (23.8 mg). Attempts at 
purification by silica gel chromatography were unsuccessful, leading to a complex mixture 
of products.  
 HRCIMS m/z for 187, found 242.1656 ([M+H]+), C16H28N3
+
 equires 242.1652. 
Other ions were present at 244.1811 (277), 246.1967 (278) and 248.2124 (279) Daltons. (For 
a full discussion of MS date please see the discussion section). 
ii) With 8 eqv. activated MnO2: A solution of crude imine 237 (385.0, 1.10 mmol) 
dissolved in methanol was transferred to a Carius tube and the methanol was removed under 
vacuum. Once evaporated to dryness, dichloromethane (6 mL) was added together with 
activated manganese dioxide (765.6 mg, 8.80 mmol, 8 eqv.) and the tube was sealed and 
heated (55 ˚C) for 7 days. After cooling, the mixture was filtered through Celite©, washed 
with chloroform and the solvent was removed to give a crude sample of 187 as a brown gum 
(319.4 mg). Washing of the Celite© with methanol gave a further sample (1.230 g) which 
also contained 187. These samples await purification.  
 HRCIMS m/z found 242.1656 ([M+H]+), C16H28N3
+
 requires 242.1652. Other ions 
were present at 244.1811 (277), 246.1967 (278) and 248.2124 (279) Daltons. (For a full 
discussion of MS date please see the discussion section). 
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Preparation of (±)-epineoptilocaulin nitrate (216)123 
 
A 0.18 M solution of guanidine in methanol was prepared by adding guanidine 
hydrochloride (86.0 mg, 0.90 mmol) to a solution of sodium methoxide (which was prepared 
by adding sodium (21 mg, 0.90 mmol) to anhydrous methanol (5.0 mL) under nitrogen). 
Guanidine in methanol (0.18 M, 2.5 mL, 0.45 mmol) was transferred to a re-sealable tube 
containing the indenone 249 (41.0 mg, 0.20 mmol) in anhydrous methanol (2.5 mL) under 
nitrogen. The tube was then flushed with nitrogen, sealed and heated at 85 ˚C for 24 h. The 
mixture was then cooled to r.t. and quenched with nitric acid HNO3 (1%, w/v, 3.0 mL) and 
diluted with chloroform (20 mL). The organic layer was separated and the aqueous layer was 
extracted with chloroform (2 x 30 mL) to give an oil (63.6 mg). Attempted purification via 
flash chromatography (3-5% MeOH in CHCl3) gave a complex mixture of products. The 
reaction was repeated a further 3 times at the same scale and the products obtained were 
combined to give 103.0 mg of crude material, which was used in the further reactions. 
Although analysis of the 1H NMR spectrum gave a complex spectrum, analysis of the 13C 
spectrum gave signals as c 154.7, 126.4, 119.4 ppm, which are indicative of (±)7-
epineoptilocaulin nitrate 216, as well as signals at 157.8/153.6, 126.4/123.2 and 121.2/118.2 
ppm, which indicate the presence of either isomeric compounds or oxidised analogues of 
216. Analysis by high resolution mass spectrometry indicated the presence of the desired 
compound with a m/z found at 248.2122 ([M+H]+) with C15H26N3
+ requiring 248.2121 
Daltons. Other masses at 246.1966 ([M+H]+) corresponding to C15H24N3 requiring 246.1966 
Daltons and at 244.1810 ([M+H]+) corresponding to with C15H22N3 requiring 244.1810 
Daltons are evident of the oxidised species mirabilin B (220) and 274. A mass at 250.2278 
([M+H]+) corresponding to C15H28N3 requiring 250.2278 Daltons corresponds to the reduced 
compound 275. (For a full discussion of MS date please see the discussion section).  
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Preparation of intermediate imine 237 
 
Small scale: A 0.36 M solution of guanidine in MeOH was prepared by adding 
guanidinium hydrochloride (170.0 mg, 1.8 mmol) to a solution of NaOMe in MeOH 
(prepared by reacting Na (42 mg, 1.8 mmol) with anhydrous MeOH (5.0 mL)). A portion of 
this solution of guanidine in MeOH (0.36 M, 0.84 mL, 0.30 mmol) was transferred to a 
Carius tube containing indenone 261 (35.0 mg, 0.17 mmol) dissolved in methanol (2.5 mL). 
The tube was sealed and heated (85 °C) for 24 hrs after which the mixture was cooled and 
the solvent was removed under reduced pressure to give crude 237 as a sticky brown oil 
(61.0 mg), which was used in the following step without further purification. Analysis by 
MS indicated the formation of 4 species at m/z 242.1653 ([M+H]+) with C15H20N3
+ requiring 
242.1652 187 (arbusculadine A), m/z 244.1809 ([M+H]+) with C15H22N3
+ requiring 
244.1808 277, m/z 246.1966 ([M+H]+) with C15H24N3
+ requiring 246.1965 278, m/z 
248.2122 ([M+H]+) with C15H26N3
+ requiring 248.2121 279. (For a full discussion of MS 
date please see the discussion section). 
Large Scale: A 2.30 M solution of guanidine in MeOH was prepared by adding 
guanidinium hydrochloride (1.10 g, 11.5 mmol) to a solution of NaOMe in MeOH (prepared 
by reacting Na (271.2 mg, 11.8 mmol) with anhydrous MeOH (5.0 mL)). A portion of this 
solution of guanidine in MeOH (2.30 M, 0.84 mL, 1.93 mmol) was transferred to a Carius 
tube containing indenone 261 (226.0 mg, 1.11 mmol) dissolved in methanol (2.5 mL). The 
tube was sealed and heated (85 °C) for 24 hrs after which the mixture was cooled and the 
solvent was removed under reduced pressure to give crude 237 as a sticky brown oil (385.0 
mg) which was used in the following step without further purification. Analysis by MS gave 
a near identical spectrum to the small scale reaction. (For a full discussion of MS date please 
see the discussion section). 
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Preparation of 5-butyl-6-methyl-1,2,5,6,7,7-hexahydro-4H-inden-4-one (249)123 
   
3-(4-Butyl-3-methyl-5-oxocyclohexyl) propanal (257) (1.19 g, 5.3 mmol) was 
dissolved in DME (13 mL) in a microwave reaction vial and then aqueous HCl (6M, 
2.16 mL) was added. The mixture was then irradiated in a microwave reaction  at 55 ˚C for 
10 minutes. After cooling to r.t., the reaction mixture was poured into NaHCO3 solution 
(aqueous 5 %, 52 mL) and extracted with diethyl ether (300 mL). The organic phase was  
washed with brine (250 mL), dried (MgSO4) and the solvent removed under reduced 
pressure to give a crude yellow oil. The crude product was purified by flash chromatography 
(10:90 EtOAc:hexane) to give 249 as a colourless oil (807 mg, 3.9 mmol, 74 % yield) as a 
3:2 mixture of isomers. 1H data was in agreement with the literature. 
Rf 0.28 (10:90 EtOAc:petroleum ether); δH 6.49 (1H, apparent quartet, J = 2,7 Hz, 
CH), 2.84-2.97 (2H, m, 2 x CH), 2.31-2.45 (1H, m, CH), 2.09-2.30 (2H, m, 2 x CH), 
1.79-2.08 (4H, m, 2 x CH2), 1.42-1.75 (3H, m, CH, CH2), 1.16-1.38 (3H, m, CH, CH2), 0.97 
(3H, d, J = 6.8 Hz, Me; minor isomer at 0.95, d, J = 6.8 Hz, Me), 0.89 (3H, t, J  = 7.0  Hz, 
Me; minor isomer 0.87, t, J = 7.0 Hz). 
  
  
159 
 
Preparation of tert-Butyl 3-oxooctanoate (253)142 
 
Sodium hydride (60 % dispersion in mineral oil, 1.53 g, 38.4 mmol, 1.2 eqv.) was 
suspended in anhydrous THF (200 mL) and cooled (0 ˚C). To this mixture, 
t-butyl 3-oxobutanoate (5.24 mL, 5.08 g, 32.0 mmol) was added drop wise and the reaction 
mixture stirred at 0 ˚C for 10 minutes. A solution of n-BuLi (2.5 M in hexane, 14.08 mL, 
35.2 mmol, 1.1 eqv.) was then added drop wise to the reaction mixture, which was stirred at 
0 ˚C for 30 minutes. Then 1-iodobutane (4.7 mL, 7.66 g, 41.6 mmol, 1.3 eqv.) was added 
and the reaction mixture was warmed to r.t. over 6 h. After cooling (0 ˚C), ammonium 
chloride solution (saturated, 200 mL) was added carefully. The reaction mixture was then 
extracted with diethyl ether (3 x 200 mL), and the combined organic extracts dried (MgSO4) 
and the solvent was removed under reduced pressure to give the crude product as a yellow 
oil. Purification by column chromatography (10:90 EtOAc:hexane) gave 253 as a colourless 
oil (4.48 g, 21 mmol, 65 % yield). Data were in agreement with the literature. 
δH 3.33 (2H, s, CH2), 2.51 (2H, t, J = 7.4 Hz, CH2), 1.11-1.63 (2H, m, CH2), 1.47 
(9H, s, 3 x Me), 1.21-1.36 (4H, m, 2 x CH2), 0.89 (3H, t, J = 7.0 Hz, Me); δC 203.7, 166.7, 
82.0, 50.8, 43.0, 31.4, 28.1, 23.3, 22.6, 14.0. 
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Preparation of (Z)-2-butyl-5-(hex-3-en-1-yl)cyclohex-2-en-1-one (254)123  
 
Potassium t-butoxide (100.0 mg, 0.89 mmol, 0.05 eqv.) was added to a cooled (0 ˚C) 
stirred solution of t-butyl 3-oxooctanoate (3.77 g, 17.59 mmol) and (E,Z)-2,6-nonadienal 
(2.57 g, 18.59 mmol, 1.0 eqv.) in anhydrous t-butanol (20 mL). The reaction mixture was 
stirred for 30 min before adding further potassium t-butoxide (400.0 mg, 3.57 mmol, 0.2 
eqv.) and heating the mixture at reflux overnight. The reaction mixture was cooled and 
quenched with aqueous HCl (1 M, 15 mL), then diluted with ether (100 mL) and separated. 
The organic phase was washed with brine (30 mL), and dried (MgSO4) and the solvent was 
removed under reduced pressure to give the crude intermediate t-butyl 3-butyl-6-(3-(Z)-
hexenyl)-2-oxocyclohex-3-ene-1-carboxylate as a yellow oil. This ester was dissolved in 
toluene (40 mL), and p-toluenesulfonic acid (685 mg, 3.61 mmol, 0.2 eqv.) was added. The 
mixture was heated at 80 ˚C overnight. After cooling to r.t., EtOAc (60  mL) was added and  
the reaction mixture was washed in turn with NaHCO3 (saturated, 20 mL), HCl (1M, 
aqueous, 15 mL) and brine (15 mL), and then dried (MgSO4). After filtration and 
evaporation, the crude yellow oil (2.27 g) was purified by flash chromatography (gradient 
elution, 1:99-2:98 EtOAc:hexane), giving 254 (1.97 g, 8.4 mmol, 48 % yield). Data were in 
agreement with the literature. 
 
Rf = 0.22 (5:95, EtOAc:petroleum ether); δH 6.66-6.69 (1H, m, CH), 5.27-5.44 (2H, 
m, 2 x CH), 2.39-2.61 (2H, m, 2 x CH), 2.15-2.22 (2H, m, CH2), 1.99-2.14 (7H, m, 3 x CH2, 
CH), 1.26-1.46 (6H, m, 3 x CH2), 0.98 (3H, t, J = 7.5 Hz, Me), 0.91 (3H, t, J = 7.1 Hz, Me); 
δC 199.9, 144.1, 140.0, 132.4, 128.4, 45.0, 35.9, 35.2, 32.7, 30.9, 29.2, 24.2, 22.6, 20.7, 14.5, 
14.1.  
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Preparation of (Z)-2-butyl-5-(hex-3-en-1-yl)-3-methylcyclohex-2-en-1-one (255)123 
  
Anhydrous cerium(III) chloride (10 g, 41 mmol, 4.8 eqv.) was stirred in THF 
(100 mL) for 4 hours under a positive argon atmosphere. The reaction mixture was cooled 
(-78 ˚C) and a solution of MeLi (1.6 M in diethyl ether, 25.6 mL, 41.0 mmol, 4.3 eqv.) was 
added drop wise to the suspension. The mixture was stirred for 1.5 h. Ketone 254 (1.97 g, 
8.39 mmol) dissolved in THF (5 mL) was then added over 5 min and the reaction mixture 
was stirred for 45 minutes. Acetic acid (aqueous 10%, 50 mL) was added and the mixture 
was warmed to r.t and diluted with diethyl ether (200 mL). The organic layer was separated 
and washed sequentially with brine (70 mL),  saturated NaHCO3 solution (50 mL) and 
further brine (70 mL), and then dried (MgSO4). The solvent was removed under reduced 
pressure to give crude 2-butyl-5-(3Z-hexenyl)-1-methylcyclohex-2-en-1-ol as a yellow oil. 
This alcohol was dissolved in dichloromethane (100 mL). NaOAc (0.35 g, 4.23 mmol, 0.5 
eqv.) and PCC (3.63 g, 16.9 mmol, 2 eqv.) were added, and the mixture was stirred at r.t. for 
4 h. The reaction mixture was poured directly onto a flash column and was eluted with 50:50 
dichloromethane:hexane to give 255 as a yellow oil (1.13 g, 4.70 mmol, 56 % yield). Data 
was in agreement with the literature.  
 δH 5.35-5.41 (1H, m, CH), 5.25-5.32 (1H, m, CH), 2.50 (1H, dd, J = 1.6, 11.8 Hz 
CH), 2.23-2.37 (3H, m, CH, CH2), 1.99-2.13 (7H, m, CH, 3 x CH2), 1.93 (3H, s, Me), 1.34-
1.44 (2H, m, CH2), 1.21-1.33 (4H, m, 2 x CH2), 0.96 (3H, t, J = 7.5 Hz, Me), 0.89 (3H, t, J 
= 7.1 Hz, Me). 
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Preparation of 2-butyl-5-(hex-3-en-1-yl)-3-methylcyclohexan-1-one (256)123 
  
Lithium metal (70 mg, 10.06 mmol, 2.2 eqv.) was added to a cooled (0 ˚C) solution 
of 2-butyl-5-(hex-3-en-1-yl)-3-methylcyclohex-2-en-1-one (255) (1.13 g, 4.57 mmol) in 
N-propylamine (5 mL) and ethylene diamine (0.55 mL, 603 mg, 10.06 mmol, 2.2 eqv.). The 
reaction mixture was stirred to r.t. over 1.5 h, at which point all the lithium had dissolved 
and the blue colour had dissipated. The mixture was diluted with water (25 mL) and the 
aqueous portion was extracted with diethyl ether (3 x 20 mL). The combined organic extracts 
were then washed with brine (30 mL) and the organic phase dried (MgSO4). The solvent was 
removed under reduced pressure to give a colourless oil. The crude product was purified by 
flash chromatography (1:99-2:98, EtOAc:hexane) to give 256 as a colourless oil (618.0 mg, 
2.47 mmol, 54 %). Data was in agreement with the literature  
Rf = 0.34 (5:95, EtOAc:petroleum ether) δH 5.33-5.41 (1H, m, CH), 5.23-5.31 (1H, 
m, CH), 2.40 (1H, ddd, J = 2.3, 4.8, 11.7 Hz, CH), 1.83-2.07 (7H, m, 3 x CH2, CH), 1.11-1.80 
(11H, m, 5 x CH2, CH), 1.06 (3H, d, J = 6.4 Hz, Me), 0.96 (3H, t, J = 7.6 Hz, Me), 0.89 (3H, 
t, J = 7.1 Hz, CH2); LRCIMS m/z 251.2 (100 %, [M+H]
+), 501.5 (50 %, [2M+H]+); 
HRCIMS m/z found 251.2369 ([M+H]+), C17H31O requires 251.2369. 
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Preparation of 3-(4-butyl-3-methyl-5-oxocyclohexyl)propanal (257)123 
 
2-Butyl-5-(hex-3-en-1-yl)-3-methylcyclohexan-1-one (256) (1.76 g, 7.12 mmol) was 
dissolved in dichloromethane (100 mL) and cooled (-78˚C), whereupon ozone was bubbled 
through the solution with stirring until the solution remained light blue. Triphenylphosphine 
(2.8 g, 10.68 mmol, 1.5 eqv.) was then added and the colourless solution was stirred to r.t. 
overnight. The solvent was evaporated at below 20 ˚C to give a crude semi-solid residue, 
which was purified by flash chromatography on triethylamine deactivated silica gel (10:90 
EtOAc:hexane) to give 257 (1.19 g, 5.3 mmol, 74 % yield) as a colourless oil in a 5:1 mixture 
of isomers. Data were in good agreement with the literature.  
δH 9.78 (1H, t, J = 1.4 Hz, CH), 2.47 (2H, dt, J = 1.4, 7.4 Hz, CH2), 2.39 (1H, ddd, J 
= 2.4, 3.4, 12.8 Hz, CH), 1.99 (1H, dt, J = 0.8, 12.7 Hz), 1.83-1.94 (2H, m, 2 x CH), 1.10-
1.94 (11 H, m, 5 x CH2, CH), 1.06 (3H, d, J = 6.4 Hz, Me, minor isomer 0.99, d, J = 6.7 Hz), 
0.88 (3H, t, J = 7.0 Hz, Me); δC 211.0, 201.9, 56.8, 48.3, 41.5, 41.3, 38.0, 37.5, 29.7, 29.0, 
25.4, 23.3, 20.9, 14.2. 
 
  
  
164 
 
Preparation of 3-(4-Butyl-3-methyl-5-oxocyclohex-3-en-1-yl)propanal (260) 
 
(Z)-2-Butyl-5-(hex-3-en-1-yl)-3-methylcyclohex-2-en-1-one (255) (790.0 mg, 
3.15 mmol) was dissolved in dichloromethane (85 mL) and pyridine (0.85 mL). The solution 
was cooled (-78 ˚C) and ozone was bubbled for 30 second intervals. After each, the progress 
of the reaction was monitored by TLC. Once the spot corresponding to 255 appeared to have 
disappeared, the reaction was quenched with triphenylphosphine (1.24 g, 4.72 mmol, 1.5 
eqv.) and the product was stored in a freezer overnight. The solvent was then evaporated 
under reduced pressure, and the crude residue was purified by flash chromatography on 
triethylamine -deactivated silica (10:90 EtOAc:hexane), to give 260 as a colourless oil 
(347.0 mg, 1.56 mmol, 50 % yield), together with recovered 255 (297.0 mg, 1.18 mmol, 
38 % yield). Data was in agreement with the literature.  
δH 9.79 (1H, s), 2.42-2.51 (3H, m, CH2, CH), 2.22-2.42 (3H, m, CH, CH2), 1.99-2.17 
(3H, m, CH2, CH), 1.93 (3H, s, Me), 1.59-1.77 (2H, m, CH2), 1.21-1.33 (4H, m, 2 x CH2), 
0.89 (3H, t, J = 7.1 Hz, Me). 
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Preparation of 5-Butyl-6-methyl-1,2,7,7a-tetrahydro-4H-inden-4-one (257)123 
  
Aldehyde 260 (347 mg, 1.56 mmol) was dissolved in DME (13 mL) in a microwave 
reaction vial together with aqueous HCl (6 M, 2.16 mL), and the mixture was irradiated in a 
microwave reactor at 55 ˚C for 10 minutes. After cooling to r.t., the reaction mixture was 
poured into NaHCO3 solution (aqueous 5 %, 30 mL) and extracted with diethyl ether (200 
mL). The organic phase was washed with brine (200 mL), dried (MgSO4) and the solvent 
removed under reduced pressure to give a crude yellow oil. Purification by flash 
chromatography on silica gel (10:90 EtOAc:hexane) gave 261 (172 mg, 0.84 mmol, 54 % 
yield) as an unstable colourless oil. Data was in agreement with the literature. 
 
Rf 0.36 (10:90, EtOAc:petroleum ether); δH 6.66 (1H, broad apparent q, J = 2.6 Hz, 
CH), 3.00-3.15 (1H, m, CH), 2.14-2.56 (7H, m, 3 x CH2, CH), 1.96 (3H, s, Me), 1.50-1.60 
(1H, m, CH), 1.20-1.36 (4H, m, 2 x CH2), 0.90 (3H, t, J =7.0 Hz, Me); δC 186.3, 154.1, 
142.6, 137.6, 136.5, 42.3, 40.9, 32.4, 32.3, 31.4, 25.3, 23.0, 21.9, 14.2.  
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Preparation of 1-hydroxypentadecane-4,6-dione (263) 
 
i) Using ethanol with an ethanolic quench: Anhydrous ethanol (1.0 mL) was added 
to a magnetically stirred suspension of sodium hydride (60% dispersion in mineral oil, 4.8 g, 
120.0 mmol, 2.40 eqv.) in diethyl ether (200 mL). The resulting suspension was cooled (5 
˚C) and γ-butyrolactone (4.5 g, 4.0 mL, 52.3 mmol, 1.05 eqv.) was added drop wise. The 
mixture was stirred for 30 minutes. 2-Undecanone (8.5 g, 49.9 mmol) was then added drop 
wise and stirring continued at r.t. for 48 hours. After complete consumption of undecanone 
(TLC, Rf = 0.74, 50:50 diethyl ether:petroleum ether), the mixture was cooled (0 ˚C) and the 
remaining unreacted sodium hydride was destroyed by the cautious addition of ethanol 
(30 mL) followed by ammonium sulfate solution (aqueous, 10 %, 300 mL). If necessary, the 
pH of the aqueous layer was adjusted to pH = 6 by the addition of further ammonium sulfate 
solution, and the organic phase was separated. The aqueous layer was extracted with diethyl 
ether (3 x 150 mL) and the combined organic extracts were dried (MgSO4). The solvent was 
removed under reduced pressure to give the crude product as a yellow oil. Purification by 
silica gel chromatography (75:25 diethyl ether:petroleum ether) gave a waxy solid which 
was recrystallized (diethyl ether/hexane) to give 268 (0.766 g, 2.99 mmol) in 6 % yield as 
pale yellow needles. 
ii) Using ethanol with an aqueous quench: Anhydrous ethanol (1.0 mL) was added 
to a magnetically stirred suspension of sodium hydride (60% dispersion in mineral oil, 4.8 g, 
120.0 mmol, 2.40 eqv.) in diethyl ether (150 mL). The resulting suspension was cooled (5 
˚C) and γ-butyrolactone (4.5 g, 4.0 mL, 52.3 mmol, 1.05 eqv.) was added drop wise. The 
mixture was stirred for 30 minutes. 2-Undecanone (8.5 g, 49.9 mmol) was then added drop 
wise and stirring continued at r.t. for 48 hours. After the complete consumption of 
undecanone (TLC, Rf = 0.74, 50:50 diethyl ether:petroleum ether), the mixture was cooled 
(0 ˚C) and the remaining unreacted sodium hydride was destroyed by the cautious addition 
of ammonium sulfate solution (aqueous, 10 %, 300 mL). If necessary, the pH of the aqueous 
layer was adjusted to pH = 6 by the addition of further ammonium sulfate solution, and the 
organic phase was separated. Work up as detailed in i) gave 268 (2.55 g, 9.98 mmol, 20 % 
yield) as pale yellow needles.  
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Using trifluoroethanol and an aqueous quench: Anhydrous trifluoroethanol (1.0 mL) 
was added to a stirred suspension of sodium hydride (60% dispersion in mineral oil, 4.8 g, 
120.0 mmol, 2.40 eqv.) in anhydrous diethyl ether (200 mL), taking care to vent the pressure 
as necessary. The resulting suspension was cooled (5 ˚C) and γ-butyrolactone (4.5 g, 4 mL, 
52.3 mmol, 1.05 eqv.) was added drop wise. The mixture was stirred for 30 minutes. 2-
Undecanone (8.5 g, 49.9 mmol) was then added dropwise and stirring continued at r.t. for 
48 h. After the complete consumption of undecanone (TLC, Rf = 0.74, 50:50 diethyl 
ether:petroleum ether), the mixture was cooled (0˚C) and ammonium sulfate solution 
(aqueous, 10 %, 300 mL) was cautiously added. If necessary, the pH of the aqueous layer 
was adjusted to pH = 6 by the addition of further ammonium sulfate solution, and the organic 
phase was separated. The aqueous layer was extracted with diethyl ether (3 x 150 mL) and 
the combined organic extracts were dried (MgSO4) and the solvent removed under reduced 
pressure to give the crude product as a yellow oil. Purification by silica gel chromatography 
(75:25 diethyl ether:petroleum ether) gave a waxy solid which was recrystallized (diethyl 
ether/hexane) to give 268 (4.29 g, 16.7 mmol, 34 % yield) as pale yellow needles. This 
reaction was repeated on the same scale and gave 268 (4.60 g, 17.9 mmol, 36 % yield) as 
pale yellow needles.  
Rf = 0.33 = (75:25 diethyl ether:petroleum ether); Mp. 56-57 
oC; δH (DMSO-d6) 1:1 
mixture of keto/enol forms: 15.61 (0.5H, s, OH enol), 5.68 (0.5H, s, CH enol), 4.49 (0.5H, t, 
J = 4.5 Hz, OH), 4.44 (0.5H, t, J = 4.5 Hz, OH), 3.66 (1H, s, 0.5 CH2 keto), 3.33-3.42 (2H, 
m, CH2), 2.47 (2H, apparent pentet, J = 7.5, CH2), 2.32 (1H, t, J = 7.4, Hz, 0.5 CH2), 2.27 
(1H, t, J = 7.4, Hz, 0.5 CH2), 1.66 (1H, tt, J = 6.4, 7.2 Hz, 0.5 CH2), 1.59 (1H, apparent 
pentet, J = 6.9 Hz, 0.5 CH2), 1.51 (1H, apparent pentet, J = 7.2 Hz, 0.5 CH2), 1.43 (1H, 
apparent pentet, J = 7.1 Hz, 0.5 CH2), 1.17-1.31 (12H, m, 6 x CH2), 0.85 (t, J = 7.0 Hz, 3H, 
CH3); δC 1:1 mixture of keto/enol forms δ 205.3, 194.6, 193.8, 99.2, 60.0, 59.9, 56.3, 31.3, 
31.3, 28.9, 28.8, 28.7, 28.7, 28.6, 28.6, 28.4, 22.1, 13.9; vmax (KBr) 3278, 2954, 2932, 2919, 
2873, 2849, 1638, 1598 cm-1; LRCIMS m/z 257.2 (23 %, [M+H]+), 239.2 (100 %, [M+H-
H2O]
+); HRCIMS m/z found 257.2107 ([M+H]+), C15H29O3
 requires 257.2111. 
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Preparation of 3-(2-amino-6-nonylpyrimidin-4-yl)propan-1-ol  (269) 
 
i) Using trifluoroethanol: Guanidine hydrochloride (1.27 g, 13.29 mmol, 1.02 eqv.) 
was added to a solution of potassium t-butoxide (1.47 g, 13.10 mmol, 1.01 eqv.) in anhydrous 
trifluroethanol (10 mL). The resulting suspension was stirred at r.t. for 30 minutes. Diketone 
268 (3.33 g, 13.01 mmol) was then added and stirring continued at r.t. for 48 h. After the 
complete consumption of 1-hydroxypentadecane-4,6-dione (TLC, Rf = 0.33, 75:25 diethyl 
ether:petroleum ether), the solvent was removed under reduced pressure to give the crude 
product as a yellow solid. Purification by silica gel chromatography (10:90 MeOH:EtOAc) 
gave 269 (905.0 mg, 3.24 mmol, 25 % yield) as an amorphous white solid. This reaction was 
repeated on an identical scale to give 269 (1.0163 g, 3.64 mmol, 28 % yield).  
The process was repeated under different conditions as follows. 
ii) Using guanidine hydrochloride: Diketone 268 (287.0 mg, 1.12 mmol) was heated 
at reflux with guanidine hydrochloride (128.0 mg, 1.35 mmol, 1.20 eqv.) in absolute ethanol 
(5 mL) for 48 h. From analysis of the 1H NMR spectrum of the crude product, only the 
formation of the elimination product 271 was apparent. 
iii) Using guanidine hydrochloride and triethylamine: Diketone 268 (529.0 mg, 1.95 
mmol) was heated at reflux with guanidine hydrochloride (236.0 mg, 2.34 mmol, 1.2 eqv.) 
in absolute ethanol (5 mL)  with triethylamine (0.54 mL, 3.9 mmol, 2 eqv. for 48 h to give 
269 (60.0 mg, 0.21 mmol, 11 % yield). 
iv) In ethanol: Potassium t-butoxide (0.22 g, 1.97 mmol, 1.01 eqv.) was suspended 
in absolute ethanol (10 mL) and guanidine hydrochloride (0.19 g, 1.97 mmol, 1.01 eqv.) was 
added. The suspension was stirred at r.t. for 2 hrs. Diketone 268 (500.0 mg, 1.90 mmol) was 
then added and the mixture was stirred at r.t. for 12 hrs to give 269 (95.4 mg, 0.34 mmol, 18 
% yield). 
v) In ethanol under reflux: Potassium t-butoxide (0.22 g, 1.97 mmol, 1.01 eqv.) was 
suspended in absolute ethanol (10 mL) and guanidine hydrochloride (0.19 g, 1.97 mmol, 
1.01 eqv.) was added. The suspension was stirred at r.t. for 2 hours. Diketone 268 (500 mg, 
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1.90 mmol) was then added and the mixture was heated at reflux for 12 h to give 269 (116.6 
mg, 0.42 mmol, 22 % yield). 
Rf = 0.33 (10:90 MeOH:CHCl3); Mp. 56-58 °C; δH 6.38 (1H, s, CH), 5.21 (2H, s, 
NH2), 3.68 (2H, t, J = 5.9 Hz, CH2), 2.68 (2H, t, J = 7.0 Hz, CH2), 2.50 (2H, t, J = 7.7 Hz, 
CH2), 1.91 (2H, apparent pentet, J = 6.9 Hz, CH2), 1.63 (2H, apparent b pentet, J = 7.4 Hz, 
CH2), 1.26 (12H, m, 6 x CH2), 0.86 (2H, t, J = 6.8 Hz, CH3); δC 172.8, 170.9, 162.7, 109.7, 
62.3, 38.0, 34.7, 32.1, 31.1, 29.7, 29.7, 29.5, 29.1, 22.9, 14.3, one quaternary not observed; 
vmax (film) 3470, 3445, 3321, 3174, 2955, 2926, 2919, 2849, 1653, 1639, 1589, 1562 cm-1; 
LRCIMS m/z 280.2 (100 %, ([M+H]+), 302.2 (10 %, [M+Na]+); HRCIMS m/z found 
280.2384 ([M+H]+), C16H30O1N3 requires 280.2383. 
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Preparation of 3-(2-imino-6-nonyl-2,3-dihydropyrimidin-4-yl)propyl methane-
sulfonate (270) and (Z)-N-(3-nonyl-6,7-dihydropyrrolo[1,2-c]pyrimidin-1(5H)-
ylidene)methanesulfonamide (273). 
 
Triethylamine (0.13 mL, 94.0 mg, 0.93 mmol, 3.0 eqv.) was added to a stirred 
solution of 3-(2-imino-6-nonyl-2,3-dihydropyrimidin-4-yl)propan-1-ol (269) (85.3 mg, 
0.31 mmol) dissolved in dichloromethane (5 mL), whereupon methanesulfonyl chloride 
(23.0 L mL, 0.34 mmol, 1.1 eqv.) was  added. After 1 h the reaction was poured through a 
short (1 cm) pad of silica, which was then eluted with an EtOAc/MeOH mixture (20:1 ca 
100 mL). Evaporation of the filtrate under reduced pressure gave 270 as a crude brown semi-
solid (31.4 mg) which was used without further purification. The crude 270 (31.4 mg, 0.087 
mmol) was dissolved in anhydrous dichloromethane (2 mL) with triethylamine (0.025 mL, 
0.18 mmol, 2.0 eqv.), The reaction mixture was then heated in a sealed tube overnight at 80 
˚C. When the reaction was complete, it was cooled to r.t. and the solvent was removed under 
reduced pressure to give a brown gum. Purification by flash chromatography (10:90 
MeOH:EtOAc) gave 273 (11.2 mg, 0.033 mmol, 11 % yield) as a gum, as well as 15 % of 
recovered starting material 269 (12.6 mg, 0.045 mmol). 
Rf = 0.28 (10:90 MeOH:EtOAc); δH 6.44 (1H, s), 4.23 (2H, t, J = 7.5 Hz), 3.24 (3H, 
s, Me), 3.15 (2H, t, J = 7.7 Hz), 2.70 (2H, t, J = 7.7 Hz), 2.26 (2H, apparent pentet, J = 7.6 
Hz, CH2), 1.72 (2H, apparent pentet, J = 5.6 Hz, CH2), 1.13-1.40 (12 H, m, 6 x CH2), 0.88 
(3H, t, J = 7.0 Hz); δC 178.6, 165.6, 154.2, 103.7, 51.7, 38.9, 32.1, 32.0, 39.8, 29.8, 29.6, 
29.5, 29.4, 28.1, 22.8, 20.3, 14.2; LRCIMS m/z 362.2 (100 %, [M+Na]+), 701.4 (15 %, 
[2M+Na]+); HRCIMS m/z found 362.1872 ([M+Na]+), C17H29O2N3SNa requires 362.1873. 
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9.0 Appendices 
X-ray data for compound 161. 
 
Table 6.  Crystal data and structure refinement details. 
  
Identification code  2013ncs0205ba     
Empirical formula  C14H20N4O1 
Formula weight  260.34 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  P121/c1  
Unit cell dimensions a = 15.698(9) Å  = 90° 
 b = 5.232(3) Å  = 112.188(7)° 
 c = 18.133(11) Å   = 90° 
Volume 1379.0(14) Å3 
Z 4 
Density (calculated) 1.254 Mg / m3 
Absorption coefficient 0.082 mm1 
F(000) 560 
Crystal Block; Yellow 
Crystal size 0.06  0.03  0.02 mm3 
 range for data collection 2.298  27.474° 
Index ranges 20  h  20, 6  k  6, 23  l  23 
Reflections collected 9423 
Independent reflections 3143 [Rint = 0.1676] 
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Completeness to  = 25.242° 99.9 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 1.000 and 0.325 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3143 / 1 / 176 
Goodness-of-fit on F2 0.903 
Final R indices [F2 > 2(F2)] R1 = 0.0687, wR2 = 0.1127 
R indices (all data) R1 = 0.2025, wR2 = 0.1529 
Extinction coefficient n/a 
Largest diff. peak and hole 0.251 and 0.244 e Å3 
  
Diffractometer: Rigaku AFC12 goniometer equipped with an enhanced sensitivity (HG) 
Saturn724+ detector mounted at the window of an FR-E+ SuperBright molybdenum 
rotating anode generator with VHF Varimax optics (70µm focus). Cell determination and 
data collection: CrystalClear-SM Expert 3.1 b27 (Rigaku, 2013). Data reduction, cell 
refinement and absorption correction: CrystalClear-SM Expert 2.1 b29 (Rigaku, 2013). 
Structure solution: SUPERFLIP (Palatinus, L. & Chapuis, G. (2007). J. Appl. Cryst. 40, 
786-790). Structure refinement: SHELXL-2013 (Sheldrick, G.M. (2008). Acta Cryst. A64, 
112-122). Graphics: OLEX2 (Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. 
A. K. & Puschmann, H. (2009). J. Appl. Cryst. 42, 339-341). 
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Table 7. Bond lengths [Å] and angles [°]. 
  
O1N2 1.251(3) 
N1C1 1.312(3) 
N1C2 1.370(4) 
N2N3 1.312(3) 
N2C7 1.410(4) 
N3C1 1.383(4) 
N4H4 0.881(2) 
N4C1 1.349(4) 
N4C8 1.458(4) 
C2C3 1.406(4) 
C2C7 1.403(4) 
C3H3 0.9500 
C3C4 1.363(4) 
C4H4A 0.9500 
C4C5 1.402(4) 
C5H5 0.9500 
C5C6 1.361(4) 
C6H6 0.9500 
C6C7 1.400(4) 
C8H8A 0.9900 
C8H8B 0.9900 
C8C9 1.504(4) 
C9H9A 0.9900 
C9H9B 0.9900 
C9C10 1.531(4) 
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C10H10A 0.9900 
C10H10B 0.9900 
C10C11 1.513(4) 
C11H11A 0.9900 
C11H11B 0.9900 
C11C12 1.519(4) 
C12H12A 0.9900 
C12H12B 0.9900 
C12C13 1.504(4) 
C13H13A 0.9900 
C13H13B 0.9900 
C13C14 1.524(4) 
C14H14A 0.9800 
C14H14B 0.9800 
C14H14C 0.9800 
 
C1N1C2 114.2(3) 
O1N2N3 118.0(3) 
O1N2C7 119.7(3) 
N3N2C7 122.3(3) 
N2N3C1 116.2(3) 
C1N4H4 124(2) 
C1N4C8 124.4(3) 
C8N4H4 111(2) 
N1C1N3 128.1(3) 
N1C1N4 121.0(3) 
N4C1N3 110.9(3) 
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N1C2C3 120.3(3) 
N1C2C7 123.2(3) 
C7C2C3 116.5(3) 
C2C3H3 119.9 
C4C3C2 120.2(3) 
C4C3H3 119.9 
C3C4H4A 119.1 
C3C4C5 121.7(3) 
C5C4H4A 119.1 
C4C5H5 119.8 
C6C5C4 120.3(3) 
C6C5H5 119.8 
C5C6H6 121.2 
C5C6C7 117.7(3) 
C7C6H6 121.2 
C2C7N2 116.1(3) 
C6C7N2 120.4(3) 
C6C7C2 123.6(3) 
N4C8H8A 108.7 
N4C8H8B 108.7 
N4C8C9 114.1(3) 
H8AC8H8B 107.6 
C9C8H8A 108.7 
C9C8H8B 108.7 
C8C9H9A 109.2 
C8C9H9B 109.2 
C8C9C10 112.3(3) 
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H9AC9H9B 107.9 
C10C9H9A 109.2 
C10C9H9B 109.2 
C9C10H10A 108.9 
C9C10H10B 108.9 
H10AC10H10B 107.7 
C11C10C9 113.3(3) 
C11C10H10A 108.9 
C11C10H10B 108.9 
C10C11H11A 108.7 
C10C11H11B 108.7 
C10C11C12 114.3(3) 
H11AC11H11B 107.6 
C12C11H11A 108.7 
C12C11H11B 108.7 
C11C12H12A 108.7 
C11C12H12B 108.7 
H12AC12H12B 107.6 
C13C12C11 114.4(3) 
C13C12H12A 108.7 
C13C12H12B 108.7 
C12C13H13A 108.9 
C12C13H13B 108.9 
C12C13C14 113.5(3) 
H13AC13H13B 107.7 
C14C13H13A 108.9 
C14C13H13B 108.9 
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C13C14H14A 109.5 
C13C14H14B 109.5 
C13C14H14C 109.5 
H14AC14H14B 109.5 
H14AC14H14C 109.5 
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H14BC14H14C 109.5 
 
 
 
Symmetry transformations used to generate equivalent atoms:  
  Table 8. Anisotropic displacement parameters [Å2 103]. The anisotropic displacement 
factor exponent takes the form: 2 2[h2a*2U11 + ... + 2 h k a* b* U12 ]. 
Atom U11 U22 U33 U23 U13 U12 
 
O1 51(1)  55(2) 51(2)  4(1) 36(1)  5(1) 
N1 37(2)  38(2) 33(2)  3(1) 16(1)  3(1) 
N2 40(2)  47(2) 38(2)  5(1) 26(2)  9(2) 
N3 39(2)  38(2) 34(2)  1(1) 21(1)  2(1) 
N4 42(2)  39(2) 40(2)  6(1) 25(2)  5(1) 
C1 34(2)  34(2) 32(2)  2(2) 15(2)  6(2) 
C2 37(2)  40(2) 27(2)  6(2) 13(2)  6(2) 
C3 41(2)  43(2) 35(2)  1(2) 16(2)  1(2) 
C4 48(2)  37(2) 34(2)  3(2) 14(2)  4(2) 
C5 46(2)  43(2) 35(2)  2(2) 16(2)  8(2) 
C6 42(2)  47(2) 32(2)  0(2) 18(2)  9(2) 
C7 33(2)  36(2) 32(2)  0(2) 12(2)  1(2) 
C8 42(2)  43(2) 38(2)  3(2) 24(2)  5(2) 
C9 42(2)  43(2) 41(2)  5(2) 24(2)  0(2) 
C10 38(2)  42(2) 38(2)  2(2) 21(2)  1(2) 
C11 39(2)  41(2) 52(2)  3(2) 25(2)  2(2) 
C12 38(2)  42(2) 42(2)  5(2) 16(2)  3(2) 
C13 50(2)  45(2) 72(3)  1(2) 30(2)  3(2) 
C14 51(2)  76(3) 79(3)  10(2) 37(2)  11(2) 
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Table 9. Hydrogen coordinates [ 104] and isotropic displacement parameters [Å2  103]. 
Atom  x y z Ueq S.o.f.
 
 
H4 4367(13) 340(30) 5466(17) 45 1 
H3 2199 8644 3685 47 1 
H4A 2281 11127 2668 48 1 
H5 3413 10448 2144 49 1 
H6 4478 7167 2637 47 1 
H8A 3184 3608 5738 46 1 
H8B 3756 1372 6313 46 1 
H9A 2735 1667 5445 48 1 
H9B 2143 641 4919 48 1 
H10A 2415 26 6563 45 1 
H10B 1745 2038 5976 45 1 
H11A 1461 3353 5819 50 1 
H11B 795 1304 5225 50 1 
H12A 1061 1725 6867 49 1 
H12B 384 282 6263 49 1 
H13A 134 5111 6144 64 1 
H13B 543 3109 5536 64 1 
H14A 1196 4394 6440 97 1 
H14B 929 1436 6595 97 1 
H14C 289 3567 7176 97 1 
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Table 10. Torsion angles [°]. 
  
O1N2N3C1 180.0(2) 
O1N2C7C2 179.2(3) 
O1N2C7C6 1.0(4) 
N1C2C3C4 179.4(3) 
N1C2C7N2 0.7(4) 
N1C2C7C6 179.1(3) 
N2N3C1N1 1.2(5) 
N2N3C1N4 178.1(3) 
N3N2C7C2 1.6(4) 
N3N2C7C6 178.2(3) 
N4C8C9C10 176.0(3) 
C1N1C2C3 179.3(3) 
C1N1C2C7 0.9(4) 
C1N4C8C9 93.3(3) 
C2N1C1N3 2.0(4) 
C2N1C1N4 177.2(3) 
C2C3C4C5 0.0(5) 
C3C2C7N2 179.1(2) 
C3C2C7C6 1.1(5) 
C3C4C5C6 0.6(5) 
C4C5C6C7 0.3(4) 
C5C6C7N2 179.6(3) 
C5C6C7C2 0.6(5) 
C7N2N3C1 0.8(4) 
C7C2C3C4 0.8(4) 
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C8N4C1N1 2.9(5) 
C8N4C1N3 176.4(3) 
C8C9C10C11 173.5(2) 
C9C10C11C12 179.3(3) 
C10C11C12C13 179.0(3) 
C11C12C13C14 179.6(3) 
  
 Symmetry transformations used to generate equivalent atoms:  
   
 
 
Table 11. Hydrogen bonds [Å and °]. 
 
 DH···A d(DH) d(H···A) d(D···A) (DHA) 
 
 N4H4...N3i 0.881(2) 2.183(9) 3.041(4) 165(3)  
 Symmetry transformations used to generate equivalent atoms:  
(i) x+1,y,z+1        
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Compound 161.  
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Appendix 2 
Anodic oxidation of 1,4-dimethoxy-2,3,5-trimethylbenzene (99) 
The anodic oxidation of 99 was performed using a platinum cathode and carbon felt 
anode. These were in turn connected to an ammeter (Amps), voltmeter (Volts) and a Farnell 
instruments LTD stabilised power supply, set to maintain a current of 1 Amp. (Figure 50) 
Both the cathode and anode were submerged in a beaker containing. 99 dissolved in 2% 
methanolic potassium hydroxide. This was maintained at a temperature of <5 °C and the 
solution vigorously stirred. (Figure 51) 
 
Figure 50. Electrochemical reaction schematic.  
 
Figure 51. Photograph of the apparatus. 
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